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ABSTRACT OF DISSERTATION

CLONING AND FUNCTIONAL CHARACTERIZATIONS OF CIRCULAR
RNAS FROM THE HUMAN MAPT LOCUS
Under pathophysiological conditions, the microtubule protein tau (MAPT) forms
neurofibrillary tangles that are the hallmark of sporadic Alzheimer’s disease as well as
familial frontotemporal dementias linked to chromosome 17 (FTDP-17). In this work, I
report that MAPT forms circular RNAs through backsplicing of exon 12 to either exon 10
or exon 7 (12à10; 12à7), and that these circular RNAs are translated into proteins.
Using stable cell lines overexpressing the circular tau RNAs 12à7 and 12à10, we
have discovered that the tau circular RNA 12à7 is translated in a rolling circle, giving rise
to multiple proteins. This circular RNA has an endogenous start codon in exon 9 and no in
frame stop codon. We purified the protein by immunoprecipitation using a 3X flag tag that
is upstream of the start codon and that will only be translated in a circular RNA. The
circular RNA 12à10 does not have a start codon and is translated when mutations that
cause FTDP-17 create a start codon (K317M and V337M) or ADAR (Adenosine
Deaminase acting on RNAs) enzymes are present. In addition, we show that the 12à10
wild type circular RNA can be translated due to RNA editing by ADAR1 and ADAR2.
ADAR enzymes edit RNA sequences changing adenosines to inosines and are referred to
as A-to-I editing (I = inosine). Inosines can be read as a guanosine, therefore editing an
AUA sequence to AUI could create a new start codon in the RNA sequence.
The circular RNAs’ translated region is similar to a seed sequence, known as K18,
that promotes tau aggregation and neurodegeneration. We hypothesize that the tau proteins
generated from the circular RNAs contribute to tau aggregation, which cause Alzheimer’s
Disease. We have designed siRNAs, specific for circular RNAs, as possible therapeutics.
We show that the siRNAs target the circular tau RNAs backsplice junction, reducing their
expression and preventing translation.
In summary, our data indicate that tau makes so far unknown circular RNAs that
are unexpectedly translated into proteins that cause tau aggregations, a hallmark of
tauopathies (AD and FTDP-17). Almost all FTDP-17 mutations are in the pre-mRNA
regions contributing to circular RNA formation, suggesting they act through circular

RNAs. Finally, we identified oligonucleotides that abolish circular RNA formation,
pointing to a novel therapeutic avenue for tauopathies.
I am thankful for the partial funding of this project by the College of Medicine
Excellence in Graduate Research Fellowship and the Max Steckler Award.
KEYWORDS: Circular RNA, Tauopathies, Alu elements, MAPT, Alzheimer’s Disease,
FTDP-17
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CHAPTER 1. INTRODUCTION
1.1

Overview

This dissertation investigates the human microtubule associated protein tau (MAPT)
gene. The main finding is the discovery of novel circular RNAs that are generated from the
tau locus (1). Not a lot is known about circular RNAs and very few circular RNAs have a
known function. The tau protein is known to be associated with many different
neurodegenerative diseases called tauopathies and is a major contributor to Alzheimer’s
disease (2). The tau protein can be hyperphosphorylated causing it to disassemble from
tubulin forming tau aggregates, which leads to neurodegeneration (3). However, little is
known about the mechanism that leads to this dysfunction of the protein.
In chapter 2, I give a review on how circular RNAs are formed in pre-mRNA
processing and summarize their identified function (4).
In chapter 3, I describe the discovery of the tau circular RNAs and look into the
correlation of circular RNA abundance with AD. The tau locus generates two circular
RNAs that consist of exons 7,9-12 (12à7) and 10-12 (12à10) (1).
Chapter 4 describes an optimized protocol of cloning reporter genes that form circular
RNAs in order to study in detail their function and processing. This protocol can be used
for any gene that generates circular RNAs showing key components to consider when
troubleshooting large complex sequences and that have repeat sequences (5). This
optimized protocol allowed us to study the function of the tau circular RNAs and their
relation to tauopathies.
In chapter 5, I look into the function of the circular tau RNAs and found that they are
translated. Both the tau circular RNAs 12à7 and 12à10 contain an open reading frame,
however, the 12à7 circular RNA contains one in-frame methionine start codon in exon 9
but no stop codon. I show that the 12à7 circular RNA is translated in a rolling circle giving
rise to proteins of different sizes that are predicted to contain the regions of the microtubule
binding domains. A peptide that consists of the four microtubule binding domains called
K18 has been shown to promote tau aggregation and paired helical filament formation (6,
7). The four microtubule binding domains reside in exons 9-12 and when translated from
the 12à7 circular RNA they can form a multimer that could initiate tau aggregation. The
12à10 circular RNA does not contain a methionine start codon and is not predicted to be
translated. However, two particular mutations in tau exon 11 (K317M) and exon 12
(V337M) that cause Frontotemporal Dementia, create a start codon allowing translation to
occur. We show that the wild type 12à10 circular RNA can be translated when there is an
overexpression of the adenosine deaminase acting on RNA (ADAR) enzymes. The active
ADAR enzymes, ADAR1 and ADAR2, may edit the RNA changing an AUA sequence to
an AUI that now is read as an AUG start codon (I = Inosine). ADAR enzymes have also
been shown to be deregulated in Alzheimer’s disease which may contribute to circular tau
RNA translation and tau pathology. Another function of the tau proteins discovered in
1

chapter 5 was the interaction with the eukaryotic translation initiation factor 4B (EIF4B).
The translated proteins from the tau circular RNAs could be regulating gene expression or
translation contributing to tauopathies.
Lastly, I show that the circular tau RNAs can be reduced by siRNAs targeting against
the backsplice junction preventing translation. The translated protein could be neurotoxic
and with the siRNAs specifically targeting the circular and not the linear RNA the siRNAs
could be used as a therapeutic drug for Alzheimer’s disease and other tauopathies.
In summary, I propose a model on what is known in the processing of the tau protein
shaded in gray in figure 1.1 A-D. The tau gene forms the linear pre-mRNA, which can be
alternatively spliced giving rise to the six major isoforms of the tau protein (Figure 1.1 AC). Tau binds to tubulin stabilizing microtubules promoting tubulin growth preventing
neurodegeneration (Figure 1.1 C). However, due to aging or brain trauma, tau can be
hyperphosphorylated promoting tau aggregation forming neurofibrillary tangles and paired
helical filaments, leading to the destabilization of microtubules and neurodegeneration
(Figure 1.1 D). I propose a model that includes the discovery of the circular tau RNAs in
yellow in figure 1.1 E-I, we hypothesize that in order for the backsplicing to occur, Alu
repeat elements are needed allowing the pre-mRNA to adopt a structure promoting
backsplicing (Figure 1.1 E). Alu repeats are intronic regions that exhibit sequence
complementarity, causing exon 12 to be close to either exon 7 or exon 10, allowing the
backsplicing to occur.
The circular tau RNA 12à7 is translated, and its proteins may have a physiological
role, but when there is an increase in translation due to overexpression of ADAR1 and
ADAR2, this may lead to a gain of function promoting tau aggregation and
neurodegeneration (Figure 1.1 D, F, I). The tau protein also binds to EIF4B and may play
a role in gene regulation or translation where an overexpression of the protein may act as
a gain of function decreasing gene expression (Figure 1.1 J). The circular RNA 12à10 is
only translated when mutations create new start codons or when there is an overexpression
of ADAR enzymes that can edit the RNA changing an adenosine to an inosine where the
inosine and can be read as a guanosine (Figure 1.1 H, I). Editing the sequence AUA to AUI
can be read as an AUG forming a new start codon. The translated protein from the 12à10
circular RNA may act as a seed sequence that can lead to tau aggregation and
neurodegeneration causing Alzheimer’s or other tauopathies (Figure 1.1 D, H, I).
The circular tau RNAs can be reduced by siRNAs, which could stop translation
preventing tau aggregation and neurodegeneration (Figure 1.1 G). So far, no one has looked
into this pathway from the circular RNAs, research has only focused on the linear tau
RNAs. Thus, this work unveiled a new mechanism to target in the formation of the possibly
neurotoxic tau proteins and can potentially prevent the progression of the tau pathology.

2

Figure 1-1 Model of Microtubule-Associated Protein Tau Linear vs Circular

Known knowledge is in gray and my finding is in yellow.
3

A. Schematic of the shortened pre-mRNA of the tau locus and how it is alternatively
spliced.
B. After alternative splicing six major RNA isoforms are formed.
C. The six major protein isoforms are translated and interacts with tubulin stabilizing
microtubules.
D. When tau no longer binds to tubulin and forms tau aggregates, disease pathology forms,
causing tubulin disassembly leading to Tauopathies.
E. The novel discovery in yellow, two circular RNAs form due to the backsplicing of exon
12 onto either exon 7 or exon 10 (12à7, 12à10).
F. 12à7 circular tau RNA is translated in a rolling circle.
G. The circular tau RNAs can be destroyed or reduced with siRNAs targeting the
backsplice junction inhibiting protein translation.
H. The 12à10 circular RNA is translated with FTDP-17 mutations K317M and V337M.
Editing enzymes (ADAR1 and ADAR2) increase protein production due to RNA editing.
The translated regions of the circular tau RNA 12à10 is predicted to be similar to the
neurotoxic peptide called K18.
I. Both circular RNAs 12à and 12à10 are translated forming multiple proteins of
different sizes, a possible indication of multiple rounds of translation. Editing enzymes
(ADAR1 and ADAR2) increase protein production due to RNA editing. The translated
region of the circular tau RNAs is predicted to be similar to the neurotoxic peptide called
K18.
J. EIF4B interacts with the protein from the tau circular RNAs possibly influencing
translation.
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CHAPTER 2. PRE-MRNAS FORMING CIRCULAR RNAS ARE A NEWLY
DISCOVERED ELEMENT OF GENE EXPRESSION
This chapter was adapted from:
Welden, J. R. and Stamm, S. (2019). “Pre-mRNA structures forming circular
RNAs.” Biochim Biophys Acta Gene Regul Mech. 2019:194410 (4)

2.1 Introduction
Circular RNAs (circRNAs) are covalently closed RNAs that are expressed in all
branches of life (8). Most circRNAs are generated through pre-mRNA back-splicing (9)
where a downstream 5' splice site is connected to an upstream 3' splice site (Figure 2.1A).
Most circRNAs contain exons of mRNAs, but circRNAs composed of pre-mRNA introns
have also been detected (10). Other mechanisms to create circRNAs like tRNA splicing
(11), self-splicing of tetrahymena rRNA (12), and the formation of circular viroid RNAs
also exist (13, 14), but are far less common.
In general, circRNAs have a much lower abundance than linear mRNAs and early
reports considered them splicing artifacts (15). As circRNAs lack a poly adenosine tail,
they are diminished in libraries made by oligo dT priming. Their widespread expression
became only apparent when next generation sequencing techniques were developed (16).
Currently it is estimated that, in general, circRNAs comprise 0.8-1% of mRNAs (16, 17).
The overall function of circRNAs remains enigmatic. CircRNAs accumulate in the
cytosol using an export pathway that depends on the RNA helicases UAP56 (DDX39B)
and URH49 (DDX39A) (18), pointing towards functions in the cytosol. Some circRNAs
have been shown to sequester miRNAs, acting as ‘sponges’ (19, 20), which indirectly
influences mRNA abundance. Numerous circRNAs are associated with ribosomes (21) and
proof of principle experiments indicated that they can be translated (22-27). In drosophila
and humans, the highest diversity and expression of circRNAs has been found in the brain
and increases during aging (28-30) suggesting tissue-specific roles for circRNAs.
The vast majority of exons in circRNAs are also present in their linear counterparts,
suggesting a competition between linear splicing and back-splicing. In some cases, this
competition can reduce linear mRNA expression (9, 31, 32), indicating a role of some
circRNAs in mRNA expression.
2.2

Types of circular RNAs

The highest expressed individual circRNAs are generated by a single large exon
through a back-splicing mechanism (33). Overall most circRNAs contain multiple exons,
mostly two exons. The number of circRNA transcripts decreases with the number of their
forming exons (33). Similar to linear mRNAs, circRNAs can be alternatively spliced (33,
34). Numerous circRNAs contain intronic sequences, but the majority of circRNAs lack
intronic sequences, suggesting that multi-exon circRNAs are generated after parts of the
5

pre-mRNA have been already spliced together, indicating that frequently linear splicing
likely occurs prior to back-splicing (28).
Reflecting the low abundance and cell-type specific expression, there is a large
discrepancy between circRNAs identified in different experiments (17) and new circRNAs
are being discovered (34). CircRNA sequences are available from various databases:
(CIRCpedia (34), circBase (35), CircFunBase (36), CircNet (37), circRNADb (38), and
PlantcircBase (39).
2.3

Mechanism of back-splicing

Back-splicing that creates circRNAs uses the same splicing machinery and most of
the splicing enhancer and silencers as linear premRNA splicing. Thus, exons present in
circRNAs are surrounded by canonical splice sites in the pre-mRNA and the formation of
circRNAs is sensitive to splicing inhibition (40). siRNA mediated depletion of splicing
factors increases formation of some circRNAs while the corresponding mRNAs were
reduced, suggesting a coupling between circRNA and mRNA formation (41). Minigene
analyses showed that, similar to linear splicing, the recognition of exons in circRNAs is
based on combinatorial control that takes into account splice site strength (40), the
concentration of hnRNPs, SR-proteins, SR-protein kinases (42, 43), and RNA-helicases
(44). For circRNAs made from single exons, the yield of circRNA formation increases with
exon length (45) and in drosophila long flanking introns favor circRNA formation (28).
2.4

Recognition of back-splicing sites depends on the pre-mRNA secondary
structure

For back-splicing to occur, the splice sites involved have to be brought into close
contact, either through a secondary structure in the RNA (Figure 2.1A) or through
interactions (Figure 2.1B). In most cases studied, these structures are generated through
base-pairing of complementary RNA sequences within the same pre-mRNA molecule.
Protein interactions have been shown for quaking I (QKI) that binds to short intronic
recognition sites flanking the back-splicing sites resulting in circRNA formation (46).
Similarly, the muscle blind protein (MBL) binds to repeat sequences flanking back-splicing
sites and also promotes circRNA formation (47). Bridging of exons through intronic
hnRNP binding sites have been shown for other proteins, such as hnRNPA1 (48) and
PTB/hnRNPI (49), suggesting a more general role for this mechanism in circRNA
formation. In lower eukaryotes that have less inverted repeats, circRNAs can be formed
through a lariat precursor, where back-splicing occurs within the circular lariat (50) (Figure
2.1C).
Due to its high expression, one of the first circRNAs identified was from the mouse
SRY gene (sex determining region Y) (51). This single exon circRNA is located in a 2.7
kb long region flanked by a large inverted repeats (> 15.5 kb) that is necessary for the
circularization (51, 52), providing the first evidence that often genomic repeat elements
6

flanking the back-splice sites generate the secondary structures necessary for proper
alignment of the splice sites. In humans, these repeat elements are often provided by Alu
elements (9) and their contribution to circRNA formation has been extensively studied
experimentally (33, 45). Similarly, reverse complementary sequences not emanating from
repeat elements have been detected in C. elegans (53). However, a genome-wide screen in
drosophila failed to detect direct repeats for the majority of circRNAs (28), although
detailed experiments using model RNAs revealed that some highly expressed drosophila
circRNAs, like laccase 2 (Figure 2.3C) rely on repeats for their formation (42).
Genome wide cloning of human RNase resistant double stranded RNA revealed
thousands of double stranded RNAs outside known repeats, further supporting the idea of
RNA double stranded structures that occur independent of repeat elements (54). Thus,
despite the current research focus on inverted repeat elements, especially Alu elements,
other RNA structures likely also facilitate back-splicing.
2.5

Alu elements form secondary structures promoting human circular RNA
formation

Sequencing of human circRNAs revealed that they are often flanked by Alu elements
in their genomic location (9, 33). Alu elements are about 300 nucleotides (nt) long short
interspersed nuclear elements (SINE) (55-57) that were derived from the 7SL-RNA in the
early primate lineage (58, 59) (Figure 2.2A, B). There are more than one million Alu
element copies in the human genome that comprise about 11% of the human genome (60).
Alu elements continue to amplify through a polymerase III-derived RNA intermediate and
it is estimated that there is about one new Alu insertion in 21 human births (61). They are
predominantly located in gene-rich regions (62), possibly because their small size does not
interfere strongly with gene regulation (55). Alu elements are subdivided into the J (Jurka,
Jerzy), S (Smith, Temple) and Y (young) subfamilies, which reflect an alphabetical
progression from the oldest (J) to the youngest (Y) Alu subtypes (63). Since different
subfamilies of Alu elements are highly similar in sequence, they can form secondary
structures when inserted in opposite orientation in a pre-mRNA transcript, referred to as
inverted repeated Alu structure (IRAlus) (55) (Figure 2.2C, example in Figure 2.3A, B)
The ability of Alu-elements to form double-stranded secondary structures and thus
their propensity to promote circRNA formation is reduced by adenosine to inosine (A->I)
editing, which is the most common post-transcriptional RNA modification in primates (64,
65). A->I editing is performed by the adenosine deaminases acting on RNA (ADAR)
family of enzymes that require RNA double strands as a template (66). Thus, the editing
of Alu elements can be used to measure whether an Alu element is in a double stranded
conformation. The double strandedness, (i.e. the formation of a secondary structure) of an
Alu-element mostly depends on the distance to the closest reversely oriented Alu element,
which is around 800 nt. The Alu-element editability decreases exponentially with longer
distances (64). Other factors affecting double strandedness include the presence of
additional competing Alu elements, which decrease double strandedness of a single Alu
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element; and the subfamily of the Alu element, where related subfamilies are edited
stronger (Figure 2.2C). ADAR knockdown increases circRNA expression in human cells
(53), further suggesting a role of Alu-element modification in human circRNA formation.
ADARs are not specific for double stranded RNAs formed by Alu elements, and thus
ADAR knockdown in mouse promotes formation of some circRNAs as well (29).
Double stranded Alu-element structures can form within an intron as well as across
an exon. Usually, only Alu elements localized across an exon in opposite directions can
promote circRNA formation (33). Often, an Alu-element can base-pair with other distinct
Alu-elements, leading to alternative circRNA formation (Figure 2.2D). Since linear
splicing reduces the distance between Alu-elements that flank exons it promotes circRNA
formation when it occurs faster than back-splicing (Figure 2.2E, F). Deletion analyses in
several model systems showed that the full Alu element is not necessary for circRNA
formation to occur (33). In fact complementary sequences as small a 30-40 nt are sufficient
and give stronger circRNA formation than longer elements (45) (Figure 2.3A).
DHX9 is an RNA helicase that selectively binds to Alu-elements located in proximity
(458 nt). DHX9 binds to an interferon-inducible form of ADAR, and knock down of DHX9
increases circRNA production (44, 67), suggesting that DHX9 destabilizes pre-mRNA
structures necessary for circRNA formation.
There is emerging evidence that Alu-elements can also act in trans, i.e. between
different pre-mRNA molecules, leading to trans-splicing (68), which could conceptually
compete with circRNA splicing.
In summary, multiple factors control the occurrence of back-splicing and thus the
formation of circRNAs. Most importantly, a double stranded pre-mRNA structure brings
back-splicing sites together. Its formation is influenced by the availability of
complementary sequences, which in turn are negatively influenced by RNA helicases,
ADAR enzymes and single-stranded RNA binding proteins. Factors that influence intron
splicing, such as splice site strength, the concentration of SR-proteins and hnRNPs as well
as the availability of exon enhancers and silencers also impact on circRNA formation
(Figure 2.2G).
2.6

Experimental Studies

The correlations between double stranded pre-mRNA structures and circRNA
formation have been tested experimentally. Current reporter gene constructs and
experimentally validated double stranded RNA structures are summarized in Figure 2.3.
The double stranded structures can be surprisingly small. For example the experimentally
determined structure needed to form circRNAs forming from ZKSCAN1 exon 2/3 is only
36 nt long and contains 7 mismatches, although the natural repeat is much longer (45),
(Figure 2.3A). It is thus not surprising that circRNAs can form without known or
identifiable repeats (40).
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2.7

Outlook

Despite their low expression when compared to their linear counterparts, circRNAs
could turn out to be biologically highly important. An increasing number of studies are
showing now that circRNAs can form proteins (23, 69). CircRNAs are highly expressed in
the brain, where they could encode new peptide hormones that are small, reflecting the
short reading frames of circRNAs and work at small concentrations. For example, αmelanocyte-stimulating hormone (α-MSH), generated from POMC is a peptide composed
of 13 amino acids that binds to the melanocortin 1 receptors with an affinity of 200 pM to
2 nM (70). Thus, the generation of novel brain-specific signaling peptides could be an
important function of circRNAs. It is notable that the development of the brain cortex in
primates correlates with the expansion of Alu elements (71), which could result in so far
unknown peptide hormones.
The formation of circRNAs depends on intronic elements that form double-stranded
RNA structures. CircRNAs and possibly their encoded peptides could be an evolutionary
force reflecting differences in intron sequences caused by the presence of species-specific
repeat elements, such as primate-specific Alu elements and SINEC_Cf elements
characteristic for various dog species (72). Similarly, deep intronic mutations characteristic
for cancer (73) and present in numerous hereditary diseases (74) could act by influencing
circRNA expression.
So far, studies of pre-mRNA structures do not take RNA modifications other than A>I editing into account. N6-Adenosine methylation (m6A) is another common mRNA
modification that could influence RNA structures and thus circRNA formation. M6A RNA
modification creates a strong binding site for YTH-domain proteins (75) that could bridge
back-splicing sites. In addition m6A modifications create hnRNPG or hnRNPC binding
sites (76) which abolishes RNA double stranded structures and was shown to change linear
alternative splicing (76). It is thus conceivable that circRNA formation is similarly
influenced by m6A RNA modifications and could be thus under epigenetic control.
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Figure 2-1 Generation of circRNAs through back-splicing

A. Back-splicing due to a pre-mRNA structure. A pre-mRNA containing exon 1, 2, and 3
is shown. The double stranded RNA structure formed by complementary regions in the
pre-mRNA brings the 5' and 3' splice site of exon 2 into close proximity, allowing backsplicing (solid arrow) leading to the formation of a circRNA (striped circle). This process
competes with the formation of linear mRNA, joining exons 1, 2 and 3, indicated by dashed
lines with arrows.
B. Back-splicing can also occur when proteins (gray shapes) multimerize after binding to
short recognition sequences that flank an exon (46), which brings the back-splicing sites
into close proximity.
C. The presence of an exon in a lariat created during the splicing reaction can also lead to
back-splicing of this exon. The exon is first present in a lariat formed by branch point 2
(bp2) in intron 2 of a three-exon substrate. Next a branch-point (bp1) in intron 1 forms a
lariat with the guanosine of the 5' splice site (dashed line with arrow), allowing backsplicing to occur (solid line with arrow) (50).
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Figure 2-2 Alu elements promote back-splicing through formation of structures in
the pre-mRNA

A. General sequence of an Alu element, “A, B”: A and B boxes as recognition sites for
DNA polymerase III. AAA: short mid A stretch; AAAA (red): terminal A stretch, TTT:
downstream T-stretch, acting as a pol III termination site, arrows, yellow direct repeats
(genomic Alu insertion site). The common depiction of an Alu element is an arrow that
shows the direction from the A box to the terminal A stretch (arrowhead).
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B. Sequence of an AluJB element with the elements highlighted from the human MAPT
gene (hg38 chr17:46,014,583-46,014,913). FLAM: free left Alu monomer (dashed box),
FRAM: free right Alu monomer (solid box). The coloring of the elements is similar to
panel A.
C. Determinants of Alu-element mediated secondary structures. Alu elements oriented in
opposite direction can form double stranded regions, measured through editing of the Aluelements. The probability to form a double stranded structure increases exponentially when
the Alu-elements are getting closer.
D. Arrangement of Alu elements in a pre-mRNA can promote alternative circRNA
splicing. Depending on the interaction (dotted line) of the Alu elements a circle between
exon 1 and 2 or a circle composed of exon 2 (dotted) can be formed.
E, F. Removal of an intron through splicing can decrease the distance between dsRNA
structure forming Alu-elements. E. shows the situation before splicing, where the Aluelements are too far apart to allow back-splicing. F: Intron removal through splicing allows
back-splicing and circRNA formation.
G. Elements controlling circRNA formation: hnRNPs and SR-proteins control general
splice site recognition and influence competition between linear and circular splicing.
Helicases influence the stability of the RNA structures promoting circular splicing, a larger
distance between the back-splicing sites, i.e. the length of the circularized exon promotes
back-splicing.

12

Figure 2-3 Experimentally characterized examples of RNA structures leading to
back-splicing.

Schematic structures and double stranded region of A. ZKSCAN1 (45), B. EPHB4 (45),
C. LACCASE2 (42) and D. HIPK3 (45) genes are shown. Experimentally validated double
stranded pre-mRNA regions are shown on the right. A “*” indicated G-U base pairing.
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CHAPTER 3. PROCESSING OF THE HUMAN MAPT LOCUS GENERATES
CIRCULAR RNAS
With permission this chapter is adapted from:
Welden, J. R., van Doorn, J., Nelson, P. T. and Stamm S. (2018). “The human
MAPT locus generates circular RNAs.” Biochim Biophys Acta 1864(9 Pt B):2753-60
(1)
3.1

Introduction

The human microtubule-associated protein Tau is highly expressed in brain and
promotes the assembly and stabilization of microtubules (77). Tau protein can mis-fold
into paired helical filaments and neurofibrillary tangles, which characterize a group of
neurodegenerative diseases known as tauopathies, that include Alzheimer’s disease (AD),
frontotemporal lobar degeneration (FTLD-TAU), progressive supranuclear palsy (PSP),
chronic traumatic encephalopathy (CTE), and primary age-related tauopathy (PART) (78).
The clearest connection between the MAPT gene and neurodegeneration is found in FTLDMAPT, as the disease is caused by many different known mutations in the MAPT locus on
chromosome 17 (79). Studies in mice indicate that tau protein is necessary for amyloidbeta induced neuronal cell death (80), and thus plays a central role in AD.
The human MAPT gene contains 16 exons, with exons 2, 3, 4a, 6, 8 and 10 being
alternatively spliced cassette exons (Figure 3.1A). Alternative splicing of these exons in
the normal adult human brain generates six major protein isoforms. These isoforms differ
at the N-terminus due to alternative exons 2 and 3 in the tau projection domain and in the
number of microtubule binding repeats due to alternative splicing of exon 10. Exon 10
encodes one of the four microtubule binding sites, and its alternative usage generates tau
isoforms with either 3 or 4 binding sites (3R, 4R) that differ in their affinity to microtubules
(81) and could thus ‘fine tune’ the interaction between the Tau protein and microtubules.
At least 19 mutations causing FTLD-MAPT have been identified in exon 10 and its
5’ splice site (79). Pathological changes in exon 10 usage without mutations in exon 10
result in tauopathies, for example PSP and corticobasal degeneration (CBD) are
characterized by 4R Tau, whereas Pick’s disease is characterized by 3R Tau. Post mortem
studies of AD brains indicated a slight increase of exon 10 usage (82-84), as well as
deregulation of protein factors that regulate exon 10 splicing, namely the SR-like protein
tra2-beta1 that promotes exon 10 usage and its kinase, clk2, that inhibits exon 10 usage
(82, 85).
In addition to the well known linear RNAs, pre-mRNAs generate circular RNAs
through a backsplicing mechanism, where a downstream 5’ splice site is joined with an
upstream 3’ splice site (86). In most cases, circRNAs are generated when the pre-mRNA
forms a loop containing the exons undergoing backsplicing. This loop can be formed by
either a large lariat or more commonly through intramolecular RNA base pairing, leading
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to double stranded RNA regions as short as 30-40 nt in length. Frequently, repeat elements
that have regions of base complementarity provide the basis of loop formation. In humans,
these elements are often Alu elements (9, 19), comprising around 11% of the human
genome (57). Due to their self complementarity Alu elements form extensive double
stranded RNA structures in pre-mRNA, which can influence alternative splicing (87) and
promote the formation of circRNAs (9). With about 50 highly expressed exceptions,
circRNAs comprise only 1-5% of their linear counterparts. Since they lack a 3’ or 5’ end,
they escape the exonucleic degradation of linear RNAs and are thus more stable. The
analysis of a few circRNAs showed that they mainly reside in the cytosol, where they can
function as microRNA sponges (19), and can undergo translation in the presence of an
internal ribosomal entry site (88). In addition, intron-containing circRNAs have been
implicated in transcriptional control in the nucleus (89).
Here, we used a PCR approach to identify circular RNAs from the human tau locus
that contain the alternatively spliced exon 10. These circular RNAs are low abundant,
comprising less than 1% of the linear tau RNA. The data shows that not all RNAs generated
from the human tau locus have been identified.
3.2

Materials and Methods

3.3

Primers

9 à 11 Forward: TGT CAA GTC CAA GAT CGG CT
9 à 11 Reverse: CTG GCC ACC TCC TGG TTT
11 à 10 Forward: GAC CTC CAA GTG TGG CTC AT
11 à 10 Reverse: TGG ACT GGA CGT TGC TAA GA
RPL13 Forward: GCC ATC GTG GCT AAA CAG GTA
RPL13 Reverse: GTT GGT GTT CAT CCG CTT GC
Tau 12à10 reverse: cag ctt ctt att aat tat ctg cac ctt tt
Tau 10à11 forward: gag gcg gca gtg tgc aa
HIPK3f: tcg gcc agt cat gta tca aa
HIPK3r: tgc ttg gct cta ctt tga gtt tc
Tau exon12 Rev: ccc aat ctt cga ctg gac tc
Tau exon 9 Forw: tgt caa gtc caa gat cgg ct
3.4

Minigene Generation

The tau exon 9-12 minigene was generated using Gibson cloning by assembling exons 9,
10, 11 and 12 in pcDNA3.1 using these primers:
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Vector1 AAGCTTAAGTTTAAACGCTAGCCAGCTTG
Vector 2 CTCGAGTCTAGAGGGCCCGTTTAAACC
Exon 9f ctggctagcgtttaaacttaagcttACGCTGGCCGCAGGGATT
Exon 9r cctgtggatttttGGCCCACGAGTGGAGATGC
Exon 10f ccactcgtgggccAAAAATCCACAGGTGATTCTGATGCC
Exon 10r gagtggggtatctGCGGCAGCCCAGTCTCAG
Exon 11f actgggctgccgcAGATACCCCACTCCTGCCTTTCCA
Exon 11r aacatcctgtaaaccatgaccccacAGTAGCTGGGACTACAGGCG
Exon 12f GTGGGGTCATGGTTTACAG
Exon 12r tttaaacgggccctctagactcgagAAACTGCAGTGACTTAGGCC
3.5

RNA Isolation

Samples were derived from short-postmortem interval (PMI) autopsies. All methods
conformed with a University of Kentucky IRB protocol. Premortem clinical evaluations
and pathological assessments were as described previously (90). The inclusion criteria that
were applied: PMI <4hrs; no evidence of frontotemporal dementia; no cancer in the brain
parenchyma; and no large infarctions in the brain, or microinfarcts found within 3cm of
the brain tissue samples. We also obtained information on agonal events for each subject,
and additional criteria for exclusion from the study were an extended interval of premortem
hypoxia, any medical ventilator use, brain edema, or large infarct. The characterization of
the samples is shown in Supplemental Figure 3.1. The RNA isolation was performed using
Trizol and the PureLink RNA mini kit from Ambion (Life Technologies).
3.6

Cell Fractionation

Cells were harvested through trypsination, washed once with PBS and then
resuspendend in Buffer A (10mM HEPES, pH 7.9; 1.5mM MgCl2, 10mM KCl, 0.5mM
DTT) and incubated on ice for 10 min. After swelling in buffer A, cells were ruptured in a
0.5 ml Dounce homogenizer using 10 strokes of the tight pestle “B”. Cytosol was recovered
by centrifugation at 2000g for 10 min. Nuclei were resuspended in Buffer S1 (0.25M
sucrose, 10mM MgCl2) and layered over 4 ml of Buffer S2 (0.35M sucrose, 10mM
MgCl2). Nuclei were recovered through 20 min of centrifugation at 3500g.
3.7

Transfection Assays

Transfection assays were performed as described (91). Briefly, DNA was incubated
with PEI (Polyethyleneimine, 1 mg/ml, (Sigma), final concentration 3 μg/μg PEI/DNA, per
300,000 cells) for 10 min and then added to HEK293 cells that were 60% confluent in sixwell plates. A GFP construct was added to visualize transfection efficiency (> 80%). The
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RNA was isolated after 24 h using the PureLink RNA Mini Kit (Ambion, Life
Technologies).
3.8

Reverse Transcription Polymerase Chain Reaction

RT-PCR was performed as described (92) using an H– MMLV reverse transcriptase
(100 U per reaction, Invitrogen) 500 μM, dNTPs, 0.5–1 μg RNA, 500 nM gene-specific
primers. PCR was performed using Platinum Taq Polymerase (Invitrogen) (200 μM
dNTPs, 500 nM primer). PCR was performed on a Mastercycler Nexus2 (Eppendorf).
Denaturation was at 94° for 30 s, extension at 68° for 30 s. Annealing temperatures and
cycles used were: 46°, 20Å~, (SNORD2), 55°, 20Å~ (HIPK3), 55°, 30Å~ (linear tau).
Circular tau was amplified using touchdown, starting at 65° lowered per cycle by 0.5° to
58° (14 cycles), followed by 16 cycles at 58°.
3.9

RNase Protection

RNase protection was performed as described (93) using the RPAIII kit
(Ambion/Invitrogen) and one million cpm of a 32P uniformly labeled probe. Hybridization
was overnight, the digestion used RNaseA and T1 for one hour.
3.10 Results
3.11 Tau generates circular RNAs through exon 12 backsplicing
No human circular MAPT RNAs have been reported in databases. Given the extensive
alternative pre-mRNA processing of the human tau gene (Figure 3.1A), we used a PCR
approach to search for possible human circular MAPT RNAs. We concentrated on exon
10, since this exon is alternatively spliced and deregulated in both Alzheimer’s disease and
FTLD-MAPT (82, 83). To amplify circular RNAs, we used a reverse primer upstream of
the forward primer, i.e. a reverse primer in exon 10 and a forward primer in exon 1, which
amplifies circular, but not linear RNAs (Figure 3.1A, C). To further enrich for circular
RNAs, we digested the RNA with RNase R, a bacterial RNA exonuclease that removes
linear RNAs (84)
As expected, RNAse R treatment removed the signal for linear MAPT, detected by
primers in exons 9 and 12 and RPL3 mRNA, but enriched the signal for circular RNAs
(Figure 3.1B). The bands from RNAse R treated RNA generated by the circular RNA
primers were subcloned and sequenced. Two of the bands corresponded to circular RNAs
made from exon12 back splicing, either to exon 10 or 7 (Figure 3.1C). The exon sequences
present in the linear MAPT mRNA were completely present in the circular RNAs,
indicating usage of the linear splice sites. Both circRNAs were divisible by 3 (288, and 681
nt, respectively) and circ12à7 contained an in-frame AUG start codon. No AUG start
codon was present in circ12à10 (Figure 3.1D, E). The other bands contained noncanonical splice sites and thus their mechanism of generation is unclear, and they could be
PCR artifacts.
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3.12 A minigene spanning exons 9 to 12 generates circ12à10
We concentrated on circ12à10, as it was the most abundant RNA. To determine the
sequences necessary for its formation, we created a minigene consisting of exons 9, 10, 11
and 12, each flanked by 1-2 kb of intronic sequence (Figure 3.2A). This minigene was
transfected into HEK293 cells and circular RNAs were detected using PCR exon junction
primers selective for the 12à10 backsplice, consisting of 10à12 reverse primer and a
forward primer in exon 10 (Figure 3.2B). In addition, I amplified linear RNA, using
primers in exons 9 and 12 (Figure 3.1A). The minigene contained the repetitive elements
surrounding exon 12 and an intronic repetitive element upstream of exon 9. After minigene
transfection, I could detect both the exon 9 to 12 linear RNA containing the alternative
exon 10, as well as the circ12à10 backsplice RNA (Figure 3.2C). Next, we tested the
expression of circRNAs using a different method. We choose RNase protection analysis
that has a linear readout but is less sensitive than RT-PCR. Using a uniformly radioactively
labeled probe exhibiting sequence complementarity towards the exon12à10 backsplice
junction (Figure 3.2B, D), we could detect a faint signal in RNA from transfected HEK293
cells, which was enriched by RNAse R treatment (Figure 3.2E). In addition, the probe
detected parts of exon 10 and 12, which derived from linear RNA indicating that RNAse
R treatment does not remove all linear RNAs. A signal of the same length could also be
detected from 50 µg of total human cortex RNA. The circular RNA signal was less than
1% of the linear RNA signal in transfected cells, indicating that despite our ability to detect
circ12à10 using RT-PCR, this RNA is very weakly expressed (Figure 3.2E). Since our
minigene can produce circular RNA, we conclude that all cis-acting sequence elements to
generate the tau circ12->10 RNA are present in exons 9 to 12 and their immediate intronic
vicinity.
3.13 Tau circ12à10 is regulated by clk2 and sensitive to mutations in exon 10
Tau circ12->10 contains exon 10, which is alternatively spliced in linear MAPT.
Several exonic mutations causing FTLD/FTD have been identified that change exon 10
usage (79). In addition, exon 10 is regulated by several trans-acting factors, most notable
tra2-beta1/TRA2B(85), promoting its inclusion as well as the cdc2-like kinase CLK2 (82,
85), the SR-protein SRSF7/9G8, protein phosphatase 1 (PP1) and its nuclear inhibiter
NIPP1 promoting exon 10 skipping (94-96).
To test a possible regulation, I transfected the tau 9-12 minigene with plasmids
expressing EGFP, CLK2, the inactive CLK2 variant CLK2KR, tra2-beta1, DYRK, 9G8,
SRPK1, NIPP1 and PP1. The SR-protein kinase SRPK1 (97), was tested as it
phosphorylates tra2-beta1. To investigate the effect of an FTLD/FTD mutation on the
formation of the circular RNA, we introduced the N279K mutation promoting exon 10
inclusion into the minigene (79).
First, I tested the effect of the trans-acting factors in MAPT linear RNA using PCR
primers in exon 9 and 12. CLK2, 9G8, NIPP1 and PP1 caused exon 10 skipping, as
expected from previous data using exon 9-12 reporter genes (Figure 3.3A). This
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experiment was repeated with a minigene harboring the N279K mutation. This exon 10
mutation (ATAA to AGAA) creates a stronger tra2-beta1 binding site, as tra2-beta1 binds
to NGAA sequences (98). The generation of this tra2-beta1 binding site promotes inclusion
of exon 10, by promoting the formation of tra2-beta1 dependent splicing enhancer
complexes. Importantly, the N279K mutation causes FTLD/FTD (79). Testing the transacting factors on this minigene revealed that the effect on exon 10 skipping was strongly
reduced for CLK2, 9G8, NIPP1 and PP1.
RNA from these experiments was next tested for the expression of the tau12à10
circRNA. CLK2 and 9G8, NIPP1 and PP1 strongly reduced the expression of this
circRNA. A similar effect was observed when I used the N279K minigene. The transacting factors had no detectable effect on the HIPK3 circular RNA (Figure 3.3C), and I
thus quantified our data by calculating the ratio between circtau12à10 and circHIPK3.
The analysis of three independent experiments showed a statistically significant reduction
of circtau12->10 caused by 9G8, NIPP1 and PP1 in both minigenes and by CLK2 in the
wild-type minigene context (Figure 3.3D).
Finally, I investigated possible synergistic effects between the SR-proteins and their
kinases and cotransfected CLK2 and SRPK1 together with tra2-beta1and 9G8 expression
clones. SRPK1 slightly increased the effect of tra2-beta1 and 9G8 on tau 12à10 circRNA
formation in the wild-type exon 10 context and had no detectable effect on the N279K
mutations. In contrast, clk2 reduced the effect of tra2-beta1 in both wild-type and N279K
background, whereas it had no effect on 9G8 (Figure 3.3E).
The data indicate that the abundance of circtau12à10 RNA can be regulated by the
cell through trans-acting factor expression, whose actions is in turn regulated through their
kinases. In addition, an FTLD/FTD mutation that promotes exon 10 inclusion also
influences tau circ12à10 RNA formation.
3.14 Tau circ12à10 RNA is predominantly localized in the cytosol
I detected tau12->10 circRNA in the human neuroblastoma cell line SH-SY5Y and
identified the endogenous RNA’s cellular localization. I employed cell fractionation using
different lysis of plasma and nuclear membranes followed by RT-PCR. The tau circ12->10
RNA was exclusively localized in the cytosol (Figure 3.4), similar to other circRNAs
analyzed (9). circHIPK3 RNA showed a similar cytosolic localization, whereas the C/D
box snoRNA SNORD2 was exclusively nuclear.
3.15 No significant correlation between circ12à10 expression and Braak stages
Tau exon 10 and Clk2 splicing is deregulated in temporal cortex in sporadic
Alzheimer’s disease (82, 85). I therefore tested brain samples from 15 subjects for a
correlation between tau circ10à12 circRNA and Braak stages (Supplemental Data 3.1,
Figure 3.5A-C). RNA from the gray matter of Superior and middle temporal gyri was used.
The amount of tau circ12à10 was normalized to circular HIPK3. Although I found
expression of tau circ 12à10 in all subjects, there was no statistically significant
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correlation with Braak stages, when the circ12à10 RNA was normalized to circHIPK3
RNA (Figure 3.5D). For the statistical analysis, only RNAs from samples with RIN
numbers larger than seven were used. In addition, we tested these samples for expression
of the kinase clk2 using primers spanning its alternative exon 4. Skipping of this exon
generates an inactive kinase isoform (99). Again, there was no correlation between the
amount of full-length clk2 and tau12à10 circRNA (Supplemental Figure 3.2).
3.16 Discussion
3.17 MAPT as a contributor to human disease
The MAPT gene and its polypeptide products are acutely relevant to human diseases.
A deregulation of MAPT is involved in Alzheimer’s Disease, Chronic Traumatic
Encephalopathy, Frontotemporal Lobar Degeneration-tau, and many other 'tauopathies'
(2).
3.18 Circular RNAs from the MAPT locus could be species specific
Here we present evidence that the human MAPT locus generates circular RNAs
through backsplicing from exon 12 to either exon 10 or 7. Our data show that the regulation
of MAPT gene expression and its molecular biology are still incompletely understood,
despite numerous studies focusing on alternative splicing of MAPT (100).
We concentrated on circ12à10, as it is the most predominant circular RNA.
Currently, human circular tau RNAs have not been reported in database. For mouse, a
backsplice from exon six to four has been identified (101, 102). We could not amplify the
human orthologue for this mouse circ6à4 RNA, nor could we identify mouse orthologues
for our described 12à10 and 12à7 circRNAs. It is thus possible that MAPT generates
species-specific circRNAs, similar to exon 10 usage that is alternatively spliced in adult
humans, whereas it is constitutively used in adult mouse (100).
CircRNA formation through backsplicing is facilitated by repetitive elements that
form regions of complementarity in the pre-mRNA, allowing to position exons for
backsplicing (9). Human MAPT contains at least 83 Alu elements, 56 on the sense strand
and 27 on the antisense strand (103). Since Alu elements are primate-specific, they could
cause a difference in circular RNA formation between mouse and humans.
We generated a minigene consisting of exons 9 to 12 with about 2 kb flanking intron
each. I found that this construct forms circtau12à10 RNA when transfected into HEK293
cells, indicating that these regions are sufficient to generate the circular RNA. Importantly,
in this construct, exon 10 is not surrounded by repetitive elements, suggesting that fardistance interaction, for example between repeats near exon 12 and 9 present in our
minigene could form the basis for circRNA formation.
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3.19 Possible functions of tau circRNAs
To gain insight into the possible function of tau circ12à10, I first determined its
cellular localization in human SH-SY5Y neuroblastoma cells. Similar to other circular
RNAs (9), tau circ 12à10 is almost exclusively cytosolic. Inspection of the sequence of
tau circ 12à10 and circtau12à7 showed that both RNAs contain a number of nucleotides
divisible by three. Tau circ12à10 contains a reading frame without a stop or start codon.
This reading frame is identical to a portion of the tau protein containing the microtubule
binding site encoded by exon 10. Despite the absence of an AUG codon, it is conceptually
possible that translation could occur, for example one of the two in frame AUA triplets
could be edited by ADAR1 or 2 to AUI, where the inosine (I) is read as a G by the initiator
tRNA, leading to protein synthesis. Further, repeat-associated non-ATG (RAN) translation
(104) from CAGs that are also present in tau circ 12à10 are possible and finally a
translation of the RNA could theoretically occur in mitochondria, that recognize AUA start
codons (105). Initiation at any of these non-AUG start codons could generate a tau protein
fragment containing a microtubule binding site. Since the circtau12à10 RNA is divisible
by three, it could be translated through a rolling circle mechanism that has been shown for
model circular RNAs (106, 107). A similar translational mechanism is possible for tau
circ12à7 that contains an in frame start codon, but no stop codon. However, both circular
Tau transcripts are very weakly expressed. Thus, their translation will be a rare event. If
translation occurs, the expected product would be a high molecular weight tau multimer
containing several microtubule binding sites.
3.20 Relation to disease
The alternative splicing regulation of tau exon 10 has been extensively studied, due
to exon 10’s involvement in human disease. Mutations that interfere with the inclusion
ratio of tau exon 10 cause frontotemporal dementia (79) and exon 10 usage as well as CLK2
splicing isoforms are changed in Alzheimer’s disease (82). We thus tested the expression
of circtau12->10 in AD brains of various Braak stages, using gray matter of the superior
and middle temporal gyrus (SMTG), but did not find a statistically significant correlation
between tau circ12->10 expression, normalized to circHIPK3. However, the translation of
circular RNAs depends on the creation of an internal ribosomal entry site likely caused by
RNA methylation (108) and thus the biological effect of the tau circRNAs might be
correlated with modifications and not abundance. In addition, our sample number was low
and we thus cannot rule out a connection with AD.
In a minigene, we re-created one FTDP-17 mutation that strengthens exon 10 usage
and found that it generates an amount of tau circ12->10 RNA similar to the wild-type in
transfection assays, indication that mutations causing frontotemporal dementia can also
form circular tau RNAs.
In summary, our data show that the MAPT locus can generate circRNAs that could
play a role in neurodegenerative diseases, which warrants further investigation.
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Figure 3-1The human MAPT gene generates circular RNAs through exon 12
backsplicing

A. Schematic structure of the human MAPT gene
Constitutive exons are in white, alternative exons are colored. Splicing patterns are
indicated by lines. The two transcriptional start sites in exons 0 and 1 are indicated by
arrows. The numbering of exons is from (100). The arrows in exons 9 and 11 indicate the
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position of primers to amplify linear MAPT mRNA, arrows in exons 10 and 11 indicate
primers to detect circular RNAs. The arrowheads indicate the 3’ ends.
B. Circular RNAs generated through backsplicing of exon 12
10 µg of total human hippocampus RNA was amplified with primers pointing outwards in
exon 10 and 11. Prior to RT-PCR, an equal part of the RNA was digested with RNase R.
The negative control was performed without reverse transcription. The PCR-products were
gel purified, subcloned and sequenced. Two bands indicated by arrows were circular RNAs
generated through backsplicing of exon 12. The other bands were PCR artifacts, i.e.
amplicons from different gene regions. *This figure was produced by Jay van Doorn.
C. Structure of the RNAs generated through exon 12 backsplicing.
D. Sequence and predicted ORFs for circ12->10 The RNA part corresponding to exon 10
is underlined, exon 11 is in regular letters and exon 12 is underlined and italic.
E. Sequence and predicted ORFs for circ12->7. Exon 7 is bold, exon 9 italic, exon 10 is
underlined, exon 11 is in regular letters and exon 12 is underlined and italic. The in frame
AUG is shown in bold.
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Figure 3-2 A minigene containing exons 9-12 generates circ12à10

A. Structure of the minigene. Exons are indicated as vertical boxes, horizontal gray boxes
indicate the genomic regions used for cloning the minigene. Blue boxes indicate repetitive
elements defined by the UCSC genome browser repeat masker. The yellow box with an
‘S’ depicts the intronless Saitohin reading frame. The drawing is to scale, as indicated.
B. Detection of circ12->10. The orientation of the circular RNA is clockwise 5’->3’. The
location of the detection primer for10_11 and rev12_10 is indicated. The probe used for
RPA is shown as a bold line.
C. Detection of RNAs made from the exon 9-12 minigene. 1 µg of the minigene was
transfected into HEK293 cells and after 24 hrs, RNAs were detected by RT-PCR. The
negative control is untransfected HEK293 cells, using circRNA primers.
D. RNase protection probe to detect circ12->10 RNA. The T7 antisense RNA is shown
with the nucleotide lengths indicated.
E. RNAse protection using RNA from transfected cells as well as human cortex. 50 µg
total RNA was used, which was digested with RNaseR, as indicated. *Dr. Stefan Stamm
produced this figure.
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Figure 3-3 The abundance of exon 10 containing circ RNA is regulated by the kinase
clk2

One µg of the tau exon 9-12 minigene was transfected into HEK293 cells together with 1
µg of the plasmids expressing the trans-acting factors indicated.
A. Linear RNA was amplified using primers in exon 9 and 12
B. Circular RNA was amplified using primers rev12-10 and forward_exon 10.
C. The circular HIPK3 RNA was amplified as a loading control
D. Quantification of the circtau to circHIPK3 ratio
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E. Quantification of a cotransfection of the SR-proteins tra2-beta1 and 9G8 in the presence
of their kinases CLK2 and SRPK1. 500 ng of each expressing vectors were cotransfected
and three independent experiments were analyzed.
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Figure 3-4 Tau circ12à10 is cytosolic.

SH-SY5Y cells were separated into cytosol and nucleus and RNA isolated from each
fraction.
A. Detection of circ12à10
B. Detection of SNORD2, a C/D box snoRNA with nuclear localization
C. Detection of circHIPK3, a circular RNA known to be cytosolic.
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Figure 3-5 The ratio between tau circ12à10 and circHIPK3 differs between
individuals

Temporal cortex from 14 patients with Braak stages 0 to 6 were analyzed by RT-PCR
amplifying (A) cricTau12->10 and (B) the abundant circHIPK3 RNA, as well as (C) linear
RPL3 mRNA. (D) shows the quantification of tau circ12->10 normalized to HIPK3. There
are no statistically significant changes between the Braak stages. (E) Summary of tau
circ12à10 abundance in Braak stages 1 and 2, compared with Braak stages 5 and 6. Red
lines indicate the averages.
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Supplemental Figure 3-1 Clinical Specimens used.

RIN: RNA integrity number
PMI: postmortem interval
Specimens were received by Dr. Peter Nelson from the Sanders Brown Center of Aging,
University of Kentucky Brain Bank.
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Supplemental Figure 3-2 CLK2 splicing abundance

Amplification of RNA using primers in exons 3 and 5 of clk2. The primers amplify two
alternative splice variants, a full-length form containing exon 4 encoding an active kinase,
and a truncated form, lacking exon 4. There was no statistically significant correlation
between exon 4 usage or total full-length clk2 abundance with tau circ12 → 10. *This
Figure was produced by Jay van Doorn.
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CHAPTER 4. MOLECULAR AND BIOLOGICAL APPROACH TO ANALYZE
CIRCULAR RNAS
With permission from JoVE and the Authors this chapter is adapted from:
Welden, J. R., Pawluchin, A., van Doorn, J., Stamm, S. Use of Alu Element
Containing Minigenes to Analyze Circular RNAs. J. Vis. Exp. (157), e59760,
doi:10.3791/59760 (2020)." (5)
4.1

Summary

This chapter describes a method to clone and analyze reporter genes generating
circular RNAs. These reporter genes are larger than constructs to analyze linear splicing
and contain Alu elements, which is challenging for cloning. To investigate the circular
RNAs, the constructs are transfected into cells and resulting RNA is analyzed using RTPCR after removal of linear RNA.
4.2

Introduction

4.3

Circular RNAs

Circular RNAs (circRNAs) are covalently closed single stranded RNAs that are
expressed in most organisms. They are generated by joining a downstream 5’ splice site to
an upstream 3’ splice site, which is called back-splicing (Figure 4A) (9). Sequences in the
pre-mRNA that exhibit base complementary as short as 30-40 nt bring back-splice sites
into proper alignment for circRNA formation (33). In humans, Alu elements (9),
representing about 11 % of the genome (57), form extensive double stranded RNA
structures in pre-mRNA due to their self-complementarity (64, 109) and thus promote the
formation of circRNAs (9).
Currently, three major functions of circRNAs have been described. Some circRNAs
bind microRNAs (miRNAs) and through sequestration act like miRNA sponges (19).
CircRNAs have been implicated in transcriptional and post transcriptional regulation,
through competition with linear splicing (110) or modulation of transcription factor activity
(89). Finally, circRNAs contain short open reading frames and proof of principle studies
show that they can be translated (22, 111). However, the function of most circRNAs
remains enigmatic. The majority of circular RNAs have been detected using nextgeneration sequencing methods (112). Detailed analyses of individual genes using targeted
RT-PCR approaches reveal that a large number of circular RNAs remains to be discovered
(44).
4.4

Use of reporter genes to analyze pre-mRNA processing

The analysis of mRNA derived from DNA reporter constructs transfected into cells
is a well-established method to study alternative pre-mRNA splicing, which can be applied
to circular RNAs. In general, the alternative exon and its surrounding introns and
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constitutive exons are amplified and cloned into a eukaryotic expression vector.
Frequently, the introns are shortened. The constructs are transfected into eukaryotic cells
and usually analyzed by RT-PCR (113, 114). This approach has been extensively used to
map regulatory splicing sites and trans-acting factors in co-transfection experiments
[reviewed in (113, 115-118)]. In addition, the generation of protein-expressing minigenes
allowed for screening of substances that change alternative splicing (119, 120).
The method has been applied to circular RNAs. Currently, at least 12 minigenes
backbones have been described in the literature and are summarized in Table 1. With the
exception of tRNA based expression system (121, 122), they are all dependent on
polymerase II promoters. Here, we describe a method to generate human reporter
minigenes to determine cis and trans-acting factors involved in the generation of circular
RNAs. An overview of the method using sequences of a published reporter gene (1) is
shown in (Figure 4.1).
4.5

Protocol

4.6

Design of the constructs

Use the UCSC genome browser (123) to identify repetitive elements necessary for
circular RNA formation and incorporate them in the constructs. Importantly, primers for
amplification need to be outside the repetitive elements.
Paste your circular RNA sequence (Supplemental Figure 4.1 is a test sequence) into
https://genome.ucsc.edu/cgi-bin/hgBlat?command=start and make sure you select the right
organism. Submit the sequence and go to browser view, zoom out 1.5-fold or as appropriate
(Figure 4.2A). The search sequence appears in the top line (Figure 4.2A, 1). Depending on
the order of the exons in the circular RNA, BLAT will not connect all the exons. In this
example, exon 12 (Figure 4.2A, 4) is not connected to 11 (Figure 4.2A, 2, 3), because exon
12 is upstream of exon 11 in the circular RNA sequence (Supplemental Figure 4.1). The
repetitive elements are in the ‘repeat masker’ track, indicated by boxes, where black to gray
color indicates the evolutionary conservation (Figure 4.2A, 5).
Mouse over the repetitive elements to identify their subtype in a floating window.
Alu elements are in the SINE (short interspersed nuclear element) line. Use the ‘default
tracks’ button under the window to reset your browser if you obtain a different picture than
Figure 4.2.
Mousing over the exons in the gene display generates a window with exon numbers
that are computer generated. These numbers do not correspond to the exon numbering
established in the literature and also change between isoforms.
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4.7

Select the sequence to be cloned in an expression vector

Download the DNA sequence shown in the window by going to view → DNA in the
top line of the UCSC genome browser. In the ‘sequencing formatting option’ select
‘extended case/color options’.
Select default case: lower and select toggle case for ‘NCBI refseq’. Select
underline, and bold, and italic for ‘repeat masker’. Click submit, you will see the exons as
capital letters and introns as small letters. Check the exon/intron borders.
In this example there is a ‘ccctttacCTTTTT’ sequence, indicating that the browser
shows the reverse complement. If this is the case, go back and select the reverse
complement box until you see the correct exon intron borders (agEXONgt), in this example
AAAAAGgtaaaggg.
Copy the file with the correct orientation (internal exons are surrounded by intronic
ag…gt) into a word processing document and highlight the exons (Supplemental Figure
4.2).
In this example, the genomic fragment encompassing exons 9-12 is around 24 kb and
thus too large to be amplified from genomic DNA. Therefore, each exon surrounded by
about 1 kb intronic region is individually amplified and these four fragments assembled in
a cloning vector. Select fragments to be amplified (exon +/- 500 nt intron). Make sure that
the intron does not begin or end in a repetitive region, as primers in these regions will not
amplify specific sequences. The selected regions are shown in Figure 4.2B, their sequences
are shown in Supplemental Figure 4.3.
Note: In general, the larger the constructs, the more difficult the cloning will be. The
fragments can be assembled either step wise, i.e. exon 9 is combined with the vector and
in the next step exon 10 is introduced into this construct via cloning until all exons are in
place, or alternatively, all fragments are assembled simultaneously. A step-wise approach
always works, but requires more time. A simultaneous assembly does not always work and
depends how well the individual fragments can be amplified from genomic DNA and on
the overall size of the construct. We therefore usually start with both approaches
simultaneously.
4.8

Design primers for cloning

Use a web tool (https://nebuilder.neb.com/#!/) to design the primers for cloning. For
example, enter fragments 9, 10, 11 and 12 and the vector sequence (Supplemental Figure
4.3) to this tool.
For the vector sequence, the insertion site is added as the last nucleotide and
subsequently the fragments are added. Since the vector numbering does not start with a
given insertion site, the site of insertion in the vector is located and the downstream part is
put in in front of the upstream sequence. In this example the inserts start directly after the
HindIII [AAGCTT] site and ends directly after the PmeI [GTTTAAAC] site of pcDNA3.1.
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The sequence from cccgctgatcag….. until ccgtaaaaaggccgc is pasted before position 1 in
the pcDNA3.1 sequence (gttgctggcgtttttcc….).
Adjust primers if their melting points are more than 4 ºC apart and do not work in
amplification. The assembly of the fragments and primer sequences designed are shown in
Supplemental Figure 4.4. Primers for cloning can also be designed manually ((124)).
4.9

PCR and amplicon detection

Standard PCR Reaction: Make a reaction mix for total volume of 50 µL per reaction, below
is for one reaction using polymerase 1
10 µL 5X Reaction Buffer; 1 µL 10 mM dNTPs; 2.5 µL 10 µM Forward Primer; 2.5 µL
10 µM Reverse Primer; 0.5 µL Polymerase 1; *Optional 10 µL 5X GC Enhancer if product
has high GC content, you can make a separate mix containing GC Enhancer to test PCR
reaction; 32.5 µL Nuclease free H2O
Aliquot 49 µL of the mix into PCR tubes per reaction sample
Add 1 µL DNA to the PCR, the amount ranges from 10 pg to 1 ng.
Spin down the samples to remove residue off the sides and place them in a PCR machine;
It is important to use the same machine, as well as, same spots in the machine when
optimizing the PCR conditions.
4.10 Optimization for longer DNA fragments for use of different polymerases
4.11 Temperature
Long range Polymerase 2, are optimized as follows:
Lower denaturation temperature (Polymerase 1: 98 ºC, Polymerase 2: 94 ºC)
Longer denaturation time (Polymerase 1: 10 s, Polymerase 2: 30 s)
Longer annealing time (Polymerase 1: 30 s, Polymerase 2: 60 s)
Longer extension time (Polymerase 1: 30 s/kb, Polymerase 2: 50 s/kb)
Lower extension temperature (Polymerase 1: 72 ºC, Polymerase 2: 65 ºC)
Annealing temperature 5 ºC below Tm of the primers
Optimize primer concentrations (five times less to five times more than the original primer
concentration)
DNA concentrations were optimized from 10 pg to 50 pg, 100 pg, 1 ng, 5 ng, 10 ng
Example of a PCR program to amplify a 15 kb product size using Polymerase 2
Initial denaturation at 94 ºC for 30 s,
DNA is denatured at 94 ºC for 30 s followed by annealing at 58 ºC for 30 s (Ta specific for
our primers determined by web-based temperature calculations that are specific for each
polymerase) and extended at 65 ºC for 12 min 30 s *Extension times may vary and need to
be optimized if fragments are larger than 10 kb.
Final Extension was at 65 ºC for 10 min with a final 4 ºC hold.
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4.12 Extension times and DNA concentrations
Longer extension times for DNA fragments over 6 kb should be 1 min / 1 kb Longer
fragments should use less DNA. Do dilutions of DNA to find optimum DNA concentration
for amplification, usually 1 pg to 1 ng for plasmids or 1 ng to 1 µg for genomic DNA.
Note: For most cloning use polymerase 1, engineered by fusing the Sso7d DNA
binding domain to a proprietary thermostable DNA polymerase(125). The polymerase has
a low error rate and due to the Sso7d domain a high processivity, needed to amplify large
(10-15 kb) genomic fragments. Due to this large fragment size, enzymatic assembly of
DNA molecules (126) is used for insertion into vectors, as this method does not require
restriction enzymes. The amplification of fragments longer than 15 kb gets increasingly
difficult with Q5 polymerase. For large fragment amplification use polymerase 2 made
from pyrococcus-like proofreading polymerase fused to Sso7d or the Long range PCR kit
that gives, however, higher error rates.
4.13 Purification of PCR products and cloning
Run ½ of the PCR products on 1% agarose gels containing 1x Gel green. Gel-green
intercalates into DNA, similar to ethidium bromide, but it is excited by light around 500
nm (cyan), a wavelength that does not damage DNA, which highly improves cloning. The
visualization of gel green stained gels is on a Dark Reader Transilluminator.
In parallel run ½ of the PCR products on a 1% gel that is stained post-run with
ethidium bromide as Gel green stained DNA does not run true to size. (Figure 4.3A, B).
Excise bands of the right size from the Gel-green stained gel and isolate DNA using
a gel and PCR cleanup kit. In deviation from its standard protocol, the DNA is eluted in
only 20 µL of double distilled water, as usually the DNA concentrations are low.
Prior to cloning, the isolated DNA is checked on an agarose gel for concentration and
integrity (Figure 4B). Aim for a 2:1 molar insert to vector ratio. When using several inserts,
the ratio is 2:2:2:1.
4.14 DNA assembly and clone detection
Cloning is done using a enzymatic DNA assembly kit, with minor modifications. The
assembly is performed for 60 min at 50 ºC and generally the lower range of DNA is used
for assembly (20-100 fmol/20 µL reaction). The whole reaction mix is added to chemical
competent cells and the whole cells plated out on a 6 cm agar plate.
Combine the vector and insert in a 1:2 molar ratio (20-500 fmol each) in 10 µL of water.
Add 10 µL DNA Assembly Master Mix.
Samples are then incubated for 60 minutes at 50 ºC.
Next, transform competent cells with the total assembly reaction. Here, E.coli strain 1 cells
are used for shorter constructs or E. coli strain 2 cells for longer or unstable constructs.
Cells should be in 50 µL volume.
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Thaw cells on ice and add 2 µL of the chilled assembled product to the competent cells.
Mix by gently flicking tube 4-5 times. Do not Vortex.
Let mixture sit on ice for 30 min.
Heat shock at 42 ºC for 30 s. Do not mix.
Transfer tube back on ice for 2 min.
Add 950 µL of room-temperature SOC Media to the tube.
Incubate the reaction tube at 37 ºC for 60 min. Shake vigorously (300 rpm)
Warm selection plates with the appropriate antibiotic during incubation at 37 ºC.
Pellet the cells through centrifugation (10,000 g, 30 seconds) and plate out on ¼ and ¾ of
cells two selection plates and incubate at 37 ºC overnight.
4.15 Validation of clones
Use colony PCR, employing PCR primers spanning the assembly sites (Figure 4.1C) for
detection.
Take a sterile toothpick and touch a single bacterial colony.
Touch the bottom of a PCR tube with the toothpick that has the colony and then streak the
toothpick on an antibiotic agar plate, incubate the streaked plate at 37 ºC or room
temperature for sensitive constructs overnight.
Overlay the PCR tube touched with the colony with a PCR mix containing the detection
primers. These are designed using primer 3 (http://bioinfo.ut.ee/primer3-0.4.0/). The
program has the option to force primer design across a defined sequence using the “[ccc]”
signs to select primers across the assembly junction. DNA from positive strains is isolated
and verified by sequencing.
4.16 Analysis of circular RNA expressing reporter genes
For analysis, reporter genes are transfected into eukaryotic cells. Here, routinely
HEK293 cells (ATTC #CRL-1573) are used as they give high transfection efficiency. To
save costs, lipofectamine is substituted with PEI (Polyethyleneimine) solutions.
PEI solution: Dissolve Linear Polyethyleneimine Max (PEI) (Polysciences, 24765-1) at 1
mg/mL in water at low pH, pH 2, bringing pH up to 7 with NaOH. Sterile filter with 0.22
µm filters and store at 4 ºC.
Split cells into six wells (approximately 150,000 cells per well) and let them grow over
night in 10% FBS in DMEM media (Sigma, D5796);
Aliquot 1 µg of reporter gene in a sterile tube and add 200 µL of sterile filtered 150 mM
NaCl, mix with the DNA by vortexing;
Add PEI solution to this mix and vortex, briefly centrifuge to collect samples at bottom of
tube. Use a ratio of 1 µg DNA/3 µL PEI;
Incubate at room temperature for 10 min and then add directly to HEK 293 cells;
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Incubate HEK293 cells at 37 ºC, 5% CO2, overnight;
RNA is then isolated for RT-PCR via an RNA isolation kit.
4.17 RNase R treatment to remove linear RNAs
Use 10 µg of total RNA in an RNase-free tube
Add 10 µL 10x RNase R buffer to RNA (0.2 M Tris-HCl (pH 8.0), 1 M KCl, 1 mM
MgCl2);
Add RNase R to RNA;
Add 1 µL glycol blue to the RNA and bring volume up to 100 µL with sterile water.
Incubate samples at 37 ºC for 30 min
Add 100 µL phenol/ chloroform, vortex for 1 min;
Centrifuge at 21,000 g for 1 min to separate phases;
Take the supernatant (aqueous phase) and add 1 volume (around 80 µL Chloroform);
Vortex for 1 min, centrifuge for 1 min to separate phases;
Take supernatant, add 1/10 vol KAc, and 2.5 vol ethanol, precipitate at -20 ºC for 1-4 h,
centrifuge at 4 ºC for 30 min at full speed (21,000 g). There will be a small blue pellet at
the bottom;
Remove supernatant, wash with 80% ethanol, let air dry for 5 min at room temperature,
dissolve in 10 µL water.
4.18 RT-PCR analysis
Use 1 µg of RNA per RT reaction;
Make reaction mix for a final total volume of 20 µL per reaction, below is for one reaction;
1 µL 10 mM dNTPs;
1 µL 0.1 M Dithiothreitol (DTT);
4 µL 5X First-Strand Buffer;
0.5 µL Reverse Transcriptase
Aliquot 6.5 µL of reaction mix into new PCR tubes;
Mix up to 5 primers in one mix. However, it is important to note some primers may misspair with other primers in the PCR (Figure 4.5), Primer sequences are in Table 4.2. We
routinely use gene-specific exon-junction primers, but priming with random hexamers is
also possible.
Add 1 µL 10 µM Reverse primer to desired RT reaction tube;
Add 1 µg of RNA to PCR reaction tube;
37

Add RNase Free H2O up to a total volume of 20 µL;
Spin tubes down to remove residue on side of tubes and place in thermocycler;
Run the RT reaction in thermocycler at 50 ºC for 50 minutes;
Store RT cDNA at -20 °C or proceed to PCR reaction.
4.19 Results
Reporter genes allow determining regulatory factors that influence circular RNA
formation. However, these reporter genes are large and contain repetitive elements that
often make DNA constructs unstable. Due to their large size, it is often necessary to delete
parts of the introns, which is achieved by amplifying genomic pieces containing the exons
and smaller flanking intronic parts. These DNA pieces are enzymatically assembled,
allowing construction without restriction enzymes.
The example of a circular RNA generated from the microtubule associated protein tau
(MAPT) shows an application of the minigene approach to analyze circular RNAs. The tau
9→12 minigene used in this example was co-transfected with different splicing factors and
the effect of these splicing factors was detected by RT-PCR (Figure 4.6). Different transacting factors influence both circular RNA and linear pre-mRNA formation. The
experiment also shows that all the sequence elements necessary for circular RNA formation
are localized in the cloned fragment.
4.20 Discussion
In general, circular RNAs are low abundant (9), which complicates the study of their
function and formation. Similar to linear RNAs (113), the use of reporter minigenes allows
the identification of cis and trans-acting factors that regulate the formation of circular
RNAs. Thus, this approach generates hypotheses that can be further tested using the
endogenous genes.
The most critical step is the design of the reporter gene. The enzymatic assembly of
DNA fragments (“Gibson cloning (126)”) facilitates this design, as it allows construction
of large reporter genes independent of restriction sites.
The back-splicing sites are brought together through flanking inverted repeats, which
should be taken into account in reporter gene construction. The repeats are annotated in the
genome browser ‘repeat track’ and selecting them shows their orientation. It should be kept
in mind that proteins can also force the back-splicing sites into a secondary structure
needed for circular RNA expression (46) and for an unbiased analysis 1-2 kb of flanking
intronic regions should be investigated.
To ensure stability of the constructs, an important consideration is the type of bacterial
strains and their growth conditions. For shorter, simple constructs standard cloning bacteria
are used, which are almost identical to DH5-alpha (huA2 Δ(argF-lacZ)U169 phoA glnV44
Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17). For longer fragments,
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containing more than 6 Alu elements, “stable” competent cells are used that lack a
recombinase (recA) and endonuclease (endA1) (F' proA+B+ lacIq ∆(lacZ)M15
zzf::Tn10 (TetR) ∆(ara-leu) 7697 araD139 fhuA ∆lacX74 galK16 galE15
e14- Φ80dlacZ∆M15 recA1 relA1 endA1 nupG rpsL (StrR) rph spoT1 ∆(mrr-hsdRMSmcrBC). If problems appear with recombination, indicated by low transformation counts,
plate the transformed bacteria on two plates and let them grow at 30 and 37 ºC, respectively.
Due to the presence of numerous repetitive elements in the minigenes, they need to be fully
sequenced using next generation sequencing, which is commercially available for around
$150 per plasmid at 2019 rates. The sequence of the example is shown in Supplemental
Figure 4.5. In addition, restriction fragment length polymorphism analysis for new larger
preparation of the constructs is routinely performed. For example, using sites that cut 1-4
times results in a characteristic band pattern that rules out recombination (Figure 4.4).
Enzymes should be selected that give a characteristic band pattern of fragments that can be
separated on an agarose gel.
Circular RNAs are analyzed with RT-PCR using exon junction primers that overlap
with the backsplicing event (Figure 4.1F). Due to the circular nature of the RNA, the
reverse (i.e. antisense) primer is upstream of the forward (i.e. sense) primer (Figure 4.1G).
Primers detecting the abundantly expressed homeodomain-interacting protein kinase 3
(HIPK3) circular RNA (9) are used as a positive control. HIPK3 and minigene specific
reverse primers are reverse transcribed in the same tube, which allows their comparison.
PCR reactions are performed with primers amplifying the linear mRNAs to compare
processing patterns of circular and linear pre-mRNAs. We frequently observed aberrant
bands when primers for linear and circular RNAs were mixed (Figure 4.5), and thus keep
the reverse transcription of these samples separate.
RT-PCR analysis of circular RNAs is challenging and need to be carefully controlled.
While sensitive and convenient, it can produce artifacts unique for circular RNAs (17). The
reverse transcriptase can move several times around the RNA circle, which generates
concatemers. Most circular RNA reporter genes generate both circular and linear RNA,
which can cross-hybridize, leading to more PCR artifacts (42, 69, 121). It is thus imperative
to sequence the PCR products and validate findings using different techniques using
Northern blots (40) or RNase protections (1).
Unexplained bands can also originate from aberrant amplification of linear RNA.
Linear RNA can be removed using the exonuclease RNaseR, which enriches circular
RNAs(84)(Figure 4.5C). RNaseR treatment helps in the initial optimization of detection
primers and can often be omitted once primers are optimized.
Alternative back-splicing can also contribute to unexplained bands as multiple circular
RNAs can be formed from a genomic locus (34). This alternative back-splicing is often the
result of competing pre-mRNA structures formed by more than two inverted repeat
elements. In addition cryptic back-splice sites can occur (40, 45). Depending on the
experimental goal, Alu-elements can be repeated or added to the constructs. The
complementary regions flanking back-splicing sites can be as short as 30-40 nt (45) and
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replacement of Alu elements with shorter complementary regions can increase circular
RNA formation (33), which can be tested to improve circular RNA formation. Once the
pre-mRNA sequences that cause back-splicing have been identified, it is thus possible to
shorten circular RNA expressing constructs, which can improve transfection efficiency in
some cases.
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Table 4-1 List of current minigenes expressing circular RNAs
MicrotubuleAssociated
Protein Tau

(1)

Circular RNA
with 1 Exon
(GFP)

(88)

circRNA from
LPAR1

(40)

Circular GFP

(127)

Circular HIPK3

(128)
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Table 4-1 Continued
epidermal
growth factor
receptor
(EGFR)

(129)

circular RNA
from tRNAs

(121,
122)

Laccase2
CircRNA

(130)

CircZNF609

(23)

Circular RNA
from POL2RA

(33, 34)
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Table 4-1 Continued
mCherry
circular RNA
with IRES

(131)

mCherry
Circular RNA

(132)
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Table 4-2 List of Primers
Circular HIPK3 Control Primers
HIPK3 Reverse

TGCTTGGCTCTACTTTGAGTTTC

HIPK3 Forward

TCGGCCAGTCATGTATCAAA
Linear Primers

Tau Exon 12 Reverse

CCCAATCTTCGACTGGACTC

Tau Exon 9 Forward

TGTCAAGTCCAAGATCGGCT
Circular Primers

circTau exon12_10 Reverse

CAGCTTCTTATTAATTATCTGCACCTTTT

circTau exon10-11 Forward

GAGGCGGCAGTGTGCAA

44

Table 4-3 Table of Materials
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Figure 4-1 Overview of the technique

A. A hypothetical gene is shown. Introns are lines, exons are boxes, Alu elements are
smaller striped boxes. Backsplicing from exon C to A creates a circular RNA. The structure
of this circular RNA is shown in panel E.
B. To create a reporter gene, exons and surrounding introns (at least 500 nt on each side)
are amplified. The constructs should contain repetitive elements, which are usually Alu
elements in humans. An exon upstream of exon A was included to provide an additional
Alu element. The genomic fragments will overlap with their flanking 25 nts.
C. Fragments are cloned into an expression vector, driven by a CMV promoter. The
successful recombination is detected by detection primers and validated by sequencing.
D. Cells are transfected with this construct and
E. circular RNA is isolated and
F. amplified using circular RNA specific primers, preferable exon junction primers. During
PCR amplification, linear RNA can also be amplified (G).
G. Orientation of the primers used to detect circular RNAs. The forward primer is in sense
orientation (i.e. has the same sequence as the RNA) and the reverse primer is in antisense
orientation (i.e. is the reverse complement of the RNA). Note that different from RT-PCR
for linear mRNAs, the reverse primer is upstream of the forward primer.
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Figure 4-2 Selection of the sequence for minigene construction

A. Browser display after the sequence shown in Supplemental Figure 1 is run against the
human genomic database using BLAT. Literature exon numbers(77) are indicated in the
gene display, they are different from the numbers given by the browser.
1. The aligned sequences are shown under ‘YourSeq’
2-4. Note that due to the circularity of the RNA, BLAT does not connect all exons with
lines as it does in linear RNA. Exons 10 and 11 (corresponding to 2 and 3) are connected,
but exon 12 (corresponding to 4) is not connected to exon 11.
5. Alu elements are shown in the repetitive element track.
B. Sequence alignment between the planned construct and genomic DNA.
6. The planned construct was run against the database using BLAT.
7. Note the inclusion of several Alu elements in the construct.
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Figure 4-3 Examples of the amplicons prior to cloning

A. Optimized PCR products separated on a 1% agarose gel containing 1x gel green. The
individual bands represent the PCR products that will be used enzymatic DNA assembly.
B. The bands from A were cut out from the gel and purified. The purified PCR products
were separated on a 1% agarose gel, which was subsequently stained with ethidium
bromide. Both gels were run in order to determine the correct banding size, as the gel green
does not run true to size.
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Figure 4-4 Restriction analysis of reporter genes

The tau 9-12 minigene used as an example was cut with restriction enzymes indicated to
rule out major recombinations. Lane 1: cut with NcoI expected sizes 735 bp, 3345 bp, 6266
bp, lane 2 cut with XbaI expected size 10346 bp, lane 3 cut with HindIII expected sizes
3951 bp, 6395 bp, lane 4 cut with SmaI expected sizes 1168 bp, 1688 bp, 2708 bp, 4782
bp.
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Figure 4-5 Effect of primer multiplexing and RNase R treatment on circular RNA
detection

A. cDNA from samples A and B derived from human brain tissues was amplified with
circular RNA primers circTau exon12_10 Reverse and circTau exon10_11 Forward. The
reverse transcription for the cDNA was performed with the primers for linear and circular
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tau RNA. The expected band corresponding to tau circular RNA is shown by a triangle.
The other strong bands are artifacts that did not match the human genome.
B. The experiment was repeated with identical PCR conditions, but the reverse
transcription was performed only with the circTau exon12_10 Reverse primer. Only the
expected band was amplified and validated through sequencing.
C. The RNA was treated with RNase R that removes linear RNA. The circular RNA is
detectable after the treatment (left), whereas linear RNA gives no longer a detectable signal
(right).
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Figure 4-6 Example of an analysis of a circRNA reporter gene

1 µg of the tau 9→12 (133) reporter gene was transfected with 1 µg of splicing factors
indicated. RNA was isolated 24 h post transfection and analyzed by RT-PCR.
A. Amplification of the linear tau mRNA. Due to alternative splicing of exon 10 two bands
are observed. Their ratio changes due to the overexpression of splicing factors (85, 134).
B. Amplification of the circular 12→10 tau RNA (1). Note the dependency of tau circRNA
expression on expression of some splicing factors, especially the cdc2 like kinase clk2 and
the SR protein 9G8.
C. The circular RNA of HIPK3 was used as a positive control indicating equal loading.
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Supplemental Figure 4-1 Tau circular RNA test sequence
GTGAACCTCCAAAATCAGGGGATCGCAGCGGCTACAGCAGCCCCGGCTCCCC
AGGCACTCCCGGCAGCCGCTCCCGCACCCCGTCCCTTCCAACCCCACCCACCC
GGGAGCCCAAGAAGGTGGCAGTGGTCCGTACTCCACCCAAGTCGCCGTCTTC
CGCCAAGAGCCGCCTGCAGACAGCCCCCGTGCCCATGCCAGACCTGAAGAAT
GTCAAGTCCAAGATCGGCTCCACTGAGAACCTGAAGCACCAGCCGGGAGGC
GGGAAGGAGGTGGCCAGGTGGAAGTAAAATCTGAGAAGCTTGACTTCAAGG
ACAGAGTCCAGTCGAAGATTGGGTCCCTGGACAATATCACCCACGTCCCTGG
CGGAGGAAATAAAAAGgtgcagataattaataagaagctggatcttagcaacgtccagtccaagtgtggctcaa
aggataatatcaaacacgtcccgggaggcggcagtGTGCAAATAGTCTACAAACCAGTTGACCTG
AGCAAGGTGACCTCCAAGTGTGGCTCATTAGGCAACATCCATCATAAACCAG
Test sequence corresponding to a circular RNA from the MAPT locus. Different exons are
indicated by underline, small caps and large caps.
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Supplemental Figure 4-2 Genomic sequence containing the planned minigene
> chr17:45,995,463-46,019,282
gttccgtgggccacactttggaaaatacagacccatgagatagaataccagactgttgaa
gtgtaacgggggcctgggaagtgcagtaacagaagcaagtttgagggtaaaggacaccca
gaggagggagggacagcatctgcatggagaggagaagagaccccccagcagcttccaggg
tgttggaagggtgcgctagtaactgctatgcatggcaggtggggaactgtacgtcagggc
acagcagcatgaagcggtatggctcgtgtggacagctagggacaggcaggcgtggagcag
gcatcctgttctgaaggccaaatcccacagaggagccagggtgctggcaggagccctgaa
ctagccgaacagctgaacagctgaacattcaccctgtggggaaagggtcagaagcgtcca
ggcttgagggcacagctgggtctcgtcactgcatcacccttatttaggataaaggccctg
aagaattgtattagaggttggcaaagcatatctaccacctcctggagccacgctggccgc
agggattataattatttccattttcaaattaaggcctctgagctcagagaggggaagtta
cttgtctgaggccacacagcttgttggagcccatctcttgacccaaagactgtggagccg
agttggccacctctctgggagcgggtattggatggtggttgatggttttccattgctttc
ctgggaaaggggtgtctctgtccctaagcaaaaaggcagggaggaagagatgcttcccca
gggcagccgtctgctgtagctgcgcttccaacctggcttccacctgcctaacccagtggt
gagcctgggaatggacccacgggacaggcagcccccagggccttttctgaccccacccac
tcgagtcctggcttcactcccttccttccttcccagGTGAACCTCCAAAATCAGGGGATC
GCAGCGGCTACAGCAGCCCCGGCTCCCCAGGCACTCCCGGCAGCCGCTCCCGCACCCCGT
CCCTTCCAACCCCACCCACCCGGGAGCCCAAGAAGGTGGCAGTGGTCCGTACTCCACCCA
AGTCGCCGTCTTCCGCCAAGAGCCGCCTGCAGACAGCCCCCGTGCCCATGCCAGACCTGA
AGAATGTCAAGTCCAAGATCGGCTCCACTGAGAACCTGAAGCACCAGCCGGGAGGCGGGAAG
gtgagagtggctggctgcgcgtggaggtgtggggggctgcgcctggaggggtagggct
gtgcctggaagggtagggctgcgcctggaggtgcgcggttgagcgtggagtcgtgggact
gtgcatggaggtgtggggctccccgcacctgagcacccccgcataacaccccagtcccct
ctggaccctcttcaaggaagttcagttctttattgggctctccactacactgtgagtgcc
ctcctcaggcgagagaacgttctggctcttctcttgccccttcagcccctgttaatcgga
cagagatggcagggctgtgtctccacggccggaggctctcatagtcagggcacccacagc
ggttccccacctgccttctgggcagaatacactgccacccataggtcagcatctccactc
gtgggccatctgcttaggttgggttcctctggattctggggagattgggggttctgtttt
gatcagctgattcttctgggagcaagtgggtgctcgcgagctctccagcttcctaaaggt
ggagaagcacagacttcgggggcctggcctggatccctttccccattcctgtccctgtgc
ccctcgtctgggtgcgttagggctgacatacaaagcaccacagtgaaagaacagcagtat
gcctcctcactagccaggtgtgggcgggtgggtttcttccaaggcctctctgtggccgtg
ggtagccacctctgtcctgcaccgctgcagtcttccctctgtgtgtgctcctggtagctc
tgcgcatgctcatcttcttataagaacaccatggcagctgggcgtagtggctcacgccta
taatcccagcactttgggaggctgaggcaggcagatcacgaggtcaggagttcgagacca
acctgaccaacagggtgaaacctcgtctctactaaaaatacaaaaatacctgggcgtggt
ggtggtgcgcgcctataatcccagctactcaggaggctgaggcaggagaatcgcttgaac
ccaggaggcagaggttgcagtgagccgagatagtgccactgcactccagtttgagcaaca
gagcgagactctgtctcaaaacaaaataaaacaaaccaaaaaaacccaccatggcttagg
gcccagcctgatgacctcatttttcacttagtcacctctctaaaggccctgtctccaaat
agagtcacattctaaggtacgggggtgttggggaggggggttagggcttcaacatgtgaa
tttgcggggaccacaattcagcccaggaccccgctcccgccacccagcactggggagctg
gggaagggtgaagaggaggctgggggtgagaaggaccacagctcactctgaggctgcaga
tgtgctgggccttctgggcactgggcctcggggagctagggggctttctggaaccctggg
cctgcgtgtcagcttgcctcccccacgcaggcgctctccacaccattgaagttcttatca
cttgggtctgagcctggggcatttggacggagggtggccaccagtgcacatgggcacctt
gcctcaaaccctgccacctccccccacccaggatcccccctgcccccgaacaagcttgtg
agtgcagtgtcacatcccatcgggatggaaatggacggtcgggttaaaagggacgcatgt
gtagaccctgcctctgtgcatcaggcctcttttgagagtccctgcgtgccaggcggtgca
cagaggtggagaagactcggctgtgccccagagcacctcctctcatcgaggaaaggacag
acagtggctcccctgtggctgtggggacaagggcagagctccctggaacacaggagggag
ggaaggaagagaacatctcagaatctccctcctgatggcaaacgatccgggttaaattaa
ggtccggccttttcctgctcaggcatgtggagcttgtagtggaagaggctctctggaccc
tcatccaccacagtggcctggttagagaccttggggaaataactcacaggtgacccaggg
cctctgtcctgtaccgcagctgagggaaactgtcctgcgcttccactggggacaatgcgc
tccctcgtctccagactttccagtcctcattcggttctcgaaagtcgcctccagaagccc
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catcttgggaccaccgtgactttcattctccagggtgcctggccttggtgctgcccaaga
ccccagaggggccctcactggcctttcctgccttttctcccattgcccacccatgcaccc
ccatcctgctccagcacccagactgccatccaggatctcctcaagtcacataacaagcag
cacccacaaggtgctcccttccccctagcctgaatctgctgctccccgtctggggttccc
cgcccatgcacctctgggggcccctgggttctgccataccctgccctgtgtcccatggtg
gggaatgtccttctctccttatctcttcccttcccttaaatccaagttcagttgccatct
cctccaggaagtcttcctggattcccctctctcttcttaaagcccctgtaaactctgacc
acactgaGCATGTGTCTGCTGCTCCCTAGTCTGGGCCATGAGTGAGGGTGGAGGCCAAGT
CTCATGCATTTTTGCAGCCCCCACAAGACTGTGCAGGTGGCCGGCCCTCATTGAATGCGG
GGTTAATTTAACTCAGCCTCTGTGTGAGTGGATGATTCAGGTTGCCAGAGACAGAACCCT
CAGCTTAGCATGGGAAGTAGCTTCCCTGTTGACCCTGAGTTCATCTGAGGTTGGCTTGGA
AGGTGTGGGCACCATTTGGCCCAGTTCTTACAGCTCTGAAGAGAGCAGCAGGAATGGGGC
TGAGCAGGGAAGACAACTTTCCATTGAAGGCCCCTTTCAGGGCCAGAACTGTCCCTCCCA
CCCTGCAGCTGCCCTGCCTCTGCCCATGAGGGGTGAGAGTCAGGCGACCTCATGCCAAGT
GTAGAAAGGGGCAGATGGGAGCCCCAGGTTATgacgtcaccatgctgggtggaggcagca
cgtccaaatctactaaagggttaaaggagaaagggtgacttgacttttcttgagatattt
tgggggacgaagtgtggaaaagtggcagaggacacagtcacagcctcccttaaatgccag
gaaagcctagaaaaattgtctgaaactaaacctcagccataacaaagaccaacacatgaa
tctccaggaaaaaagaaaaagaaaaatgtcatacagggtccatgcacaagagcctttaaa
atgacccgctgaagggtgtcaggcctcctcctcctggactggcctgaaggctccacgagc
ttttgctgagacctttgggtccctgtggcctcatgtagtacccagtatgcagtaagtgct
caataaatgtttggctacaaaagaggcaaagctggcggagtctgaagaatccctcaaccg
tgccggaacagatgctaacaccaaagggaaaagagcaggagccaagtcacgtttgggaac
ctgcagaggctgaaaactgccgcagattgctgcaaatcattgggggaaaaacggaaaacg
tctgttttcccctttgtgcttttctctgttttcttctttgtgcttttctctgttttcagg
atttgctacagtgaacatagattgctttggggccccaaatggaattattttgaaaggaaa
atgcagataatcaggtggccgcactggagcaccagctgggtaggggtagagattgcaggc
aaggaggaggagctgggtggggtgccaggcaggaagagcccgtaggccccgccgatcttg
tgggagtcgtgggtggcagtgttccctccagactgtaaaagggagcacctggcgggaaga
gggaattcttttaaacatcattccagtgcccgagcctcctggacctgttgtcatcttgag
gtgggcctcccctgggtgactctagtgtgcagcctggctgagactcagtggccctgggtt
cttactgctgacacctaccctcaacctcaaccactgcggcctcctgtgcaccctgatcca
gtggctcattttccactttcagtcccagctctatccctatttgcagtttccaagtgcctg
gtcctcagtcagctcagacccagccaggccagcccctggttcccacatcccctttgccaa
gctcatccccgccctgtttggcctgcgggagtgggagtgtgtccagacacagagacaaag
gaccagcttttaaaacattttgttggggccaggtgtggtggctcacacctaatcccaaca
cctggggaggccaaggcagaaggatcacttgagtccaggagttcaagaccagcctgggca
acatagggagaccctgtctctacaattttttttttaattagctgggcctgttggcactct
cctgtagttccagctactctagaggctgaggtgggaggactgcttgagcctgggaggtca
gggctgcaatgagccatgttcacaccactgaacgccagcctgggcgagaccctgtatcaa
aaaagtaaagtaaaatgaatcctgtacgttatattaaggtgccccaaattgtacttagaa
ggatttcatagttttaaatacttttgttatttaaaaaattaaatgactgcagcatataaa
ttaggttcttaatggaggggaaaaagagtacaagaaaagaaataagaatctagaaacaaa
gataagagcagaaataaaccagaaaacacaaccttgcactcctaacttaaaaaaaaaaat
gaagaaaacacaaccagtaaaacaacatataacagcattaagagctggctcctggctggg
cgcggtggcgcatgcctgtaatcccaacactttgggaggccgatgctggaggatcacttg
agaccaggagttcaaggttgcagtgagctatgatcataccactacaccctagcctgggca
acacagtgagactgagactctattaaaaaaaaaatgctggttccttccttatttcattcc
tttattcattcattcagacaacatttatggggcacttctgagcaccaggctctgtgctaa
gagcttttgcccccagggtccaggccaggggacaggggcaggtgagcagagaaacagggc
cagtcacagcagcaggaggaatgtaggatggagagcttggccaggcaaggacatgcaggg
ggagcagcctgcacaagtcagcaagccagagaagacaggcagacccttgtttgggacctg
ttcagtggcctttgaaaggacagcccccacccggagtgctgggtgcaggagctgaaggag
gatagtggaacactgcaacgtggagctcttcagagcaaaagcaaaataaacaactggagg
cagctggggcagcagagggtgtgtgttcagcactaaggggtgtgaagcttgagcgctagg
agagttcacactggcagaagagaggttggggcagctgcaagcctctggacatcgcccgac
aggacagagggtggtggacggtggccctgaagagaggctcagttcagctggcagtggccg
tgggagtgctgaagcaggcaggctgtcggcatctgctggggacggttaagcaggggtgag
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ggcccagcctcagcagcccttcttggggggtcgctgggaaacatagaggagaactgaaga
agcagggagtcccagggtccatgcagggcgagagagaagttgctcatgtggggcccaggc
tgcaggatcaggagaactggggaccctgtgactgccagcggggagaagggggtgtgcagg
atcatgcccagggaagggcccaggggcccaagcatgggggggcctggttggctctgagaa
gatggagctaaagtcactttctcggaggatgtccaggccaatagttgggatgtgaagacg
tgaagcagcacagagcctggaagcccaggatggacagaaacctacctgagcagtggggct
ttgaaagccttggggcggggggtgcaatattcaagatggccacaagatggcaatagaatg
ctgtaactttcttggttctgggccgcagcctgggtggctgcttccttccctgtgtgtatt
gatttgtttctcttttttgagacagagtcttgctgggttgcccaggctggagtgcagtgg
tgcgatcatagctcactgcagccttgaagtcctgagctcaagagatccttccacctcagc
ctcctgagtagttgggaccacaggcttgcaccacagtgcccaactaatttcttatatttt
ttgtagagatggggtttcactgtgtcgcccaggatggtcttgaactcctgggctcaagtg
atcctcctgcctcagcctcgcaaattgctgggattacaggtgtgagccaccatgcccgac
cttctctttttaagggcgtgtgtgtgtgtgtgtgtgtgtgggcgcactctcgtcttcacc
ttcccccagccttgctctgtctctacccagtcacctctgcccatctctccgatctgtttc
tctctccttttacccctctttcctccctcctcatacaccactgaccattatagagaactg
agtattctaaaaatacattttatttatttattttgagacagagtctcactctgtcaccca
ggctggagtgcagtggtgcaatctcggctcactgcaacctccgcctcccaggttgaagca
actctcctgcctcagcctccctagtagctgggattacaagcacacaccaccatgcctagc
aaatttttatatttttagtagaggaggggtgtcaccatgtttgccaagctggtctcaaac
tcctggcctcaggtgatctgcctaccttggtctcccaaagtgctgggattacaggtgtga
gccaccacgcctgcccttaaaaatacattatatttaatagcaaagccccagttgtcactt
taaaaagcatctatgtagaacatttatgtggaataaatacagtgaatttgtacgtggaat
cgtttgcctctcctcaatcagggccagggatgcaggtgagcttgggctgagatgtcagac
cccacagtaagtggggggcagagccaggctgggaccctcctctaggacagctctgtaact
ctgagaccctccaggcatcttttcctgtacctcagtgcttctgaaaaatctgtgtgaatc
aaatcattttaaaggagcttgggttcatcactgtttaaaggacagtgtaaataattctga
aggtgactctaccctgttatttgatctcttctttggccagctgacttaacaggacataga
caggttttcctgtgtcagttcctaagctgatcaccttggacttgaagaggaggcttgtgt
gggcatccagtgcccaccccgggttaaactcccagcagagtattgcactgggcttgctga
gcctggtgaggcaaagcacagcacagcgagcaccaggcagtgctggagacaggccaagtc
tgggccagcctgggagccaactgtgaggcacggacggggctgtggggctgtggggctgca
ggcttggggccagggagggagggctgggctctttggaacagccttgagagaactgaaccc
aaacaaaaccagatcaaggtctagtgagagcttagggctgctttgggtgctccaggaaat
tgattaaaccaagtggacacacacccccagccccacctcaccacagcctctccttcaggg
tcaaactctgaccacagacatttctcccctgactaggagttccctggatcaaaattggga
gcttgcaacacatcgttctctcccttgatggtttttgtcagtgtctatccagagctgaag
tgtaatatatatgttactgtagctgagaaattaaatttcaggattctgatttcataatga
caaccattcctcttttctctcccttctgtaaatctaagattctataaacggtgttgactt
aatgtgacaattggcagtagttcaggtctgctttgtaaatacccttgtgtctattgtaaa
atctcacaaaggcttgttgccttttttgtggggttagaacaagaaaaagccacatggaaa
aaaaatttcttttttgtttttttgtttgcttgtttttttgagacagagtttcactctgtc
gcccaggctggagtgcagtggtgcgatctccgcccactgcaagctccacctcccgggttc
atgctattctcctgtctcagcctcccaagtagctgggactgcaggtgcccgccaccacac
ctggctaatttttttgtatttttagtagagacggggtttcaccgtgttagccaggatggt
ctcaatctcctgacctcgtcatctgcctgcctcggcctcccaaagtgctgagattacagg
cgtgagccaccgtgcccggccagaaaaaaacatttctaagtatgtggcagatactgaatt
attgcttaatgtcctttgattcatttgtttaatttctttaatggattagtacagaaaaca
aagttctcttccttgaaaaactggtaagttttctttgtcagataaggagagttaaataac
ccatgacatttccctttttgcctcggcttccaggaagctcaaagttaaatgtaatgatca
ctcttgtaattatcagtgttgatgcccttcccttcttctaatgttactctttacattttc
ctgctttattattgtgtgtgttttctaattctaagctgttcccactcctttctgaaagca
ggcaaatcttctaagccttatccactgaaaagttatgaataaaaaatgatcgtcaagcct
acaggtgctgaggctactccagaggctgaggccagaggaccacttgagcccaggaatttg
agacctgggctgggcagcatagcaagactctatctccattaaaactatttttttttattt
aaaaaataatccgcaaagaaggagtttatgtgggattccttaaaatcggagggtggcatg
aattgattcaaagacttgtgcagagggcgacagtgactccttgagaagcagtgtgagaaa
gcctgtcccacctccttccgcagctccagcctgggctgaggcactgtcacagtgtctcct
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tgctggcaggagagaatttcaacattcaccaaaaagtagtattgtttttattaggtttat
gaggctgtagccttgaggacagcccaggacaactttgttgtcacatagatagcctgtggc
tacaaactctgagatctagattcttctgtggctgcttctgacctgagaaagttgcggaac
ctcagcgagcctcacatggcctccttgtccttaacgtggggacggtgggcaagaaaggtg
atgtggcactagagatttatccatctctaaaggaggagtggattgtacattgaaacacca
gagaaggaattacaaaggaagaatttgagtatctaaaaatgtaggtcaggcgctcctgtg
ttgattgcagggctattcacaatagccaagatttggaagcaacccaagtgtccatcaaca
gacaaatggataaagaaaatgtggtgcatatacacaatggaatactattcagccatgaaa
aagaatgagaatctgtcatttgaaacaacatggatggaactggaggacattatgttaagt
gaaataagccagacagaaggacagacttcacatgttctcacacatttgtgggagctaaaa
attaaactcatggagatagagagtagaaggatggttaccagaggctgaggagggtggagg
ggagcagggagaaagtagggatggttaatgggtacaaaaacgtagttagcatgcatagat
ctagtattggatagcacagcagggtgacgacagccaacagtaatttatagtacatttaaa
aacaactaaaagagtgtaattggactggctaacatggtgaaaccccgtctctactaaaaa
tacaaaaattagctgggcatggtggctcacgcctgtaatcccagcactttgggaggccga
ggcgggccgatcacgaggtcaggagatcgagaccatcctagctaacatggtgaaaccccg
tctctactacaaatacaaaaaaaagaaaaaattagccgggcatggtggtgggcgcctgta
gtcccagctactcgggaggctgaggcaggagaatggcgtgaacccgggaggcggagcttg
cagtgagccgagatcgcgccactgcactccagcctgggcgacaaggcaagattctatctc
aaaaaaataaaaataaaataaaataaaataataaaataaaataaaataaaataaaataaa
taaaataaaataaaatgtataattggaatgtttataacacaagaaatgataaatgcttga
ggtgatagataccccattcaccgtgatgtgattattgcacaatgtatgtctgtatctaaa
tatctcatgtaccccacaagtatatacacctactatgtacccatataaatttaaaattaa
aaaattataaaacaaaaataaataagtaaattaaaatgtaggctggacaccgtggttcac
gcctgtaatcccagtgctttgtgaggctgaggtgagagaatcacttgagcccaggagttt
gagaccggcctgggtgacatagcgagaccccatcatcacaaagaatttttaaaaattagc
tgggcgtggtagcacataccggtagttccagctacttgggagaccgaggcaggaggattg
cttgagcccaggagtttaaggctgcagtgagctacgatggcgccactgcattccagcctg
ggtgacagagtgagagcttgtctctattttaaaaataataaaaagaataaataaaaataa
attaaaatgtaaatatgtgcatgttagaaaaaatacacccatcagcaaaaagggggtaaa
ggagcgatttcagtcataattggagagatgcagaataagccagcaatgcagtttctttta
ttttggtcaaaaaaaataagcaaaacaatgttgtaaacacccagtgctggcagcaatgtg
gtgaggctggctctctcaccagggctcacagggaaaactcatgcaacccttttagaaagc
catgtggagagttgtaccgagaggttttagaatatttataactttgacccagaaattcta
ttctaggactctgtgttatgaaaataacccatcatatggaaaaagctcctttcagaaaga
ggttcatgggaggctgtttgtattttttttttctttgcatcaaatccagctcctgcagga
ctgtttgtattattgaagtacaaagtggaatcaatacaaatgttggatagcaggggaaca
atattcacaaaatggaatgggacatagtattaaacatagtgcttctgatgaccgtagacc
atagacaatgcttaggatatgatatcacttcttttgttgttttttgtattttgagacgaa
gtctcattctgtcacccaggctggagttcagtggcgccatctcagctcactgcaacctcc
atctcccgggttcaagctattctccttcctcaacctcccgagtagctgggttgcgcacca
ccatgcctggctaacttttgtatttttagtacagacggggtttcaccacgttggccaggc
tgctcttgaactcctgacgtcaggtgatccaccagccttgacctcccaaagtgctaggat
tacaggagccactgtacccagcctaggatatgatatcacttcttagagcaagatacaaaa
ttgcatgtgcacaataattctaccaagtataggtatacaggggtagttatatataaatga
gacttcaaggaaatacaacaaaatgcaatcgtgattgtgttagggtggtaagaaaacggt
ttttgctttgatgagctctgttttttaaaatcgttatattttctaataaaaatacatagt
cttttgaaggaacataaaagattatgaagaaatgagttagatattgattcctattgaaga
ttcagacaagtaaaattaaggggaaaaaaaacgggatgaaccagaagtcaggctggagtt
ccaaccccagatccgacagcccaggctgatggggcctccagggcagtggtttccacccag
cattctcaaaagagccactgaggtctcagtgccattttcaagatttcggaagcggcctgg
gcacggctggtccttcactgggatcaccacttggcaattatttacacctgagacgaataa
aaaccagagtgctgagattacaggcatggtggcttacgcttgtaatcggctttgggaagc
cgaggtgggctgattgcttgagcccaggagtttcaaactatcctggacaacatagcatga
cctcgtctctacaaaaaatacaaaaaatttgccaggtgtggtggcatgtgcctgtggtcc
cagctacttgggaggctgaagtaggagaatcccctgagccctgggaagtcgaggctgcac
tgagccgtgatggtgtcactgcactccagcctgggtgacaaagtgagaccctatctcaca
aagaaaaaaaacaaaacaaaaaacccaaagcacactgtttccactgtttccagagttcct
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gagaggaaaggtcaccgggtgaggaagacgttctcactgatctggcagagaaaatgtcca
gtttttccaactccctaaaccatggttttctatttcatagttcttaggcaaattggtaaa
aatcatttctcatcaaaacgctgatattttcacacctccctggtgtctgcagaaagaacc
ttccagaaatgcagtcgtgggagacccatccaggccacccctgcttatggaagagctgag
aaaaagccccacgggagcatttgctcagcttccgttacgcacctagtggcattgtgggtg
ggagagggctggtgggtggatggaaggagaaggcacagcccccccttgcagggacagagc
cctcgtacagaagggacaccccacatttgtcttccccacaaagcggcctgtgtcctgcct
acggggtcagggcttctcaaacctggctgtgtgtcagaatcaccaggggaacttttcaaa
actagagagactgaagccagactcctagattctaattctaggtcagggctaggggctgag
attgtaaaaatccacaggtgattctgatgcccggcaggcttgagaacagccgcagggagt
tctctgggaatgtgccggtgggtctagccaggtgtgagtggagatgccggggaacttcct
attactcactcgtcagtgtggccgaacacatttttcacttgacctcaggctggtgaacgc
tcccctctggggttcaggcctcacgatgccatccttttgtgaagtgaggacctgcaatcc
cagcttcgtaaagcccgctggaaatcactcacacttctgggatgccttcagagcagccct
ctatcccttcagctcccctgggatgtgactcaacctcccgtcactccccagactgcctct
gccaagtccgaaagtggaggcatccttgcgagcaagtaggcgggtccagggtggcgcatg
tcactcatcgaaagtggaggcgtccttgcgagcaagcaggcgggtccagggtggcgtgtc
actcatccttttttctggctaccaaagGTGCAGATAATTAATAAGAAGCTGGATCTTAGC
AACGTCCAGTCCAAGTGTGGCTCAAAGGATAATATCAAACACGTCCCGGGAGGCGGCAGT
gtgagtaccttcacacgtcccatgcgccgtgctgtggcttgaattattaggaagtggtgt
gagtgcgtacacttgcgagacactgcatagaataaatccttcttgggctctcaggatctg
gctgcgacctctgggtgaatgtagcccggctccccacattcccccacacggtccactgtt
cccagaagccccttcctcatattctaggagggggtgtcccagcatttctgggtcccccag
cctgcgcaggctgtgtggacagaatagggcagatgacggaccctctctccggaccctgcc
tgggaagctgagaatacccatcaaagtctccttccactcatgcccagccctgtccccagg
agccccatagcccattggaagttgggctgaaggtggtggcacctgagactgggctgccgc
ctcctcccccgacacctgggcaggttgacgttgagtggctccactgtggacaggtgaccc
gtttgttctgatgagcggacaccaaggtcttactgtcctgctcagctgctgctcctacac
gttcaaggcaggagccgattcctaagcctccagcttatgcttagcctgcgccaccctctg
gcagagactccagatgcaaagagccaaaccaaagtgcgacaggtccctctgcccagcgtt
gaggtgtggcagagaaatgctgcttttggcccttttagatttggctgcctcttgccagga
gtggtggctcgtgcctgtaattccagcactttgggagactaaggcgggaggttcgcttga
gcccaggagttcaagaccagcctgggcaacaatgagacccctgtgtctacaaaaagaatt
aaaattagccaggtgtggtggcacgcacctgtagtcccagctacttgggaggctgaggtg
ggaggattgcctgagtccgggaggcggaagttgcaaggagccatgatcgcgccactgcac
ttcaacctaggcaacagagtgagactttgtctcaaaaaacaatcatataataattttaaa
ataaatagatttggcttcctctaaatgtccccggggactccgtgcatcttctgtggagtg
tctccgtgagattcgggactcagatcctcaagtgcaactgacccacccgataagctgagg
cttcatcatcccctggccggtctatgtcgactgggcacccgaggctcctctcccaccagc
tctcttggtcagctgaaagcaaactgttaacaccctggggagctggacgtatgagaccct
tggggtgggaggcgttgatttttgagagcaatcacctggccctggctggcagtaccggga
cactgctgtggctccggggtgggctgtctccagaaaatgcctggcctgaggcagccaccc
gcatccagcccagagggtttattcttgcaatgtgctgctgcttcctgccctgagcacctg
gatcccggcttctgccctgaggccccttgagtcccacaggtagcaagcgcttgccctgcg
gctgctgcatggggctaactaacgcttcctcaccagtgtctgctaagtgtctcctctgtc
tcccacgccctgctctcctgtccccccagtttgtctgctgtgaggggacagaagaggtgt
gtgccgcccccacccctgcccgggcccttgttcctgggattgctgttttcagctgtttga
gctttgatcctggttctctggcttcctcaaagtgagctcggccagaggaggaaggccatg
tgctttctggttgaagtcaagtctggtgccctggtggaggctgtgctgctgaggcggagc
tggggagagagtgcacacgggctgcgtggccaacccctctgggtagctgatgcccaaaga
cgctgcagtgcccaggacatctgggacctccctggggcccgcccgtgtgtcccgcgctgt
gttcatctgcgggctagcctgtgacccgcgctgtgctcgtctgcgggctagcctgtgtcc
cgcgctctgcttgtctgcggtctagcctgtgacctggcagagagccaccagatgtcccgg
gctgagcactgccctctgagcaccttcacaggaagcccttctcctggtgagaagagatgc
cagcccctggcatctgggggcactggatccctggcctgagccctagcctctccccagcct
gggggccccttcccagcaggctggccctgctccttctctacctgggacccttctgcctcc
tggctggaccctggaagctctgcagggcctgctgtccccctccctgccctccaggtatcc
tgaccaccggccctggctcccactgccatccactcctctcctttctggccgttccctggt
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ccctgtcccagcccccctccccctctcacgagttacctcacccaggccagagggaagagg
gaaggaggccctggtcataccagcacgtcctcccacctccctcggccctggtccaccccc
tcagtgctggcctcagagcacagctctctccaagccaggccgcgcgccatccatcctccc
tgtcccccaacgtccttgccacagatcatgtccgccctgacacacatgggtctcagccat
ctctgccccagttaactccccatccataaagagcacatgccagctgacaccaaaataatt
cgggatggttccagtttagacctaagtggaaggagaaaccaccacctgccctgcaccttg
ttttttggtgaccttgataaaccatcttcagccatgaagccagctgtctcccaggaagct
ccagggcggtgcttcctcgggagctgactgataggtgggaggtggctgcccccttgcacc
ctcaggtgaccccacacaaggccactgctggaggccctggggactccaggaatgtcaatc
agtgacctgccccccaggccccacacagccatggctgcatagaggcctgcctccaaggga
cctgtctgtctgccactgtggagtccctacagcgtgccccccacaggggagctggttctt
tgactgagatcagctggcagctcagggtcatcattcccagagggagcggtgccctggagg
ccacaggcctcctcatgtgtgtctgcgtccgctcgagcttactgagacactaaatctgtt
ggtttctgctgtgccacctacccaccctgttggtgttgctttgttcctattgctaaagac
aggaatgtccaggacactgagtgtgcaggtgcctgctggttctcacgtccgagctgctga
actccgctgggtcctgcttactgatggtctttgctctagtgctttccagggtccgtggaa
gcttttcctggaataaagcccacgcatcgaccctcacagcgcctcccctctttgaggccc
agcagataccccactcctgcctttccagcaagatttttcagatgctgtgcatactcatca
tattgatcacttttttcttcatgcctgattgtgatctgtcaatttcatgtcaggaaaggg
agtgacatttttacacttaagcgtttgctgagcaaatgtctgggtcttgcacaatgacaa
tgggtccctgtttttcccagaggctcttttgttctgcagggattgaagacactccagtcc
cacagtccccagctcccctggggcagggttggcagaatttcgacaacacatttttccacc
ctgactaggatgtgctcctcatggcagctgggaaccactgtccaataagggcctgggctt
acacagctgcttctcattgagttacacccttaataaaataatcccattttatcctttttg
tctctctgtcttcctctctctctgcctttcctcttctctctcctcctctctcatctccag
GTGCAAATAGTCTACAAACCAGTTGACCTGAGCAAGGTGACCTCCAAGTGTGGCTCATTA
GGCAACATCCATCATAAACCAGgtagccctgtggaaggtgagggttgggacgggagggtg
cagggggtggaggagtcctggtgaggctggaactgctccagacttcagaaggggctggaa
aggatattttaggtagacctacatcaaggaaagtgttgagtgtgaaacttgcgggagccc
aggaggcgtggtggctccagctcgctcctgcccaggccatgctgcccaagacaaggtgag
gcgggagtgaagtgaaataaggcaggcacagaaagaaagcacatattctcggccgggcgc
tgtggctcacgcctgtaattccagcactttgggaggccaaggtgggtggatcatgaggtc
aggagattgagaccatcctggctaacacagtgaaaccccgtctctactaaaaatacaaaa
aattagccgggcgtggtggtgggcgcctgtagtcccagctactccggaggctgaggcagg
aaaatggcgtgaacccggaaggcggagcttgcagtgagcggagtgagcagagatcgcgcc
actgcactccagcctgggcgacagagcgagactccgtctcaaaaaaaaaaagcacatgtt
ctcgcttctttgtgggatccaggagatagagaatagaaggatggttaccagaggctggga
agggtagtgaggggatggtggggggatggtcaatgggtacaaaaaaaatagaataagacc
tagtatttgatagtgcaacagggtgactatagtcaataataatttaattgtacatttaaa
aataactaaaagatagccgggtgcagtggcttacgtctgtaatcccagtactttgggagg
ctgaggtgggcgtttgagaccagcctggccaacatggtgaaaccccatctctactaaaaa
tacaaaaattagccaggcatggtggcgggcgcctgtaatcccagctactcgggaggctga
ggcaggagaatcacttgaacctgggaggcagaggttgcagtgagccgagatcttgccact
gcactccagcctgggtgacagtgaaactccgtctcaaaaataaaaataaaaatacagctg
ggcacggtggctcacgcctgtaatcccagcactttgggaggccgaggcgagcggatcaca
aggtcaggagatatagaccatcctggctaacacggtgaaacccggtctctactaaaaata
caaaaaattagccaggcgtggtggcaggtgcctatagtcccagctactcacaaggctgag
gcaggagaatggcatgaacctgggaggcggagcttgcagtgagccgagattgtgccactg
cactccagcctgggcgagagagtgagactccgtctcaaaacaaaaacaaaaacaaaaaca
aaaacaaacacacaacaaaaacctaaaagaatataaatggattgtttgtaacacaaagga
caaatgtttgaggggatggataccccattttccatgatgtgattattatacattgtgtgt
ctgtatcaaaacatctcatgagccccataaatatatacacctaactatgtacccacaaaa
attaaaaaaatatattttttaaggtgaagagggaggcgagatgctggccttaacccctaa
cccgttgttctccctgcaagctgtccacagggcctctcagactcgaggttcagctatatg
gatgcatgagcttggtccccagccaacatgggagacacttcaccatcggcagcagctaca
gcacaggaaccctgggtcactgccatgtcccctctgtgactttgtttaaacagaaaatga
tgctctgggccggctgtggtggcccacacctataatcccagcaccttgggaggcgggggt
gggcagattgcctgaggtcaggagttggagatcagcctggccgacatggcgaaaccccat
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gtctactaaaaatacaaaaactagccaggcatggtggcacatgcctgtaatcccagctac
ttgggaggctgaagcaggagaatcacttgaacccaggaggcagaggctgagtgagccaag
atcgtgccaatgcactccagcttgggtgagggagtgagactccgtctcaaaaaaaaaaaa
aaagaaagaaaaagaaaagaaagtgatcctactggaaccatgcttactcccctccccacc
tcacactgtgtagaaattagtgctgtcggccaggcgcggtggctcatgcctgtaatcgca
gcactttgggaggccaaggcaggcggatcacgaggtcaggagatcaagaccatcctggct
aacacagtgaaaccctgtctctactaaaaatacaaaaaattagccgggcatggtggcagg
cacctgtagtcccaactacttgggaggctgaggcaggagaatggcatgaacctgggaggc
ggagcttgcagtgagccaagatcgcgccactgcataccagcctaggtgacagagtgagac
tcagcaaaaaaagaaagaaagaaagaaagaaatcagtgctgtctatacttctttctgcag
tgatggaaatattctgtatctgtgctgtccagtatagtagccactagctacatgtggcac
ttgaaacatggctggtacagttgaggaagagtggctgccatatcggacgacacagctata
gattctgtcaccccaccccgagagtccagagcggggacttctgccttaggccctattcag
ggctgatttttacttgaacccttactgtgggaagagaaggccatgagaagttcagtctag
aatgtgactccttattttctggctcccttggacactttgtgggatttagtctccctgtgg
aaagtattccacaagtggtgccaccaccccagctgtgagagcagctgggagctgcttttg
tcatctttccctggaaagtcctgtgggctgtctcttcctcatgccttgtcccatgcttgg
gcatggtgtcaagcgtcaggagggagaaagggtccttatttatttatttagagagggacc
cttcttctgttcccaggctggagtgcagtggtgcgatctcggctcactgcaacctccgcc
tcctgggttcaagtgattctcctgcctcagcctcctgagtagctgagattacaggcacat
gccaacatgcctggctaattttttttttttttttttttttttttttttgagatggagttg
tactctcattgcccaggctggaatgtaatggcacaatctcggctcactgcaacctccacc
tcctggattcaagcaattctcctgtctcagcttcccaagtagctgggattacaggtgccc
gccaccatgctcaactaatttttgtattttttttttagtagagacgaggtttcaccatgt
tggtcagactggtctcaaactcctgacctcaggtgatccacctgcctcggcctcccaaag
tgctaggattacaggcatgagccaccacgcccggcctgaaagggttcttatttagtgtgc
attttgacattcaatttaattccaaggtcttgtggggtcatggtttacaggatgttgata
tagaaaagacttcacttaatgggccgggcgcagtggctcatgcctgtaatcccagcactt
tgggaggccgaggcaggcagatcaggaggtcaggagattgagaccatcctggctaacaca
gtgaaaccccatctctactgaaaatacaaaaaattagctgggcgtggtggcaggcacctg
tagtcccagccactcggttggctgaggcaggagaatggcatgaacccgggaggcggagct
tgcagtgagcagagaccatgccactgcactccagcctgggcgacagagcaagactctgtc
tcaagaaaaaaaaaaaaaaaacagactttacttactggaagccaaccaatgtatatttag
agtaatttttcctgggctgagctgtcatttacttttgcagtatctcaagaagaagagttt
acagtgtaaatatttgatgcacactttgattatatagatgaagcaaactattttcaagag
ctttgcaaggacttacttgtatccaaacaccattctaaaggagtcttacctacttctaaa
ggctggtctctacttggaaccacttgcttggccctggttcaagtcctgctgcaaacctgg
aagtcctgtcattgtcttcttccctccagagcagtggcacccaatctaatttttgctgtg
ccccagcagcccctggcactttgccctgtagactgcagacctcatgtaatgtatgttaag
tccacagaaccacagaagatgatggcaagatgctcttgtgtgtgttgtgttctagGAGGT
GGCCAGGTGGAAGTAAAATCTGAGAAGCTTGACTTCAAGGACAGAGTCCAGTCGAAGATT
GGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAAAAGgtaaagggggta
gggtgggttggatgctgcccttgggtatatgggcattaatcaagttgagtggacaaaggc
tggtccagttcccagaggaggaaaacagaggcttctgtgttgactggctggatgtgggcc
ctcagcagcatccagtgggtctccactgcctgtctcaatcacctggagctttagcacgtt
tcacacctgggccccaacctggagaggctgaccaatgggtctcaggggcagctcggttgc
tggagtttttgtttttatttatttttatgtatttaaggcagggtctctgtattagtccat
tctcacactgctaataaagacatacccaagactgggtaatttataaaggaaagaggttta
atggactcacagttccacatggctggggaggcctcaaaatcatggcggaaggcaaaggag
aagcaaaggcatttcttacatggcgacaggcaagagagcgtgtgcaggggaactcccatt
tataaaaccatcagacctcatgagatttattcactatcatgagaacagcatgggaaagac

Exons are highlighted in color and repetitive elements are underlined, italic and bold. Gray
shading indicates flanking regions of low complexity that can be used to generate primers.
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Supplemental Figure 4-3 Sequences of the planned reporter gene
Vector
cccgctgatcagcctcgactgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtg
ccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggggggtggggtggg
gcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctatggcttctgaggcgga
aagaaccagctggggctctagggggtatccccacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgc
agcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttcccc
gtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgatg
gttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaa
actggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctg
atttaacaaaaatttaacgcgaattaattctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcaga
agtatgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaag
catgcatctcaattagtcagcaaccatagtcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctc
cgccccatggctgactaattttttttatttatgcagaggccgaggccgcctctgcctctgagctattccagaagtagtgaggaggct
tttttggaggcctaggcttttgcaaaaagctcccgggagcttgtatatccattttcggatctgatcaagagacaggatgaggatcgtt
tcgcatgattgaacaagatggattgcacgcaggttctccggccgcttgggtggagaggctattcggctatgactgggcacaaca
gacaatcggctgctctgatgccgccgtgttccggctgtcagcgcaggggcgcccggttctttttgtcaagaccgacctgtccggt
gccctgaatgaactgcaggacgaggcagcgcggctatcgtggctggccacgacgggcgttccttgcgcagctgtgctcgacg
ttgtcactgaagcgggaagggactggctgctattgggcgaagtgccggggcaggatctcctgtcatctcaccttgctcctgccga
gaaagtatccatcatggctgatgcaatgcggcggctgcatacgcttgatccggctacctgcccattcgaccaccaagcgaaaca
tcgcatcgagcgagcacgtactcggatggaagccggtcttgtcgatcaggatgatctggacgaagagcatcaggggctcgcgc
cagccgaactgttcgccaggctcaaggcgcgcatgcccgacggcgaggatctcgtcgtgacccatggcgatgcctgcttgcc
gaatatcatggtggaaaatggccgcttttctggattcatcgactgtggccggctgggtgtggcggaccgctatcaggacatagcg
ttggctacccgtgatattgctgaagagcttggcggcgaatgggctgaccgcttcctcgtgctttacggtatcgccgctcccgattc
gcagcgcatcgccttctatcgccttcttgacgagttcttctgagcgggactctggggttcgaaatgaccgaccaagcgacgccca
acctgccatcacgagatttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttccgggacgccggctggatg
atcctccagcgcggggatctcatgctggagttcttcgcccaccccaacttgtttattgcagcttataatggttacaaataaagcaata
gcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctgtatac
cgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacata
cgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccgcttt
ccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttc
cgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggtta
tccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgc
gttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgac
aggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgt
ccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagct
gggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagaca
cgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtg
gtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggta
gctcttgatccggcaaacaaaccaccgctggtagcggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaa
gaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaa
ggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatg
cttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatac
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gggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaacc
agccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagcta
gagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggc
ttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctcc
gatcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaa
gatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaa
tacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggat
cttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggt
gagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttc
aatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttccgc
gcacatttccccgaaaagtgccacctgacgtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgc
tctgatgccgcatagttaagccagtatctgctccctgcttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctaca
acaaggcaaggcttgaccgacaattgcatgaagaatctgcttagggttaggcgttttgcgctgcttcgcgatgtacgggccagat
atacgcgttgacattgattattgactagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgtta
cataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagt
aacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatat
gccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttccta
cttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttga
ctcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcg
taacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctctctggctaactag
agaacccactgcttactggcttatcgaaattaatacgactcactatagggagacccaagctggctagcgtttaaacttaagctt
Exon 9 fragment
acgctggccgcagggattataattatttccattttcaaattaaggcctctgagctcagagaggggaagttacttgtctgaggccaca
cagcttgttggagcccatctcttgacccaaagactgtggagccgagttggccacctctctgggagcgggtattggatggtggttg
atggttttccattgctttcctgggaaaggggtgtctctgtccctaagcaaaaaggcagggaggaagagatgcttccccagggcag
ccgtctgctgtagctgcgcttccaacctggcttccacctgcctaacccagtggtgagcctgggaatggacccacgggacaggca
gcccccagggccttttctgaccccacccactcgagtcctggcttcactcccttccttccttcccagGTGAACCTCCAAA
ATCAGGGGATCGCAGCGGCTACAGCAGCCCCGGCTCCCCAGGCACTCCCGGC
AGCCGCTCCCGCACCCCGTCCCTTCCAACCCCACCCACCCGGGAGCCCAAGA
AGGTGGCAGTGGTCCGTACTCCACCCAAGTCGCCGTCTTCCGCCAAGAGCCG
CCTGCAGACAGCCCCCGTGCCCATGCCAGACCTGAAGAATGTCAAGTCCAAG
ATCGGCTCCACTGAGAACCTGAAGCACCAGCCGGGAGGCGGGAAGgtgagagtgg
ctggctgcgcgtggaggtgtggggggctgcgcctggaggggtagggctgtgcctggaagggtagggctgcgcctggaggtg
cgcggttgagcgtggagtcgtgggactgtgcatggaggtgtggggctccccgcacctgagcacccccgcataacaccccagt
cccctctggaccctcttcaaggaagttcagttctttattgggctctccactacactgtgagtgccctcctcaggcgagagaacgttct
ggctcttctcttgccccttcagcccctgttaatcggacagagatggcagggctgtgtctccacggccggaggctctcatagtcag
ggcacccacagcggttccccacctgccttctgggcagaatacactgccacccataggtcagcatctccactcgtgggcc
Exon 10 fragment
aaaaatccacaggtgattctgatgcccggcaggcttgagaacagccgcagggagttctctgggaatgtgccggtgggtctagc
caggtgtgagtggagatgccggggaacttcctattactcactcgtcagtgtggccgaacacatttttcacttgacctcaggctggt
gaacgctcccctctggggttcaggcctcacgatgccatccttttgtgaagtgaggacctgcaatcccagcttcgtaaagcccgct
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ggaaatcactcacacttctgggatgccttcagagcagccctctatcccttcagctcccctgggatgtgactcgacctcccgtcact
ccccagactgcctctgccaagtccgaaagtggaggcatccttgcgagcaagtaggcgggtccagggtggcgcatgtcactcat
cgaaagtggaggcgtccttgcgagcaagcaggcgggtccagggtggcgtgtcactcatccttttttctggctaccaaagGTG
CAGATAATTAATAAGAAGCTGGATCTTAGCAACGTCCAGTCCAAGTGTGGCT
CAAAGGATAATATCAAACACGTCCCGGGAGGCGGCAGTgtgagtaccttcacacgtcccat
gcgccgtgctgtggcttgaattattaggaagtggtgtgagtgcgtacacttgcgagacactgcatagaataaatccttcttgggctc
tcaggatctggctgcgacctctgggtgaatgtagcccggctccccacattcccccacacggtccactgttcccagaagccccttc
ctcatattctaggagggggtgtcccagcatttctgggtcccccagcctgcgcaggctgtgtggacagaatagggcagatgacgg
accctctctccggaccctgcctgggaagctgagaatacccatcaaagtctccttccactcatgcccagccctgtccccaggagcc
ccatagcccattggaagttgggctgaaggtggtggcacctgagactgggctgccgcagataccccactc
Exon 11 fragment
tgcctttccagcaagatttttcagatgctgtgcatactcatcatattgaccacttttttcttcatgcctgattgtgatctgtcaatttcatgt
caggaaagggagtgacatttttacacttaagcgtttgctgagcaaatgtctgggtcttgcacaatgacaatgggtccctgtttttccc
agaggctcttttgttctgcagggattgaagacactccagtcccacagtccccagctcccctggggcagggttggcagaatttcga
caacacatttttccaccctgactaggatgtgctcctcatggcagctgggaaccactgtccaataagggcctgggcttacacagctg
cttctcattgagttacacccttaataaaataatcccattttatcctttttgtctctctgtcttcctctctctctgcctttcctcttctctctcctc
ctctctcatctccagGTGCAAATAGTCTACAAACCAGTTGACCTGAGCAAGGTGACCT
CCAAGTGTGGCTCATTAGGCAACATCCATCATAAACCAGgtagccctgtggaaggtgagg
gttgggacgggaaggtgcagggggtggaggagtcctggtgaggctggaactgctccagacttcagaaggggctggaaagga
tattttaggtagacctacatcaaggaaagtgttgagtgtgaaacttgcgggagcccaggaggcgtggtggctccagctcgctcct
gcccaggctatgctgcccaagacaaggtgaggcgggagtgaagtgaaataaggcaggcacagaaagaaagcacatattctc
ggccgggcgctgtggctcacgcctgtaatcccagcactttgggaggccaaggtgggtggatcatgaggtcaggagattgagac
catcctggctaacacagtgaaaccccgtctctactaaaaatacaaaaaattagccgggcgtggtggcgggcgcctgtagtccca
gctact
exon 12 fragment
gtggggtcatggtttacaggatgttgatatagaaaagacttcacttaatgggccgggcgcagtggctcatgcctgtaatcccagca
ctttgggaggccgaggcaggcagatcaggaggtcaggagattgagaccatcctggctaacacagtgaaaccccatctctactg
aaaatacaaaaaattagctgggcgtggtggcaggcacctgtagtcccagccactcggttggctgaggcaggagaatggcatga
acccgggaggcggagcttgcagtgagcagagaccatgccactgcactccagcctgggcgacagagcaagactctgtctcaa
gaaaaaaaaaaaaaaaacagactttacttactggaagccaaccaatgtatatttagagtaatttttcctgggctgagctgtcatttact
tttgcagtatctcaagaagaagagtttacagtgtaaatatttgatgcacactttgattatatagatgaagcaaactattttcaagagcttt
gcaaggacttacttgtatccaaacaccattctaaaggagtcttacctacttctaaaggctggtctctacttggaaccacttgcttggc
cctggttcaagtcctgctgcaaacctggaagtcctgtcattgtcttcttccctccagagcagtggcacccaatctaatttttgctgtgc
cccagcagcccctggcactttgccctgtagactgcagacctcatgtaatgtatgttaagtccacagaaccacagaagatgatggc
aagatgctcttgtgtgtgttgtgttctagGAGGTGGCCAGGTGGAAGTAAAATCTGAGAAGCTT
GACTTCAAGGACAGAGTCCAGTCGAAGATTGGGTCCCTGGACAATATCACCC
ACGTCCCTGGCGGAGGAAATAAAAAGgtaaagggggtagggtgggttggatgctgcccttgggtatat
gggcattaatcaagttgagtggacaaaggctggtccagttcccagaggaggaaaacagaggcttctgtgttgactggctggatg
tgggccctcagcagcatccagtgggtctccactgcctgtctcaatcacctggagctttagcacgtttcacacctgggccccaacct
ggagaggctgaccaatgggtctcaggggcagctcggttgctggagtttttgtttttatttatttttatgtatttaaggcagggtctctgt
attagtccattctcacactgctaataaagacatacccaagactgggtaatttataaaggaaagaggtttaatggactcacagttcca
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catggctggggaggcctcaaaatcatggcggaaggcaaaggagaagcaaaggcatttcttacatggcgacaggcaagagag
cgtgtgcaggggaactcccatttataaaaccatcagacctcatgagatttattcactatcatgagaacagcatgggaaagacccg
cccccatgattcagttacctcccactgggtccctcccatgacacatggaattatgggagctacaattcaagatgagatttgggtgg
ggacacagccaaaccatatcagtctccctctgtcatccaggctggagtgcactggcatgatctcggctcactgcagcctctacct
ccctgggtcaggtgatcttcccacctcagcctcccaggtagctggaactacaggtacctgccactatgcctggctaaatattttgta
tttcctgtggagacgaggttttgccacgttgcccaggctggtcttgaactcctgaggtcaagcaatatgcccacctcggcctccca
aggtgctgggattacaggtgtgagccacagtgctcggcctaagtcactgcagtttctcgagtctagagggcccgtttaaa

The vector sequence and the planned genomic fragments are shown.
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Supplemental Figure 4-4 Primer design for assembly

The sequence from Supplemental Figure 4.3 was entered into the builder tool.
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Supplemental Figure 4-5 Sequence of the tau 9à12 reporter gene used as an
example.
GTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATC
GACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGG
CGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTT
ACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAG
CTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCT
GTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTAT
CGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA
CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTT
GAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGC
GCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCG
GCAAACAAACCACCGCTGGTAGCGGTTTTTTTGTTTGCAAGCAGCAGATTAC
GCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCT
GACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTAT
CAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCA
ATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAG
TGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGAC
TCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAG
TGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCA
ATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTAT
CCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCG
CCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTC
ACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGC
GAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCT
CCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGC
AGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGA
CTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAG
TTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACT
TTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGA
TCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGA
TCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAG
GCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACT
CATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCAT
GAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCG
CGCACATTTCCCCGAAAAGTGCCACCTGACGTCGACGGATCGGGAGATCTCC
CGATCCCCTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAA
GCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGC
AAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATC
TGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACG
CGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATT
AGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCC
CGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTA
66

TGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGT
ATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGT
ACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCC
AGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTC
ATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATA
GCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGA
GTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCC
GCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAA
GCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATT
AATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCT
TACGCTGGCCGCAGGGATTATAATTATTTCCATTTTCAAATTAAGGCCTCTGA
GCTCAGAGAGGGGAAGTTACTTGTCTGAGGCCACACAGCTTGTTGGAGCCCA
TCTCTTGACCCAAAGACTGTGGAGCCGAGTTGGCCACCTCTCTGGGAGCGGG
TATTGGATGGTGGTTGATGGTTTTCCATTGCTTTCCTGGGAAAGGGGTGTCTC
TGTCCCTAAGCAAAAAGGCAGGGAGGAAGAGATGCTTCCCCAGGGCAGCCG
TCTGCTGTAGCTGCGCTTCCAACCTGGCTTCCACCTGCCTAACCCAGTGGTGA
GCCTGGGAATGGACCCACGGGACAGGCAGCCCCCAGGGCCTTTTCTGACCCC
ACCCACTCGAGTCCTGGCTTCACTCCCTTCCTTCCTTCCCAGGTGAACCTCCA
AAATCAGGGGATCGCAGCGGCTACAGCAGCCCCGGCTCCCCAGGCACTCCCG
GCAGCCGCTCCCGCACCCCGTCCCTTCCAACCCCACCCACCCGGGAGCCCAA
GAAGGTGGCAGTGGTCCGTACTCCACCCAAGTCGCCGTCTTCCGCCAAGAGC
CGCCTGCAGACAGCCCCCGTGCCCATGCCAGACCTGAAGAATGTCAAGTCCA
AGATCGGCTCCACTGAGAACCTGAAGCACCAGCCGGGAGGCGGGAAGGTGA
GAGTGGCTGGCTGCGCGTGGAGGTGTGGGGGGCTGCGCCTGGAGGGGTAGG
GCTGTGCCTGGAAGGGTAGGGCTGCGCCTGGAGGTGCGCGGTTGAGCGTGGA
GTCGTGGGACTGTGCATGGAGGTGTGGGGCTCCCCGCACCTGAGCACCCCCG
CATAACACCCCAGTCCCCTCTGGACCCTCTTCAAGGAAGTTCAGTTCTTTATT
GGGCTCTCCACTACACTGTGAGTGCCCTCCTCAGGCGAGAGAACGTTCTGGC
TCTTCTCTTGCCCCTTCAGCCCCTGTTAATCGGACAGAGATGGCAGGGCTGTG
TCTCCACGGCCGGAGGCTCTCATAGTCAGGGCACCCACAGCGGTTCCCCACC
TGCCTTCTGGGCAGAATACACTGCCACCCATAGGTCAGCATCTCCACTCGTGG
GCCAAAAATCCACAGGTGATTCTGATGCCCGGCAGGCTTGAGAACAGCCGCA
GGGAGTTCTCTGGGAATGTGCCGGTGGGTCTAGCCAGGTGTGAGTGGAGATG
CCGGGGAACTTCCTATTACTCACTCGTCAGTGTGGCCGAACACATTTTTCACT
TGACCTCAGGCTGGTGAACGCTCCCCTCTGGGGTTCAGGCCTCACGATGCCAT
CCTTTTGTGAAGTGAGGACCTGCAATCCCAGCTTCGTAAAGCCCGCTGGAAA
TCACTCACACTTCTGGGATGCCTTCAGAGCAGCCCTCTATCCCTTCAGCTCCC
CTGGGATGTGACTCGACCTCCCGTCACTCCCCAGACTGCCTCTGCCAAGTCCG
AAAGTGGAGGCATCCTTGCGAGCAAGTAGGCGGGTCCAGGGTGGCGCATGTC
ACTCATCGAAAGTGGAGGCGTCCTTGCGAGCAAGCAGGCGGGTCCAGGGTGG
CGTGTCACTCATCCTTTTTTCTGGCTACCAAAGGTGCAGATAATTAATAAGAA
GCTGGATCTTAGCAACGTCCAGTCCAAGTGTGGCTCAAAGGATAATATCAAA
CACGTCCCGGGAGGCGGCAGTGTGAGTACCTTCACACGTCCCATGCGCCGTG
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CTGTGGCTTGAATTATTAGGAAGTGGTGTGAGTGCGTACACTTGCGAGACAC
TGCATAGAATAAATCCTTCTTGGGCTCTCAGGATCTGGCTGCGACCTCTGGGT
GAATGTAGCCCGGCTCCCCACATTCCCCCACACGGTCCACTGTTCCCAGAAG
CCCCTTCCTCATATTCTAGGAGGGGGTGTCCCAGCATTTCTGGGTCCCCCAGC
CTGCGCAGGCTGTGTGGACAGAATAGGGCAGATGACGGACCCTCTCTCCGGA
CCCTGCCTGGGAAGCTGAGAATACCCATCAAAGTCTCCTTCCACTCATGCCCA
GCCCTGTCCCCAGGAGCCCCATAGCCCATTGGAAGTTGGGCTGAAGGTGGTG
GCACCTGAGACTGGGCTGCCGCAGATACCCCACTCCTGCCTTTCCAGCAAGA
TTTTTCAGATGCTGTGCATACTCATCATATTGACCACTTTTTTCTTCATGCCTG
ATTGTGATCTGTCAATTTCATGTCAGGAAAGGGAGTGACATTTTTACACTTAA
GCGTTTGCTGAGCAAATGTCTGGGTCTTGCACAATGACAATGGGTCCCTGTTT
TTCCCAGAGGCTCTTTTGTTCTGCAGGGATTGAAGACACTCCAGTCCCACAGT
CCCCAGCTCCCCTGGGGCAGGGTTGGCAGAATTTCGACAACACATTTTTCCAC
CCTGACTAGGATGTGCTCCTCATGGCAGCTGGGAACCACTGTCCAATAAGGG
CCTGGGCTTACACAGCTGCTTCTCATTGAGTTACACCCTTAATAAAATAATCC
CATTTTATCCTTTTTGTCTCTCTGTCTTCCTCTCTCTCTGCCTTTCCTCTTCTCTC
TCCTCCTCTCTCATCTCCAGGTGCAAATAGTCTACAAACCAGTTGACCTGAGC
AAGGTGACCTCCAAGTGTGGCTCATTAGGCAACATCCATCATAAACCAGGTA
GCCCTGTGGAAGGTGAGGGTTGGGACGGGAAGGTGCAGGGGGTGGAGGAGT
CCTGGTGAGGCTGGAACTGCTCCAGACTTCAGAAGGGGCTGGAAAGGATATT
TTAGGTAGACCTACATCAAGGAAAGTGTTGAGTGTGAAACTTGCGGGAGCCC
AGGAGGCGTGGTGGCTCCAGCTCGCTCCTGCCCAGGCTATGCTGCCCAAGAC
AAGGTGAGGCGGGAGTGAAGTGAAATAAGGCAGGCACAGAAAGAAAGCAC
ATATTCTCGGCCGGGCGCTGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAG
GCCAAGGTGGGTGGATCATGAGGTCAGGAGATTGAGACCATCCTGGCTAACA
CAGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGG
CGGGCGCCTGTAGTCCCAGCTACTGTGGGGTCATGGTTTACAGGATGTTGATA
TAGAAAAGACTTCACTTAATGGGCCGGGCGCAGTGGCTCATGCCTGTAATCC
CAGCACTTTGGGAGGCCGAGGCAGGCAGATCAGGAGGTCAGGAGATTGAGA
CCATCCTGGCTAACACAGTGAAACCCCATCTCTACTGAAAATACAAAAAATT
AGCTGGGCGTGGTGGCAGGCACCTGTAGTCCCAGCCACTCGGTTGGCTGAGG
CAGGAGAATGGCATGAACCCGGGAGGCGGAGCTTGCAGTGAGCAGAGACCA
TGCCACTGCACTCCAGCCTGGGCGACAGAGCAAGACTCTGTCTCAAGAAAAA
AAAAAAAAAAACAGACTTTACTTACTGGAAGCCAACCAATGTATATTTAGAG
TAATTTTTCCTGGGCTGAGCTGTCATTTACTTTTGCAGTATCTCAAGAAGAAG
AGTTTACAGTGTAAATATTTGATGCACACTTTGATTATATAGATGAAGCAAAC
TATTTTCAAGAGCTTTGCAAGGACTTACTTGTATCCAAACACCATTCTAAAGG
AGTCTTACCTACTTCTAAAGGCTGGTCTCTACTTGGAACCACTTGCTTGGCCC
TGGTTCAAGTCCTGCTGCAAACCTGGAAGTCCTGTCATTGTCTTCTTCCCTCC
AGAGCAGTGGCACCCAATCTAATTTTTGCTGTGCCCCAGCAGCCCCTGGCACT
TTGCCCTGTAGACTGCAGACCTCATGTAATGTATGTTAAGTCCACAGAACCAC
AGAAGATGATGGCAAGATGCTCTTGTGTGTGTTGTGTTCTAGGAGGTGGCCA
GGTGGAAGTAAAATCTGAGAAGCTTGACTTCAAGGACAGAGTCCAGTCGAAG
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ATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAAAAGG
TAAAGGGGGTAGGGTGGGTTGGATGCTGCCCTTGGGTATATGGGCATTAATC
AAGTTGAGTGGACAAAGGCTGGTCCAGTTCCCAGAGGAGGAAAACAGAGGC
TTCTGTGTTGACTGGCTGGATGTGGGCCCTCAGCAGCATCCAGTGGGTCTCCA
CTGCCTGTCTCAATCACCTGGAGCTTTAGCACGTTTCACACCTGGGCCCCAAC
CTGGAGAGGCTGACCAATGGGTCTCAGGGGCAGCTCGGTTGCTGGAGTTTTT
GTTTTTATTTATTTTTATGTATTTAAGGCAGGGTCTCTGTATTAGTCCATTCTC
ACACTGCTAATAAAGACATACCCAAGACTGGGTAATTTATAAAGGAAAGAGG
TTTAATGGACTCACAGTTCCACATGGCTGGGGAGGCCTCAAAATCATGGCGG
AAGGCAAAGGAGAAGCAAAGGCATTTCTTACATGGCGACAGGCAAGAGAGC
GTGTGCAGGGGAACTCCCATTTATAAAACCATCAGACCTCATGAGATTTATTC
ACTATCATGAGAACAGCATGGGAAAGACCCGCCCCCATGATTCAGTTACCTC
CCACTGGGTCCCTCCCATGACACATGGAATTATGGGAGCTACAATTCAAGAT
GAGATTTGGGTGGGGACACAGCCAAACCATATCAGTCTCCCTCTGTCATCCA
GGCTGGAGTGCACTGGCATGATCTCGGCTCACTGCAGCCTCTACCTCCCTGGG
TCAGGTGATCTTCCCACCTCAGCCTCCCAGGTAGCTGGAACTACAGGTACCTG
CCACTATGCCTGGCTAAATATTTTGTATTTCCTGTGGAGACGAGGTTTTGCCA
CGTTGCCCAGGCTGGTCTTGAACTCCTGAGGTCAAGCAATATGCCCACCTCG
GCCTCCCAAGGTGCTGGGATTACAGGTGTGAGCCACAGTGCTCGGCCTAAGT
CACTGCAGTTTCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCG
ACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCC
TTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAAT
TGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGC
AGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATG
CGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGG
GTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTT
ACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGC
TTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAA
TCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCA
AAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGAC
GGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTT
CCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAG
GGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAA
TTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCC
CCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAG
CAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAA
GCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATC
CCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAAT
TTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGA
AGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGG
AGCTTGTATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTC
GCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGA
GAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCC
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GCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGA
CCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGG
CTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAG
CGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTC
ATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGC
GGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACA
TCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGAT
GATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGC
TCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGC
CTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACT
GTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCG
TGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTT
ACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGAC
GAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCC
CAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGG
GCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGA
TCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATG
GTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCA
CTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGT
ATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCC
TGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGC
ATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTG
CGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCAT
TAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTT
CCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCG
GTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATA
ACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTA
AAAAGGCCGC
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CHAPTER 5. FUNCTION OF MAPT CIRCULAR RNAS
5.1

Introduction

After finding that the human MAPT gene generates circular RNAs due to the
processing of the pre-mRNA (43) (Figure 5.1 A-C), I started to investigate their functional
characteristics. The circular tau RNA 12à7 contains one in-frame start codon in exon 9
and no stop codon, as mentioned in chapter 3 (Figure 3.1 C). We found that the circular tau
RNA 12à7 is translated in a rolling circle giving rise to a multimeric protein. The 12à7
protein could then potentially promote tau aggregation and neurofilament tau tangles,
causing neurodegeneration and tauopathies. Since tau is one of the major contributors to
Alzheimer’s disease and other neurodegenerative diseases, this mechanistic approach
would be a novel pathway for the disease pathology. The protein generated from the 12à7
circular RNA may play a role under normal physiological conditions in the brain.
The circular RNA 12à10 does not contain a start codon or a stop codon. However, it
has been found that 53 mutations in the MAPT gene give rise to hereditary frontotemporal
dementia (79). The majority of these mutations are located in exons 9-13, regions that
control circular RNA formation, where two specific mutations create methionine start
codons in exon 11 (K317M) and exon 12 (V337M). These mutations would create a start
codon in the circular RNA 12à10 causing translation to occur. We show that these
mutations allow this circular RNA to be translated, and the encoded protein could
potentially lead to tau aggregation or neurofilament tangles.
It is not clear how neurofibrillary tau tangles (NFT) develop. It was shown that the
‘K18’ peptide encompassing tau repeats R1-R4, acts as a ‘seed peptide’, promoting tau
aggregation into paired helical filaments (6) and neurofibrillary tau tangles (NFT) (7).
Strikingly, the proteins encoded by tau circular RNA encode R1-R4 (tau circ 12à7) or R2R4 (tau circ12à10). Thus, tau multimers encoded by circular RNAs could act as a seed
sequence that promotes tau aggregation and NFT formation, similar to the structurally
related ‘K18’ peptide (Figure 5.1 D, E).
RNA editing enzymes, known as adenosine deaminase acting on RNA (ADAR), can
also contribute to circular tau RNA translation. The catalytically active enzymes, ADAR1
and ADAR2, edit adenosines to inosines (A-to-I), where the inosine will be read as a
guanosine. The sequence AUA could be edited to AUI and be read as an AUG start codon.
We show that the 12à10 circular RNA that does not have a start codon is translated when
the catalytically active ADAR enzymes are overexpressed. It has been shown that a
deregulation of RNA editing can contribute to Alzheimer’s disease (135). The deregulation
of the ADAR enzymes may act on the tau circular RNAs and the circular RNAs translated
proteins could potentially contribute to tauopathies.
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5.2

Experimental Approach

Two systems were utilized to test for circular RNA expression and protein
translation. First, we tested endogenous tau circular RNA expression, in different areas of
human brain tissue. The protein could not be tested, as there is no antiserum specific for
the protein generated by the circular RNA versus the linear. Antiserum targeting the
peptide junction specific for the circular RNA protein and not the linear RNA protein was
made but did not work. The second system used was Human Embryonic Kidney 293T cells
(HEK 293T). Human embryonic kidney 293T cells were stably or transiently transfected
to express the tau circular RNAs 12à7 and 12à10.
In order to test protein expression, I used an expression vector that contains Alu
components from the Zinc finger protein with KRAB and SCAN domains 1 (ZKSCAN1)
gene. ZKSCAN1 encodes a strongly expressed circular RNA. The processing of this
circular RNA is due to the short intronic repeat elements, known as Alu elements, that have
complementary sequences that bind and bring the exons into close proximity (45). The
ZKSCAN1 Alu elements were cloned into our tau cDNA constructs that contained exons
7, 9-12 and exons 10-12 (Figure 5.2 A-D, Supplemental Figure 5.1-5.4, 5.8). In order to
fully recapitulate the human system and make the tau expression constructs more authentic,
I removed the ZKSCAN1 intronic regions and inserted a shortened sequence of the tau
intron. The tau intronic regions contain the tau Alu element and repeat sequences in both
the left and right intron (Figure 5.3 A-C, Supplemental Figure 5.5-5.8).
The ZKSCAN1 model has a more robust expression than the model with authentic
tau Alu. Thus, I used the ZKSCAN1 model for mass spectrometry purposes to have enough
protein for detection.
5.3

Materials and Methods

5.4

Tau Primers for cloning

Primer Name

Primer Sequence

pcDNA 9-12_fwd

AGGGAGTTCTCTGGGAATGTG

pcDNA 9-12_rev

GGCCCACGAGTGGAGATG

JB and MER5A_fwd

agcatctccactcgtgggccCATAGTCTTTTGAAGGAA
CATAAAAGATTATGAAGAAATG

JB and MER5A_rev

acattcccagagaactccctGCGGCTGTTCTCAAGCCTG

V337_to_M_F

AGGTGGCCAGaTGGAAGTAAA

V337_to_M_R

CCTGGTTTATGATGGATGTTG

K_TO_M Mut_F

GACCTGAGCAtGGTGACCTCC

K_TO_M Mut_R

AACTGGTTTGTAGACTATTTGC
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7_12_both_auth_alu_vec_fwd

GGGGGCTGATGGTGACTACAAAGACCATG

7_12_both_auth_alu_vec_rev

GTTTCCTTACTTCTAAATACATTCAAATATGT
ATCC

7_12_both_aut_alu_insert_fwd

GTATTTAGAAGTAAGGAAACCACCTTTG

7_12_both_aut_alu_insert_rev

TGTAGTCACCATCAGCCCCCTGTAAATG

5.5

Tau Sequencing primers

Primer Name

Primer Sequence

JB_MER5Adetect_for

ccacccataggtcagcatct

JB_MER5Adetect_rev

gcctgacttctggttcatcc

Zkscan forward

GAATTCAGTGACAGTGGAG

ZKscan rev

TAATGCCTACCAGGTTCATTAC

KM_mut_seq_for

ACA CGT CCC GGG AGG C

Tau exon 7 rev

CTGCGATCCCCTGATTTTGG

Tau exon 11 for

GTGTGCAAATAGTCTACAAACCA

Tau exon 12 rev

AGGGACCCAATCTTCGACTG

Exon 12 forward

GAG GTG GCC AGG TGG AA

Exon 10 forward

GTG CAG ATA ATT AAT AAG AAG CTG

Exon 10 rev

CTG CCG CCT CCC GGG

Exon 11 reverse

TGG TTT ATG ATG GAT GTT GCC T

Exon 7Wflag_for

GGG GCT GAT GGT GAC TAC AA

Exon 9 forward

GTG AAC CTC CAA AAT CAG GG

Exon 9 reverse

CTT CCC GCC TCC CGG C
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5.6

Tau Primer location

5.7

Cell Culture

Human Embryonic Kidney Cells (HEK) 293T (ATCC, CRL-3216) were cultured in
Dulbecco’s Modified Eagles Medium – High Glucose (DMEM)(Sigma, D5796) with 10%
fetal bovine serum (Azer Scientific, ES56817). Cells were grown in a humidified incubator
at 37˚C with 5% CO2. Stable cell lines were selected and maintained by adding 1µg/ml of
Hygromycin B (Sigma-Aldrich, 10843555001) to the cell culture media.
5.8

Generation of Stable Cells

HEK 293T cells were co-transfected with 5 µg of the pcDNA3.1 expression vector
that contained the tau minigenes, with 0.33µgs of linear hygromycin (Takara Bio, 631625).
The DNA was combined and mixed in 200µl sterile-filtered 150 mM NaCl (Fisher
Scientific,
BP-358-212),
then
Linear
Polyethyleneimine
Hydrochloride
(PEI)(Polysciences, 24765-1) was added to the DNA mix at 3µg/µg (PEI/DNA). The DNA
was incubated for 10 mins then added directly to cells in 100mm cell culture dish (Azer
Scientific, ES56269). The media was changed after 24 hrs. The cells were then split at 25%
confluency with Trypsin-EDTA (0.25%), phenol red (Fisher Scientific, 25200114), into a
multiwell cell culture plate. The cells were selected by adding 1µg/ml of Hygromycin B
(Sigma-Aldrich, 10843555001) to the cell culture media and then expanded.
5.9

Transient Transfection

Transient transfection was performed in HEK 293T cells. The controls and tau
expression constructs for this cell line were in a pcDNA 3.1 vector. 2µg of DNA was mixed
with 200 µl of sterile 150 mM NaCl (Fisher Scientific, BP-358-212) and 6 µl of Linear
Polyethyleneimine Hydrochloride (PEI) (Polysciences, 24765-1). The DNA was incubated
at room temperature for 10 mins and then added to the cells. The cells were cultured in a
150 mm dish (Azer Scientific, ES56268), and transfected at 60% confluency. The cells
were lysed and analyzed 96 hrs post transfection.
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5.10 siRNA Transfection
Transient transfection was performed in HEK 293T cells. Cells were plated in a 6well plate (VWR, 10062-892) at a density of 300,000 cells per well. All of the samples had
200 ng of eGFP for transfection efficiency and loading control. One microgram of the tau
expression construct, zkscan 7-12 WT, was mixed with 150 µl of sterile Opti-MEM
medium (ThermoFisher Scientific, 31985062). The 12to7 junction siRNA was added to the
mix at different concentrations, 0.40 µM, 2 µM, and 4 µM, and then vortexed and incubated
at room temperature for 5 minutes. In another tube, 150 µl of sterile Opti-MEM medium
and 10 µl of Lipofectamine 2000 (Fisher Scientific, 11668030) were mixed. The two
mixtures were combined, vortexed and incubated for 10 minutes at room temperature.
After 10 minutes, the media was removed, and the DNA mixture was added to the cells.
The cells were incubated for 20 minutes at 37˚C 5% CO2. After 20 minutes, 2 ml of DMEM
10% FBS media were added to the cells and incubated for 24 hrs. After 24hrs, the media
was replaced with fresh media for 48 hrs. After 48 hrs, the cells are lysed and analyzed for
protein. The same was done for the zkscan 10-12 VM expression construct and 12to10
junction siRNAs. The siRNAs sequences are shown in Table 5.1.
5.11 Immunoprecipitation
The cells were spun at 14,000g at 4˚C for 10 mins to pellet. The cell pellet was
washed 3 times with ice-cold phosphate buffered saline (PBS) (Sigma-Aldrich, 59331C1000ML) to remove culture medium contaminants. The cell pellets were then resuspended
in ice-cold lysis buffer: 50 mM Tris-HCL, pH 7.4 at 4˚C (Sigma-Aldrich, 648315-100ML),
150 mM NaCl (Fisher Scientific, BP-358-212), 1 mM EDTA (Bioland Scientific,
EDTA01); supplemented with 0.5% Nonidet P-40 (Sigma-Aldrich, I8896-50ML), and
complete min EDTA-free protease inhibitor cocktail (Sigma-Aldrich, 11836170001), at a
1:4 pellet weight:volume ratio. The protease inhibitor cocktail tablets were added fresh
before each use. The lysed cell pellet was then freeze thawed two times by incubating on
dry ice for ~10 mins, then transferred to 37˚C bath until only a small amount of ice remains.
The lysed cell pellet was spun again at 14,000g at 4˚C for 10 mins to remove cell insoluble
products.
The supernatant was then transferred to a new clean tube and boiled at 95˚C for 5
mins. The supernatant was spun again at 14,000g at 4˚C for 10 mins. The supernatant was
transferred to a new clean tube and analyzed by Qubit 4 Fluorometer (Fisher Scientific,
Q33238, Q33211) for the total protein concentration.
The supernatant was then pre-cleared with mouse IgG Agarose beads (SigmaAldrich, A0919-2ML). The volume of beads used was determined via Qubit at 10 µl of
beads to each 1 mg of total protein. Benzonase (Sigma-Aldrich, E1014-25KU) with 1 mM
Magnesium Chloride (MgCl2) (Sigma-Aldrich, M8266-100G) were added to the
supernatant mixture with the mouse IgG beads for 30 mins shaking at 37˚C and then
rotating at 4˚C for 30 mins. The supernatant was spun at 14,000g at 4˚C for 5 mins to pellet
the mouse IgG agarose beads. The supernatant was then transferred to a new tube and
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mixed with Anti-FLAG M2 Magnetic Beads (Sigma-Aldrich, M8823-1ML). The antiFLAG M2 magnetic beads and lysate were incubated at 4˚C on a rotating wheel overnight.
The beads were then pelleted using a magnetic rack, and the supernatant was
removed and disposed. The magnetic flag M2 beads were washed three times in lysis
buffer, then another three times in fresh 50 mM Ammonium Bicarbonate (Sigma-Aldrich,
09830-500G). The beads were resuspended in 5X Sodium Dodecyl Sulfate (SDS) loading
buffer: 0.25% Bromophenol Blue (Fisher Scientific, B-392-5G), 0.5M Dithiothreitol
(DTT) (IBI Scientific, IB21040), 50% Glycerol (Fisher Scientific, BP229-1), 10% SDS
(Sigma-Aldrich, L3771-500G), 0.25M pH 6.8 Tris-HCl (Sigma-Aldrich, 10812846001).
The flag magnetic beads were then boiled at 95˚C for 2 mins. The beads were pelleted
again using the magnetic rack and the supernatant “sample” was transferred to a new clean
tube.
5.12 Western Blot
The IP samples were run on precast any kD Mini-PROTEAN acrylamide gels (BioRad, 4569035) for 45 mins at 160 Volts and 2 amps in 1X SDS running buffer. The protein
samples were then transferred from the gel to a nitrocellulose membrane (Bio-Rad,
1704270) in a Trans-Blot Turbo Transfer System (Bio-Rad, 1704150) 25V 2.5 Amps for 3
mins. The stacking sponge was presoaked in Transfer buffer (Bio-Rad, 1704270).
The nitrocellulose membranes were blocked with 10 ml of blocking buffer
(Phosphate Buffered Saline, 10% Tween 20 (PBST), 5% Milk) three times for 20 mins
each. After blocking the nitrocellulose membrane, the blocking buffer is discarded, and the
primary antibody solution (6 ml PBST, 6 µl primary antibody (1:1000 dilution), 1X Bovine
Serum Albumin (BSA), 0.1% Sodium Azide) is added. The membrane was placed on a
rocking platform overnight at 4˚C. The primary antibodies used were: Anti 4R-tau (Cosmo
Bio, CAC-TIP-4RT-P01), Anti-FLAG M2-Peroxidase (Sigma-Aldrich, A8592-1MG),
Anti-EIF4B (Cell Signaling Technology, 3592S). The next day, the primary antibodies are
then discarded, and the membrane is washed for 20 mins two times with PBST. The
secondary antibody solution (10 ml PBST, 5% Milk, 1:10000 dilution secondary antibody)
is added to the nitrocellulose membrane at room temperature rocking on a platform for 1
hr. The secondary antibody used for Anti 4R-Tau and Anti-EIF4B was Anti-Rabbit IgG
H&L (Horse Radish Peroxidase) (Abcam, ab6802).
After the secondary antibody incubation, the solution is discarded. The membrane
is then washed three times for 20 mins with PBST. After the last wash discard the solution
and add 1:1 ratio, 500 µl each, of the SuperSignal West Pico PLUS Chemiluminescent
Substrate (Fisher Scientific, 34577). Let the membrane sit for 2 mins then Image using
ChemiDoc MP Imaging system (Bio-Rad, 12003154).
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5.13 RNase Protection
RNase protection was performed as described (93) using the RPAIII kit
(Ambion/Invitrogen) and one million cpm of a 32P uniformly labeled probe. Hybridization
was overnight, the digestion used RNaseA and T1 for one hour (43).
5.14 Mass Spectrometry
The immunoprecipitation was prepared as stated above (Figure 5.7) and the samples
on the Flag M2 magnetic beads were sent to Dr. Alex Campos from the Medical Discovery
Institute in La Jolla, California for analysis.
5.15 Results
5.16 Expression of tau circular RNA 12à7
To detect the endogenous circular RNA 12à7 from human brain tissue (Table5.2)
and transfected cells, RNase protection probes were designed to hybridize to the backsplice
junction with 60 nucleotides (nt) hybridizing to exon 12 and 40 nt hybridizing to exon 7
(Figure5.4 A, C. Figure 5.5 A-C). The protected band of 100 nt indicates the circular RNA,
and two bands at 60 and 40 nt indicate the linear RNA. We show that the endogenous
expression of the tau circular RNA 12à7 is expressed in different regions of human brain
tissue (Figure 5.6).
In order to find sequences necessary and sufficient for circular RNA expression, I
used the cloning procedure as described previously in chapter 2 (5) to overexpress the tau
circular RNA 12à7. In this model, we first used a heterologous system, ZKSCAN1.
ZKSCAN1 encodes a zinc-protein and expresses one of the most abundant human circular
RNAs. We used the intronic regions that contained the Alu elements, which promotes
circular RNA formation due to the short intronic repeats that have base complementarity,
bringing the downstream exon 3 into close proximity to the upstream exon 2 (45). The tau
exons 7,9-12 were cloned in a pcDNA3.1 expression vector between the two ZKSCAN1
short intronic repeat segments (Figure 5.2 D). The RNase protection probes were designed
to detect the endogenous circular RNAs (Figure 5.4. A), and the circular RNA that contains
the artificial 3X flag tag in the ZKSCAN1 model (Figure 5.4 C). Stably transfected human
embryonic kidney (HEK) 293T cells, that express the ZKSCAN1 tau 12à7 circular RNA,
were validated for circular RNA expression (Figure 5.6).
The circular RNA 12à7 is expressed in both human brain tissue and transfected
cells. However, there are no antibodies available to distinguish between the protein
generated from the linear RNA and the circular RNA. Therefore, we designed the
expression constructs incorporating a 3X flag tag upstream of the start codon of the circular
RNA. Translation of the 3X flag tag will only occur from the circular RNA. We purify the
protein by immunoprecipitating with an anti-flag antibody and detect the protein with an
anti-tau antibody by western blot.
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To test for translation the immunoprecipitation protocol was optimized
(Figure 5.7), where we lysed the cells and performed two freeze thaw cycles to break open
the cells. The cell debris was recovered by centrifugation, and the lysate supernatant was
boiled at 95˚C for five minutes, to break apart tubulin and other enzymes and protein
complexes from the tau protein, as tau is heat stable (136). In pilot experiments, we found
that the protein encoded by the circular RNA is also heat stable. The lysate is spun again
and mixed with Mouse IgG agarose beads to pre-clear any non-specific binding proteins,
along with Benzonase that degrades DNA and RNA that is present in the lysate. The preclearing step is incubated at 4˚C for one hour on a rotating wheel. This step allows some
denatured proteins to renature and bind again to interacting proteins. The lysate is now
immunoprecipitated with anti-flag M2 magnetic beads to purify the protein generated from
the circular RNA. The flag tag is located in exon 7 with the start codon in exon 9. Therefore,
the only way to generate the flag sequence is by translation of a circular RNA. The
immunoprecipitation is incubated at 4˚C on a rotating wheel overnight and then washed
and boiled in SDS loading buffer. The boiled eluent is separated on an acrylamide gel, then
transferred to a nitrocellulose membrane, and analyzed by western blot with anti-flag and
anti-tau antibodies.
The circular tau 12à7 RNA is translated due to the naturally occurring methionine
(start codon) in exon 9. The circular tau 12à7 RNA gives rise to multiple proteins at
different sizes, potentially indicating the rolling circle translation and multimeric protein
(Figure 5.8, A-B). As there is no stop codon, an unusual sequence element or RNA
structure may implement termination of the translated protein. Translation could
potentially be stalled due to RNA recoding or editing. RNA editing, by ADAR enzymes,
edit adenosines to inosines and have been shown to promote translational stalling by
inducing context-dependent recoding (137). The immunoprecipitation purifies the protein
with the flag tag and then the protein is detected using two antibodies, anti-flag and antitau.
5.17 Frontotemporal Dementia mutations create new start codons
Human brain tissue was analyzed by RNase protection for the circular 12à10 RNA
expression described in chapter 3 (Figure 3.2 E). The cellular expression constructs
expressing the ZKSCAN1 and tau authentic Alu element 12à10 circular RNAs were
validated by RNase protection using probes that hybridize to the backsplice junction
(Figure 5.4 B, D. Figure 5.5 A-C). The probes contain 60 nucleotides of exon 12 and 40
nucleotides of exon 10, and the ZKSCAN1 constructs contain a partial 3X flag tag
sequence in exon 10. The ZKSCAN1 probes were designed for the stable and transient
transfected cells expressing the circular RNA 12à10 with the 3X flag tag, the endogenous
probes do not have the 3X flag tag sequence. The circular 12à10 RNA was detected by
RNase protection for both ZKSCAN1 and tau authentic Alu element constructs (Figure 5.9
A-B).
Two mutations in tau exons 11 (K317M) and 12 (V337M) lead to Frontotemporal
Dementia (138), creating start codons in the circular RNA 12à10. These mutations are
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predicted to initiate translation forming a protein that contains the microtubule binding
domains R2-R4. Immunoprecipitation was performed for the 12à10 circular RNA, as
indicated previously for the 12à7 translated circular RNA (Figure 5.7). The circular tau
RNA 12à10 with ZKSCAN1 and authentic tau Alu element have a 3X flag tag
incorporated in exon 10, similar to the 12à7 circular RNA. Translation of the 3X flag tag
will only occur from the circular RNA 12à10, but not the linear since the start codons are
located downstream in exon 11 and 12. The ZKSCAN1 10-12 constructs were tested for
translation together with the constructs containing the tau authentic Alu element (Figure
5.10 A-C). The wild type circular RNA is not translated and is only translated with the
FTDP-17 mutations that incorporate a start codon (Figure 5.10 B-C). Protein translation is
reduced when the ZKSCAN1 Alu element is replaced with the authentic tau Alu element
(Figure 5.10 C).
To analyze the protein generated from the circular RNA 12à10 with the V337M
mutation, I immunoprecipitated the protein described before using the anti-flag M2
magnetic beads and added Benzonase to degrade DNA and RNA in the lysate to avoid
nucleic acid mediated interactions. The beads were incubated overnight at 4˚C on a rotating
wheel and washed the next day in lysis buffer and fresh 50 mM ammonium bicarbonate.
The magnetic beads with the purified protein bound were then frozen and shipped to Dr.
Alex Campos at the Medical Discovery Institute in La Jolla, California for Mass
Spectrometry analysis. Dr. Campos digested the protein on the beads with trypsin and then
performed mass spectrometry. In the analysis we detected the sequence containing the
V337M mutation from the circular RNA with amino acids upstream of the methionine,
indicating the protein was translated from the circular RNA (Figure 5.11).
5.18 ADAR enzymes promote circular tau RNA translation
Adenosine deaminase acting on RNA (ADAR) is a protein coding gene that encodes
enzymes responsible for RNA editing. The enzyme recodes the RNA sequence
deaminating adenosines into inosines and is referred to as A-to-I editing. This modification
changes the RNA sequence, where adenosines are inosines and are now read as guanosines
by the ribosome. For instance, the nucleotide sequence AUA can be converted to AUI,
which would be read as an AUG, forming a new start codon. It has been shown that a
deregulation of RNA editing can contribute to Alzheimer’s disease (135). Two editing
enzymes, ADAR also known as ADAR1 and ADARB1 also known as ADAR2, are
catalytically active enzymes that catalyze the hydrolytic deamination of adenosines to
inosines of double-stranded RNA structures. ADARB2 also known as ADAR3 is
catalytically inactive and lacks editing activity. ADAR3 prevents the binding of other
ADAR enzymes to their targets in vitro and decreases the efficiency of these enzymes.
The effect of ADARs on protein translation was investigated with the catalytically
active ADARs, ADAR1 and ADAR2, and the inactive ADAR3. Transient transfected HEK
293T cells were co-transfected with the ADAR enzymes and the ZKSCAN1 tau 10-12
V337M and 7-12 WT constructs, and protein analysis was performed as previously
described above. Protein expression was increased when overexpressing the catalytically
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active ADAR1 and ADAR2 enzymes (Figure 5.12 A-B) for both the 10-12 VM and 7-12
WT expression constructs. Protein expression was not affected with the inactive ADAR3
(Figure 5.12 A-C). Translation of the circular RNA 12à10 wild type was not observed.
However, when there is an overexpression of the editing enzymes, ADAR1 and ADAR2,
the circular RNA 12à10 wild type is translated (Figure 5.12 C). A deregulation of ADAR
enzymes may be acting on the circular RNAs causing more editing to occur and allowing
more protein to be translated from the circular tau RNAs, which could contribute to
tauopathies and Alzheimer’s disease.
5.19 Interaction with EIF4B
Eukaryotic translation initiation factor 4B (EIF4B) is a helicase ribosomal protein
required for mRNA to bind with ribosomes and to be translated. In our mass-spectrometry
analysis EIF4B was detected as one of the abundant peptides from the immunoprecipitation
with the circular RNA 12à10 V337M. We validated this interaction by
immunoprecipitating with anti-flag beads and detected endogenous EIF4B with anti-serum
by western blot. The experiment was done in the presence of Benzonase, an endonuclease
that attacks and degrades all forms of DNA and RNA (Figure 5.13 A). Binding of
endogenous EIF4B was detected for both the tau circular RNAs 12à7 and 12à10, after
being boiled in the lysate and pulled down with an anti-flag immunoprecipitation (Figure
5.13 A-C).
5.20 siRNAs can be used as potential therapy for Tauopathies
I showed that the circular tau RNA 12à7 can be translated, and in instances where
mutations and editing introduce start codons, the circular tau RNA 12à10 is translated.
These translated proteins, when over expressed, may lead to a neurotoxic protein that could
mimic the ‘K18’ peptide promoting neurodegeneration (6). Therefore, we designed
siRNAs targeting the backsplice junction of the circular tau RNAs (Table 5.1). The siRNA
would be specific for the circular tau RNA and not the linear due to this design and could
therefore be used as a therapeutic drug, preventing tau pathologies.
The siRNAs were transfected into stable HEK 293T cells at different concentrations
for both the ZKSCAN1 tau 7-12 wild type and 10-12 V337M. The protein was purified by
immunoprecipitating with a 3X flag tag as previously described and detected by western
blot with an anti-flag antibody. Protein levels were reduced with increasing concentrations
indicating translation inhibition (Figure 5.14 A-C).
5.21 Discussion
5.22 MAPT as a contributor to tauopathies
The microtubule-associated protein tau, under pathophysiological conditions,
forms neurofibrillary tangles that are the hallmark of sporadic Alzheimer’s disease and
familial frontotemporal dementia linked to chromosome 17 (FTDP-17) (3).
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5.23 Function of tau circular RNAs
In this chapter we have discovered a function for the circular tau RNAs showing that
the endogenous tau 12à7 circular RNA with the original start codon in exon 9 is translated.
The translated protein is much larger than most circular RNAs (681 nt = 227 amino acids)
and may have a physiological role. For smaller circular RNAs, the translated peptides may
be acting as a neuropeptide due to the smaller size (150 nt = 50 amino acids), which is a
characteristic of most circular RNAs. The circular tau RNA 12à10 is translated when
mutations or possible editing introduce start codons. The mutations that cause
Frontotemporal Dementia (K317M and V337M) may be acting on the circular RNA
causing the translated protein to induce the pathology. The proteins generated from the
12à10 circular RNA could be causing tau aggregation and neurofilament tangles, since it
contains the region of the microtubule binding domains similar to the K18 seed segment.
Adenosine deaminase acting on RNA (ADAR) is a protein coding gene that encodes
an enzyme responsible for RNA editing by site-specific deamination of adenosines. This
enzyme destabilizes double-stranded RNA through conversion of adenosines to inosines.
The catalytically active enzymes, ADAR1 and ADAR2, catalyze the hydrolytic
deamination of adenosine to inosine in double-stranded RNA referred to as A-to-I RNA
editing (139-141). ADAR3 is catalytically inactive lacking the editing activity. ADAR3
prevents the binding of other ADAR enzymes to their targets and decreases the efficiency
of these enzymes. ADAR3 is capable of binding to both double stranded and single
stranded RNA. Deregulation of ADAR enzymes have been linked to a variety of
neurodegenerative and neurological disorders (142, 143). The ADAR enzymes that are
deregulated in Alzheimer’s disease may be acting on the circular RNAs, which contribute
to the pathology. We have shown that an overexpression of the active enzymes, ADAR1
and ADAR2, increase circular tau RNA translation and protein production. We also
discovered that the 12à10 wild type circular RNA, that has no start codon, is translated
when ADAR1 and ADAR2 are present. The tau circular RNAs' editing may introduce new
start codons, and a deregulation of RNA editing may cause an overabundance of protein
production, causing the tau pathology.
We have found that the circular tau RNAs protein interacts with the eukaryotic
translation initiation factor 4B (EILF4B). EIF4B is a protein encoding gene and is required
for the initiation of mRNA to ribosomes. EIF4B functions in close association with other
initiation factors, EIF4-F and EIF4-A. EIF4B binds near the 5´-terminal cap of mRNA in
the presence of EIF4-F and ATP. EIF4B promotes the ATPase activity and the ATPdependent RNA unwinding activity of both EIF4-A and EIF4-F. The interaction of the
circular tau RNAs protein with EIF4B may explain a potential function for the circular
RNAs. The circular tau RNAs may be regulating translation of other genes by reducing the
amount of EIF4B needed to bind competing mRNAs to ribosomes.
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5.24 Tau circular RNAs disease relevance
The MAPT gene generates so far unknown circular RNAs that are unexpectedly
translated producing proteins that are predicted to be similar to a neurotoxic peptide known
as K18. The K18 peptide is a segment of the tau microtubule binding domains and promotes
tau aggregation and neurofibrillary tangles (6). Mutations in the tau locus that cause FTDP17 reside mainly in exon 9-13, regions that control circular RNA formation and may be
acting on the circular RNAs instead of the linear RNAs. This novel pathway has never been
looked into before with the circular tau RNAs producing proteins that can contribute to
neurodegeneration. The circular tau RNAs can be a new target for drug therapies in
combating tau pathology. We have shown that protein production can be reduced with
siRNAs that target the backsplice junction of both the 12à7 and 12à10 circular RNA.
Currently there is no cure for tauopathies, and treatment is limited in slowing down the
pathology. The siRNAs could be used as a potential therapy by preventing the circular tau
RNAs from being translated, preventing the tau pathology from occurring or accumulating.
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Table 5-1 siRNA sequences targeting circular tau RNA backsplice junctions.
Provisional Patent Filed UK: #2539
Silencer® Select by Life Technologies
12to10 junction

Sense Strand: 5´AUAAAAAGGUGCAGAUAAUtt 3´
Antisense Strand: 3´AUUAUCUGCACCUUUUUAUtt
5´

12à10 RNA
Sequence

Exon 12/Exon 10: AUAAAAAG/GUGCAGAUAAU
Silencer® Select by Life Technologies

12to7 junction V3

Sense Strand: 5´AGGAAAUAAAAAGGGGGCUtt 3´
Antisense Strand: 3´AGCCCCCUUUUUAUUUCCUcc
5´

12à7 RNA Sequence

Exon 12/Exon 7: AGGAAAUAAAAAG/GGGGCUtt
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Table 5-2 Human Brain Samples
mRef# Age
Gender Race

Braak
Stage

PMI
(Hours)

Brain
Weight

Brain Bank

(Grams)
5464

31

Female

Asian

N/A

16

1210

NIH
NeuroBioBank

5357

51

Female

White

N/A

8

1320

NIH
NeuroBioBank

5298

31

Male

White

N/A

10

N/A

NIH
NeuroBioBank

1161

84

Female

White

0

2.50

1230

UK Sanders
Brown-Center on
aging
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Figure 5-1 Tau pre-mRNA processing model
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A. Shortened schematic of the tau locus and alternative splicing of the exons.
B. Backsplicing of exon 12 onto exon 7 or exon 10 forming the two tau circular RNAs.
The Alu elements have base complementarity forming the secondary structure needed for
backsplicing to occur.
C. Tau circular RNAs 12à7 is translated forming proteins of different sizes due to possible
multiple rounds of translation. The 12à10 circular RNA is translated when FTDP-17
mutations are introduced that create start codons, also giving rise to multiple proteins of
different sizes.
D. Both circular RNAs proteins are predicted to be similar to the neurotoxic ‘K18’ peptide
that contains only the microtubule binding domains.
E. The proteins translated from the circular tau RNAs may act like the ‘K18’ peptide and
promote tau aggregation and neurofibrillary tangles creating the tau pathology
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Figure 5-2 Tau circular RNA expression constructs with ZKSCAN1 alus

ZKSCAN Alu constructs with cDNA from tau exons 10-12 WT (A), 10-12 K317M (B),
10-12 V337M (C), and 7,9-12 WT (D). The yellow box is 3X flag tag and striped boxes
are ZKSCAN Alu sequences.
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Figure 5-3 Tau expression constructs with authentic tau alus

Both authentic Tau Alu constructs with cDNA from tau exons 10-12 WT (A), 10-12
K317M (B), 10-12 V337M (C). The yellow box is 3X flag tag and striped boxes are Alu
sequence. Grey and black boxes are repeat sequences.
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Figure 5-4 RNase protection probe sequences

RNase protection probe sequences used to detect endogenous and zkscan tau linear and
circular RNA 12à7 and 12à10.
A. Tau exon 12 all caps regular text on the left and exon 7 all caps, bold, and underlined
on the right
B. Tau exon 12 all caps regular text on the left and exon 10 all caps, bold, and underlined
on the right
C. Tau exon 12 all caps regular text on the left and exon 7 all caps, bold, and underlined
in the middle and lower case regular text is part of flag sequence.
D. Tau exon 12 all caps regular text on the left and exon 10 all caps, bold, and underlined
in the middle and lower case regular text is part of flag sequence.
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Figure 5-5 RNase protection approach to detect circular RNAs

A. Schematic overview: circular RNAs are detected with a radioactive antisense RNA.
This hybridizes to the circular RNA junction (12à7 or 12à10). 60 nt in exon 12 are
protected and 40 nt in exon 7 or 10 respectively.
B. Hybridization to linear RNA. A tau mRNA isoform from exon 7 to 12 is shown. The
hybridization of the probe to this mRNA is indicated.
C. Anticipated results: The full-length, 100 nt long protected fragment corresponds to the
circular RNA and is very weakly expressed. The probe also hybridizes to Linear forms
of tau, i.e. the linear form that contains exon 12, 7 and 10, resulting in much stronger
bands. Exon 10 is alternatively spliced, and thus the intensity of this band varies.
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Figure 5-6 RNase protection Brain regions and stable cells expressing tau circular
12à7

20 µg total brain RNA from 3 individuals from various regions were analyzed using RNAse
protection with probe A (endogenous tau 12_7_junction probe) (Figure 5.3A). Bands at
100 nt are protected circular 12à7 junction. Numbers indicate length in nucleotides.
Patient 5464 Hippocampus. Patient 5357 Frontal cortex. Patient 5298 Hypothalamus.
Patient 1161 Entorhinal Cortex. Patient 1161 White Matter. Patient 1161 Grey Matter. e.
coli tRNA (junction). Probe junction. Stable HEK 293T ZKSCAN1 tau 7-12 WT. e. coli
tRNA (ZKSCAN1). Probe (ZKSCAN1). *This figure was produced by Dr. Giorgi
Margvelani.
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Figure 5-7 Optimized Immunoprecipitation Protocol

Immunoprecipitation protocol to purify the protein generated from circular tau RNA using
a 3X flag tag. The IP used anti-flag M2 magnetic beads to purify protein generated from
the circular RNA and not the linear RNA.
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Figure 5-8 Protein expression of stable cells expressing ZKSCAN1 tau 7-12 WT
circular RNA

Stable cell lines expressing circular 12à7 RNA generated from ZKSCAN1 tau 7-12 WT
construct were lysed and Immunoprecipitated using a 3X flag pulldown. All tau cellular
expression constructs contain 3X flag tag. eGFP contained 3X flag tag.
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A. Immunoprecipitation schematic pulling down protein generated from circular tau RNA
with 3X flag tag. The Western Blot was detected with anti-flag antibody and an antitau antibody that has an epitope in exon 10.
B. Protein expression generated from ZKSCAN1 tau 7-12 WT circular RNA. Detection
by anti-flag and tau antibodies. The peptide diagrams on the left are depicted as 1, 2
and 3 rounds of translation. The F is for 3X flag tag.
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Figure 5-9 RNase protection HEK 293T cells expressing circular tau 12à10

RNase protection from stable HEK 293T cell lines expressing tau 12à10 circular RNAs.
*This figure was produced by Dr. Giorgi Margvelani.
A. Stable HEK 293T cells expressing Tau authentic alus 10-12 WT, KM, VM. Band
at 100 nt indicates protected splice junction. The circle depicts the protected
junction from the circular RNA and the linear fragments exons 12 and 10.
B. Stable HEK 293T cells expressing ZKSCAN1 tau 10-12 WT, KM, VM. Band at
100 nt indicates protected splice junction. The circle depicts the protected junction
from the circular RNA and the linear fragments exons 12 and 10.
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Figure 5-10 Protein expression of stable cells expressing 10-12 circular RNAs
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Stable cell lines expressing circular 12à10 RNA generated from ZKSCAN1 and the
authentic tau alus 10-12 WT, K317M, and V337M constructs were lysed and
Immunoprecipitated using a 3X flag pulldown. All tau cellular expression constructs
contain 3X flag tag. eGFP contained 3X flag tag.
A. Immunoprecipitation schematic pulling down protein generated from circular tau RNA
with 3X flag tag. The Western Blot was detected with anti-flag and anti-tau antibodies.
The anti-tau antibody has an epitope in exon 10.
B. Protein expression with ZKSCAN1 alus in circular tau 12à10 constructs. Detected by
anti-flag and tau antibodies. Only the mutants K317M and V337M are translated. The
protein diagrams on the left are depicted as 1 round and 2 round translation. The F is
for 3X flag tag.
C. Protein expression with authentic tau alus in circular tau 12à10 constructs. Detected
by anti-flag and tau antibodies. Only the mutants K317M and V337M are translated.
The protein diagrams on the left are depicted as 1 round and 2 round translation. The F
is for 3X flag tag.
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Figure 5-11 Mass Spectrometry Analysis Zkscan 10-12 VM

Mass Spectrometry analysis from stable HEK 293T cells expressing ZKSCAN1 tau 10-12
VM circular RNA. Peptide number 4 depicts the V337M mutation and start codon,
indicating circular translation. Protein was pulled down using flag M2 magnetic beads and
digested with Trypsin.
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Figure 5-12 Protein translation of circular tau RNAs 12à7 and 12à10 affected by
ADAR enzymes

Stable cell lines expressing circular 12à7 WT, 12à10 V337M, and 12à10 WT
transfected with ADARs 1-3. 96 hrs post transfection cells were immunoprecipitated and
analyzed by western blot with anti-flag and tau antibodies.
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A. Circular RNA 12à7 increased protein expression with ADAR1 and ADAR2. There
was no effect on protein translation with ADAR3. Western blot was detected with both
anti-flag and anti-tau antibodies. 4 µgs each of ADAR1, ADAR2 and ADAR3 were
transfected. The protein diagrams on the left are depicted as 1 round and 2 round
translation. The F is for 3X flag tag.
B. Circular RNA 12à10 V337M increased protein expression with ADAR1 and ADAR2.
There was no effect on protein translation with ADAR3. Western blot was detected
with both anti-flag and anti-tau antibodies. 2 µgs of ADAR1 and ADAR2 and 4 µgs of
ADAR3 were transfected. The protein diagrams on the left are depicted as 1 round and
2 round translation. The F is for 3X flag tag.
C. Circular RNA 12à10 WT is translated with ADAR1 and ADAR2 active enzymes.
Translation does not occur without the ADAR enzymes 1 and 2. WT and the inactive
ADAR3 does not generate protein. Western blot was detected with both anti-flag and
anti-tau antibodies. 4 µgs each of ADAR1, ADAR2 and ADAR3 were transfected in
the cells. The peptide diagrams on the left are depicted as 1 round and 2 round
translation. The F is for 3x Flag tag
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Figure 5-13 EIF4B interacts with tau protein generated from the circular RNA.

EIF4B detected from Mass Spectrometry after tau IP pulldown with anti-flag antibody was
blotted with Anti-EIF4B and detected the endogenous enzyme.
A. Immunoprecipitation schematic pulling down peptide generated from circular tau
RNA with 3X flag tag. The Western Blot was detected with anti EIF4B antibody.
B. Endogenous expression of EIF4B after 3X flag IP pulldown from stable cells
expressing ZKSCAN1 tau circular RNA 12à7.
C. Endogenous expression of EIF4B after 3X flag IP pulldown from stable cells
expressing ZKSCAN1 tau circular RNA 12à10.
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Figure 5-14 siRNAs destroy circular tau RNAs and prohibit protein translation

Stable cells expressing ZKSCAN1 tau 7-12 WT and ZKSCAN1 10-12 VM were
transfected in a 6-well plate with siRNAs at different concentrations. Cells were lysed 72
hrs post transfection, Immunoprecipitated, and analyzed by western blot.
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A. Schematic depicting siRNA binding to backsplice junction of 12à7 and 12à10
circular RNA. Yellow box in exon 7 and exon 10 is 3X flag.
B. Increasing concentrations of siRNA targeting 12-7 backsplice junction prohibits
protein translation from the 12à7 circular RNA. The negative control was stable cells
not transfected with siRNA. The peptide diagrams on the left are depicted as 1 and 2
rounds of translation. The F is for 3X flag tag.
C. Increasing concentrations of siRNA targeting 12-10 backsplice junction prohibits
protein translation from the 12à10 circular RNA. 3X flag eGFP was included as
negative control along with stable cells without siRNAs. The peptide diagrams on the
left are depicted as 1 and 2 rounds of translation. The F is for 3X flag tag.
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Supplemental Figure 5-1 ZKSCAN1 tau 7-12 WT Sequence
AGTGACAGTGGAGATTGTACAGTTTTTTCCTCGATTTGTCAGGAttttttttttttgacgga
gtttaacttcttgtctcccaggtaggaagtgcagtggcgtaatctcggctcactacaacctccacctcctgggttcaagcgtttctcc
tgcctcagctttccgagtagctgggattacaggcgcctgccaccatgccctgctgacttttgtatttttagtagagacggggtttcac
catgttggccaggctggtcttgaactcctgaccgcaggcgattggcctgcctcggcctcccaaagtgctgagattacaggcgtg
agccaccacccccggccTCAGGAGCGTTCTGATAGTGCCTCGATGTGCTGCCTCCTATA
AAGTGTTAGCAGCACAGATCACTTTTTGTAAAGGTACGTACTAATGACTTTTT
TTTTATACTTCAGGGGGCTGATGGTGACTACAAAGACCATGACGGTGATTAT
AAAGATCATGACATCGATTACAAGGATGACGATGACAAGAAAACGAAGATC
GCCACACCGCGGGGAGCAGCCCCTCCAGGCCAGAAGGGCCAGGCCAACG
CCACCAGGATTCCAGCAAAAACCCCGCCCGCTCCAAAGACACCACCCAGCT
CTGGTGAACCTCCAAAATCAGGGGATCGCAGCGGCTACAGCAGCCCCGGC
TCCCCAGGCACTCCCGGCAGCCGCTCCCGCACCCCGTCCCTTCCAACCCC
ACCCACCCGGGAGCCCAAGAAGGTGGCAGTGGTCCGTACTCCACCCAAGT
CGCCGTCTTCCGCCAAGAGCCGCCTGCAGACAGCCCCCGTGCCCATGCCA
GACCTGAAGAATGTCAAGTCCAAGATCGGCTCCACTGAGAACCTGAAGCAC
CAGCCGGGAGGCGGGAAGGTGCAGATAATTAATAAGAAGCTGGATCTTAGC
AACGTCCAGTCCAAGTGTGGCTCAAAGGATAATATCAAACACGTCCCGGGAG
GCGGCAGTGTGCAAATAGTCTACAAACCAGTTGACCTGAGCAAGGTGACCTC
CAAGTGTGGCTCATTAGGCAACATCCATCATAAACCAGGAGGTGGCCAGGTG
GAAGTAAAATCTGAGAAGCTTGACTTCAAGGACAGAGTCCAGTCGAAGATTG
GGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAAAAGGTAAG
AAGCAAGGTTTCATTTAGGGGAAGGGAAATGATTCAGGACGAGAGTCTTTGT
GCTGCTGAGTGCCTGTGATGAAGAAGCATGTTAGTcctgggcaacgtagcgagaccccatct
ctacaaaaaatagaaaaattagccaggtatagtggcgcacacctgtgattccagctacgcaggaggctgaggtgggaggattg
cttgagcccaggaggttgaggctgcagtgagctgtaatcatgccactactccaacctgggcaacacagcaaggaccctgtctca
aaaGCTACTTACAGAAAAGAATTAggctcggcacggtagctcacacctgtaatcccagcactttgggaggc
tgaggcgggcagatcacttgaggtcaggagtttgagaccagcctggccaacatggtgaaaccttgtctctactaaaaatatgaaa
attagccaggcatggtggcacattcctgtaatcccagctactcgggaggctgaggcaggagaatcacttgaacccaggaggtg
gaggttgcagtaagccgagatcgtaccactgtgctctagccttggtgacagagcgagactgtcttaaaaaaaaaaaaaaaaaaa
aaagaattaattaaaaatttaaaaaaaaatgaaaaaaaGCTGCATGCTTGTTTTTTGTTTTTAGTTATT
CTACATTGTTGTCATTATTACCAAATATTGGGGAAAATACAACTTACAGACCA
ATCTCAGGAGTTAAATGTTACTACGAAGGCAAATGAACTATGCGTAATGAAC
CTGGTAGGCATTA
Tau Exon 7 is highlighted in Brown, 3X flag tag in yellow, exon 9 highlighted in
Grey, exon 10 is highlighted in Red, Exon 11 in Blue, Exon 12 in Green. ZKSCAN1 Alu
elements indicated in lowercase. Highlighted in light green are sequencing primers.
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Supplemental Figure 5-2 ZKSCAN1 tau 10-12 WT sequence
AGTGACAGTGGAGATTGTACAGTTTTTTCCTCGATTTGTCAGGAttttttttttttgacgga
gtttaacttcttgtctcccaggtaggaagtgcagtggcgtaatctcggctcactacaacctccacctcctgggttcaagcgtttctcc
tgcctcagctttccgagtagctgggattacaggcgcctgccaccatgccctgctgacttttgtatttttagtagagacggggtttcac
catgttggccaggctggtcttgaactcctgaccgcaggcgattggcctgcctcggcctcccaaagtgctgagattacaggcgtg
agccaccacccccggccTCAGGAGCGTTCTGATAGTGCCTCGATGTGCTGCCTCCTATA
AAGTGTTAGCAGCACAGATCACTTTTTGTAAAGGTACGTACTAATGACTTTTT
TTTTATACTTCAGGTGCAGATAATTAATGACTACAAAGACCATGACGGTGATT
ATAAAGATCATGACATCGATTACAAGGATGACGATGACAAGAAGAAGCTGG
ATCTTAGCAACGTCCAGTCCAAGTGTGGCTCAAAGGATAATATCAAACACGT
CCCGGGAGGCGGCAGTGTGCAAATAGTCTACAAACCAGTTGACCTGAGCAA
GGTGACCTCCAAGTGTGGCTCATTAGGCAACATCCATCATAAACCAGGAGGT
GGCCAGGTGGAAGTAAAATCTGAGAAGCTTGACTTCAAGGACAGAGTCCAG
TCGAAGATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATA
AAAAGGTAAGAAGCAAGGTTTCATTTAGGGGAAGGGAAATGATTCAGGACG
AGAGTCTTTGTGCTGCTGAGTGCCTGTGATGAAGAAGCATGTTAGTcctgggcaac
gtagcgagaccccatctctacaaaaaatagaaaaattagccaggtatagtggcgcacacctgtgattccagctacgcaggaggc
tgaggtgggaggattgcttgagcccaggaggttgaggctgcagtgagctgtaatcatgccactactccaacctgggcaacaca
gcaaggaccctgtctcaaaaGCTACTTACAGAAAAGAATTAggctcggcacggtagctcacacctgtaatc
ccagcactttgggaggctgaggcgggcagatcacttgaggtcaggagtttgagaccagcctggccaacatggtgaaaccttgt
ctctactaaaaatatgaaaattagccaggcatggtggcacattcctgtaatcccagctactcgggaggctgaggcaggagaatca
cttgaacccaggaggtggaggttgcagtaagccgagatcgtaccactgtgctctagccttggtgacagagcgagactgtcttaa
aaaaaaaaaaaaaaaaaaaagaattaattaaaaatttaaaaaaaaatgaaaaaaaGCTGCATGCTTGTTTTTTG
TTTTTAGTTATTCTACATTGTTGTCATTATTACCAAATATTGGGGAAAATACA
ACTTACAGACCAATCTCAGGAGTTAAATGTTACTACGAAGGCAAATGAACTA
TGCGTAATGAACCTGGTAGGCATTA
Tau Exon 10 is highlighted in Red, 3X flag tag in Yellow, Exon 11 in Blue, Exon
12 in Green. ZKSCAN1 Alu elements indicated in lowercase. Highlighted in light green
are sequencing primers.
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Supplemental Figure 5-3 ZKSCAN1 tau 10-12 K317M Sequence
AGTGACAGTGGAGATTGTACAGTTTTTTCCTCGATTTGTCAGGAttttttttttttgacgga
gtttaacttcttgtctcccaggtaggaagtgcagtggcgtaatctcggctcactacaacctccacctcctgggttcaagcgtttctcc
tgcctcagctttccgagtagctgggattacaggcgcctgccaccatgccctgctgacttttgtatttttagtagagacggggtttcac
catgttggccaggctggtcttgaactcctgaccgcaggcgattggcctgcctcggcctcccaaagtgctgagattacaggcgtg
agccaccacccccggccTCAGGAGCGTTCTGATAGTGCCTCGATGTGCTGCCTCCTATA
AAGTGTTAGCAGCACAGATCACTTTTTGTAAAGGTACGTACTAATGACTTTTT
TTTTATACTTCAGGTGCAGATAATTAATGACTACAAAGACCATGACGGTGATT
ATAAAGATCATGACATCGATTACAAGGATGACGATGACAAGAAGAAGCTGG
ATCTTAGCAACGTCCAGTCCAAGTGTGGCTCAAAGGATAATATCAAACACGT
CCCGGGAGGCGGCAGTGTGCAAATAGTCTACAAACCAGTTGACCTGAGCATG
GTGACCTCCAAGTGTGGCTCATTAGGCAACATCCATCATAAACCAGGAGGTG
GCCAGGTGGAAGTAAAATCTGAGAAGCTTGACTTCAAGGACAGAGTCCAGTC
GAAGATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAA
AAGGTAAGAAGCAAGGTTTCATTTAGGGGAAGGGAAATGATTCAGGACGAG
AGTCTTTGTGCTGCTGAGTGCCTGTGATGAAGAAGCATGTTAGTcctgggcaacgtag
cgagaccccatctctacaaaaaatagaaaaattagccaggtatagtggcgcacacctgtgattccagctacgcaggaggctgag
gtgggaggattgcttgagcccaggaggttgaggctgcagtgagctgtaatcatgccactactccaacctgggcaacacagcaa
ggaccctgtctcaaaaGCTACTTACAGAAAAGAATTAggctcggcacggtagctcacacctgtaatcccag
cactttgggaggctgaggcgggcagatcacttgaggtcaggagtttgagaccagcctggccaacatggtgaaaccttgtctcta
ctaaaaatatgaaaattagccaggcatggtggcacattcctgtaatcccagctactcgggaggctgaggcaggagaatcacttga
acccaggaggtggaggttgcagtaagccgagatcgtaccactgtgctctagccttggtgacagagcgagactgtcttaaaaaaa
aaaaaaaaaaaaaaagaattaattaaaaatttaaaaaaaaatgaaaaaaaGCTGCATGCTTGTTTTTTGTTTT
TAGTTATTCTACATTGTTGTCATTATTACCAAATATTGGGGAAAATACAACTT
ACAGACCAATCTCAGGAGTTAAATGTTACTACGAAGGCAAATGAACTATGCG
TAATGAACCTGGTAGGCATTA
Tau Exon 10 is highlighted in Red, 3X flag tag in Yellow, Exon 11 in Blue, Exon
12 in Green. ZKSCAN1 Alu elements indicated in lowercase. Highlighted in light green
are sequencing primers. K317M mutation AAG to ATG is Bold and underlined in exon 11.
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Supplemental Figure 5-4 ZKSCAN1 tau 10-12 V337M Sequence
AGTGACAGTGGAGATTGTACAGTTTTTTCCTCGATTTGTCAGGAttttttttttttgacgga
gtttaacttcttgtctcccaggtaggaagtgcagtggcgtaatctcggctcactacaacctccacctcctgggttcaagcgtttctcc
tgcctcagctttccgagtagctgggattacaggcgcctgccaccatgccctgctgacttttgtatttttagtagagacggggtttcac
catgttggccaggctggtcttgaactcctgaccgcaggcgattggcctgcctcggcctcccaaagtgctgagattacaggcgtg
agccaccacccccggccTCAGGAGCGTTCTGATAGTGCCTCGATGTGCTGCCTCCTATA
AAGTGTTAGCAGCACAGATCACTTTTTGTAAAGGTACGTACTAATGACTTTTT
TTTTATACTTCAGGTGCAGATAATTAATGACTACAAAGACCATGACGGTGATT
ATAAAGATCATGACATCGATTACAAGGATGACGATGACAAGAAGAAGCTGG
ATCTTAGCAACGTCCAGTCCAAGTGTGGCTCAAAGGATAATATCAAACACGT
CCCGGGAGGCGGCAGTGTGCAAATAGTCTACAAACCAGTTGACCTGAGCAAG
GTGACCTCCAAGTGTGGCTCATTAGGCAACATCCATCATAAACCAGGAGGTG
GCCAGATGGAAGTAAAATCTGAGAAGCTTGACTTCAAGGACAGAGTCCAGTC
GAAGATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAA
AAGGTAAGAAGCAAGGTTTCATTTAGGGGAAGGGAAATGATTCAGGACGAG
AGTCTTTGTGCTGCTGAGTGCCTGTGATGAAGAAGCATGTTAGTcctgggcaacgtag
cgagaccccatctctacaaaaaatagaaaaattagccaggtatagtggcgcacacctgtgattccagctacgcaggaggctgag
gtgggaggattgcttgagcccaggaggttgaggctgcagtgagctgtaatcatgccactactccaacctgggcaacacagcaa
ggaccctgtctcaaaaGCTACTTACAGAAAAGAATTAggctcggcacggtagctcacacctgtaatcccag
cactttgggaggctgaggcgggcagatcacttgaggtcaggagtttgagaccagcctggccaacatggtgaaaccttgtctcta
ctaaaaatatgaaaattagccaggcatggtggcacattcctgtaatcccagctactcgggaggctgaggcaggagaatcacttga
acccaggaggtggaggttgcagtaagccgagatcgtaccactgtgctctagccttggtgacagagcgagactgtcttaaaaaaa
aaaaaaaaaaaaaaagaattaattaaaaatttaaaaaaaaatgaaaaaaaGCTGCATGCTTGTTTTTTGTTTT
TAGTTATTCTACATTGTTGTCATTATTACCAAATATTGGGGAAAATACAACTT
ACAGACCAATCTCAGGAGTTAAATGTTACTACGAAGGCAAATGAACTATGCG
TAATGAACCTGGTAGGCATTA
Tau Exon 10 is highlighted in Red, 3X flag tag in Yellow, Exon 11 in Blue, Exon
12 in Green. ZKSCAN1 Alu elements indicated in lowercase. Highlighted in light green
are sequencing primers. V337M mutation GTG to ATG is Bold and underlined in exon 12.
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Supplemental Figure 5-5 Tau authentic alus 10-12 WT sequence
gtaaggaaaccacctttgaaaagaaccaggctgctctgctgtggtttgcaaatgtggggtttgtttatttg
ttttttagcctcaaagacctttcttcaaatgagttctggcatagaagcaccgtgtaaaatagttagaattc
tgggcaaaggggaaaagagagctgggggccatccctctcagcaccccacaggctctcatagcagcagctcc
taagacacctggtgggaccttggtttcgaaatcgctactctaaggctgggcacggtggctcacacctgtaa
tcccagctctttaggaggccgaggagggtggatcacctgagatcaggagttcgagaccagcctggctaaca
tggcaaaaccctgtctctactaaaaatacaaaaattagccgggcgtggtgttatgcgtggtggtaatcgca
gctactcgggaggctgaggcacaaggattgcttgaaccccagaggcagaggttgtagttagctccagcttg
ggcgacagagcaagaccctgtcgcaaaaattgtttaaaaaacaaacccaaaattgctactctcattgggtt
cctttgcccattcctgattttggcaagagaaatgcttccagattgccctgatctgggtaggacagcatcac
gccatagcaacactgccccgtgagctcactgccccctcaactagcttgtggtccttggttaatgtcagttt
cttttttgagtttgtgttatgtctaagggtcatctgctgggtaacggaacccagggactgccctagtccct
agactgtgccatgcccgactctgccagctttgtcagtgatgctggtgctcgcctcctcgggtgctcgcctg
gtctgagcacacccaaggagttcttgaggccttagggttgtttgcgagagaatgaaagaacacgacctagc
tctctttagcatccttggtcaggttcaacactgcccccaggggcctctggtggagccaaccaccatcagcc
aaataaatccataattagagtcagaaaatggatgtctgcatatgtgtagtgcactaatgtcctgccgatga
ttgacatggagtggagagtgacctgatcattgctgtgagctctgctggccttggcacaactcatgctgata
actaatgcacacagttcctctgggaggaaatgtcctcagggaacttggagtttgggtggggatgtgggttt
gtgtgcccagcaagcccttgtggttgtagcagacactagtggcatctaggaggcaaagggtcaccccagtc
ttagccacgttttgagtcaaggtggcggagtggggctggtgttgactcttggtggcagtaacttttcccaa
tggtgaaaaacccctctatcatgtttcatttacagGTGCAGATAATTAATGACTACAAAGA

CCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGAC
AAGAAGAAGCTGGATCTTAGCAACGTCCAGTCCAAGTGTGGCTCAAAGGATA
ATATCAAACACGTCCCGGGAGGCGGCAGTGTGCAAATAGTCTACAAACCAGTTG
ACCTGAGCAAGGTGACCTCCAAGTGTGGCTCATTAGGCAACATCCATCATAA
ACCAGGAGGTGGCCAGGTGGAAGTAAAATCTGAGAAGCTTGACTTCAAGGA
CAGAGTCCAGTCGAAGATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCG
GAGGAAATAAAAAGgtaaagggggtagggtgggttggatgctgcccttgggtatatgggcattaa
tcaagttgagtggacaaaggctggtccagttcccagaggaggaaaacagaggcttctgtgttgactggctg
gatgtgggccctcagcagcatccagtgggtctccactgcctgtctcaatcacctggagctttagcacgttt
cacacctgggccccaacctggagaggctgaccaatgggtctcaggggcagctcggttgctggagtttttgt
ttttatttatttttatgtatttaaggcagggtctctgtattagtccattctcacactgctaataaagacat
acccaagactgggtaatttataaaggaaagaggtttaatggactcacagttccatatggctggggaggcct
caaaatcatggcggaaggcaaaggagaagcaaaggcatgtcttacatggcaacaggcaagagagcgtgtgc
aggggaactcccatttataaaaccatcagacctcatgagatttattcactatcatgagaacagcatgggaa
agacccgcccccatgattcagttacctcccactgggtccctcccatgacacatggaattatgggagctaca
attcaagatgagatttgggtggggacacagccaaaccatatcagtctccctctgtcatccaggctggagtg
cactggcatgatctcggctcactgcagcctctacctccctgggtcaggtgatcttcccacctcagcctccc
aggtagctggaactacaggtacctgccactatgcctggctaaatattttgtatttcctgtggagacgaggt
tttgccacgttgcccaggctggtcttgaactcctgaggtcaagcaatatgcccacctcggcctcccaaggt
gctgggattacaggtgtgagccacagtgctcggcctaagtcactgcagttttta

Tau Exon 10 is highlighted in Red, 3X flag tag in Yellow, Exon 11 in Blue, Exon
12 in Green. Tau Alu elements indicated in lowercase bold and underlined. Sequencing
primers Exon 11 forward: GTGTGCAAATAGTCTACAAACCA Exon 12 reverse:
AGGGACCCAATCTTCGACTG.
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Supplemental Figure 5-6 Tau both authentic alus 10-12 K317M sequence
gtaaggaaaccacctttgaaaagaaccaggctgctctgctgtggtttgcaaatgtggggtttgtttatttg
ttttttagcctcaaagacctttcttcaaatgagttctggcatagaagcaccgtgtaaaatagttagaattc
tgggcaaaggggaaaagagagctgggggccatccctctcagcaccccacaggctctcatagcagcagctcc
taagacacctggtgggaccttggtttcgaaatcgctactctaaggctgggcacggtggctcacacctgtaa
tcccagctctttaggaggccgaggagggtggatcacctgagatcaggagttcgagaccagcctggctaaca
tggcaaaaccctgtctctactaaaaatacaaaaattagccgggcgtggtgttatgcgtggtggtaatcgca
gctactcgggaggctgaggcacaaggattgcttgaaccccagaggcagaggttgtagttagctccagcttg
ggcgacagagcaagaccctgtcgcaaaaattgtttaaaaaacaaacccaaaattgctactctcattgggtt
cctttgcccattcctgattttggcaagagaaatgcttccagattgccctgatctgggtaggacagcatcac
gccatagcaacactgccccgtgagctcactgccccctcaactagcttgtggtccttggttaatgtcagttt
cttttttgagtttgtgttatgtctaagggtcatctgctgggtaacggaacccagggactgccctagtccct
agactgtgccatgcccgactctgccagctttgtcagtgatgctggtgctcgcctcctcgggtgctcgcctg
gtctgagcacacccaaggagttcttgaggccttagggttgtttgcgagagaatgaaagaacacgacctagc
tctctttagcatccttggtcaggttcaacactgcccccaggggcctctggtggagccaaccaccatcagcc
aaataaatccataattagagtcagaaaatggatgtctgcatatgtgtagtgcactaatgtcctgccgatga
ttgacatggagtggagagtgacctgatcattgctgtgagctctgctggccttggcacaactcatgctgata
actaatgcacacagttcctctgggaggaaatgtcctcagggaacttggagtttgggtggggatgtgggttt
gtgtgcccagcaagcccttgtggttgtagcagacactagtggcatctaggaggcaaagggtcaccccagtc
ttagccacgttttgagtcaaggtggcggagtggggctggtgttgactcttggtggcagtaacttttcccaa
tggtgaaaaacccctctatcatgtttcatttacagGTGCAGATAATTAATGACTACAAAGA

CCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGAC
AAGAAGAAGCTGGATCTTAGCAACGTCCAGTCCAAGTGTGGCTCAAAGGATA
ATATCAAACACGTCCCGGGAGGCGGCAGTGTGCAAATAGTCTACAAACCAGTTG
ACCTGAGCATGGTGACCTCCAAGTGTGGCTCATTAGGCAACATCCATCATAA
ACCAGGAGGTGGCCAGGTGGAAGTAAAATCTGAGAAGCTTGACTTCAAGGA
CAGAGTCCAGTCGAAGATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCG
GAGGAAATAAAAAGgtaaagggggtagggtgggttggatgctgcccttgggtatatgggcattaa
tcaagttgagtggacaaaggctggtccagttcccagaggaggaaaacagaggcttctgtgttgactggctg
gatgtgggccctcagcagcatccagtgggtctccactgcctgtctcaatcacctggagctttagcacgttt
cacacctgggccccaacctggagaggctgaccaatgggtctcaggggcagctcggttgctggagtttttgt
ttttatttatttttatgtatttaaggcagggtctctgtattagtccattctcacactgctaataaagacat
acccaagactgggtaatttataaaggaaagaggtttaatggactcacagttccatatggctggggaggcct
caaaatcatggcggaaggcaaaggagaagcaaaggcatgtcttacatggcaacaggcaagagagcgtgtgc
aggggaactcccatttataaaaccatcagacctcatgagatttattcactatcatgagaacagcatgggaa
agacccgcccccatgattcagttacctcccactgggtccctcccatgacacatggaattatgggagctaca
attcaagatgagatttgggtggggacacagccaaaccatatcagtctccctctgtcatccaggctggagtg
cactggcatgatctcggctcactgcagcctctacctccctgggtcaggtgatcttcccacctcagcctccc
aggtagctggaactacaggtacctgccactatgcctggctaaatattttgtatttcctgtggagacgaggt
tttgccacgttgcccaggctggtcttgaactcctgaggtcaagcaatatgcccacctcggcctcccaaggt
gctgggattacaggtgtgagccacagtgctcggcctaagtcactgcagttttta

Tau Exon 10 is highlighted in Red, 3X flag tag in Yellow, Exon 11 in Blue, Exon
12 in Green. Tau Alu elements indicated in lowercase bold and underlined. Sequencing
primers Exon 11 forward: GTGTGCAAATAGTCTACAAACCA Exon 12 reverse:
AGGGACCCAATCTTCGACTG. K317M mutation AAG to ATG is Bold and underlined
in exon 11.
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Supplemental Figure 5-7 Tau both authentic alus 10-12 V337M sequence
gtaaggaaaccacctttgaaaagaaccaggctgctctgctgtggtttgcaaatgtggggtttgtttatttg
ttttttagcctcaaagacctttcttcaaatgagttctggcatagaagcaccgtgtaaaatagttagaattc
tgggcaaaggggaaaagagagctgggggccatccctctcagcaccccacaggctctcatagcagcagctcc
taagacacctggtgggaccttggtttcgaaatcgctactctaaggctgggcacggtggctcacacctgtaa
tcccagctctttaggaggccgaggagggtggatcacctgagatcaggagttcgagaccagcctggctaaca
tggcaaaaccctgtctctactaaaaatacaaaaattagccgggcgtggtgttatgcgtggtggtaatcgca
gctactcgggaggctgaggcacaaggattgcttgaaccccagaggcagaggttgtagttagctccagcttg
ggcgacagagcaagaccctgtcgcaaaaattgtttaaaaaacaaacccaaaattgctactctcattgggtt
cctttgcccattcctgattttggcaagagaaatgcttccagattgccctgatctgggtaggacagcatcac
gccatagcaacactgccccgtgagctcactgccccctcaactagcttgtggtccttggttaatgtcagttt
cttttttgagtttgtgttatgtctaagggtcatctgctgggtaacggaacccagggactgccctagtccct
agactgtgccatgcccgactctgccagctttgtcagtgatgctggtgctcgcctcctcgggtgctcgcctg
gtctgagcacacccaaggagttcttgaggccttagggttgtttgcgagagaatgaaagaacacgacctagc
tctctttagcatccttggtcaggttcaacactgcccccaggggcctctggtggagccaaccaccatcagcc
aaataaatccataattagagtcagaaaatggatgtctgcatatgtgtagtgcactaatgtcctgccgatga
ttgacatggagtggagagtgacctgatcattgctgtgagctctgctggccttggcacaactcatgctgata
actaatgcacacagttcctctgggaggaaatgtcctcagggaacttggagtttgggtggggatgtgggttt
gtgtgcccagcaagcccttgtggttgtagcagacactagtggcatctaggaggcaaagggtcaccccagtc
ttagccacgttttgagtcaaggtggcggagtggggctggtgttgactcttggtggcagtaacttttcccaa
tggtgaaaaacccctctatcatgtttcatttacagGTGCAGATAATTAATGACTACAAAGA

CCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGAC
AAGAAGAAGCTGGATCTTAGCAACGTCCAGTCCAAGTGTGGCTCAAAGGATA
ATATCAAACACGTCCCGGGAGGCGGCAGTGTGCAAATAGTCTACAAACCAGTTG
ACCTGAGCAAGGTGACCTCCAAGTGTGGCTCATTAGGCAACATCCATCATAA
ACCAGGAGGTGGCCAGATGGAAGTAAAATCTGAGAAGCTTGACTTCAAGGA
CAGAGTCCAGTCGAAGATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCG
GAGGAAATAAAAAGgtaaagggggtagggtgggttggatgctgcccttgggtatatgggcattaa
tcaagttgagtggacaaaggctggtccagttcccagaggaggaaaacagaggcttctgtgttgactggctg
gatgtgggccctcagcagcatccagtgggtctccactgcctgtctcaatcacctggagctttagcacgttt
cacacctgggccccaacctggagaggctgaccaatgggtctcaggggcagctcggttgctggagtttttgt
ttttatttatttttatgtatttaaggcagggtctctgtattagtccattctcacactgctaataaagacat
acccaagactgggtaatttataaaggaaagaggtttaatggactcacagttccatatggctggggaggcct
caaaatcatggcggaaggcaaaggagaagcaaaggcatgtcttacatggcaacaggcaagagagcgtgtgc
aggggaactcccatttataaaaccatcagacctcatgagatttattcactatcatgagaacagcatgggaa
agacccgcccccatgattcagttacctcccactgggtccctcccatgacacatggaattatgggagctaca
attcaagatgagatttgggtggggacacagccaaaccatatcagtctccctctgtcatccaggctggagtg
cactggcatgatctcggctcactgcagcctctacctccctgggtcaggtgatcttcccacctcagcctccc
aggtagctggaactacaggtacctgccactatgcctggctaaatattttgtatttcctgtggagacgaggt
tttgccacgttgcccaggctggtcttgaactcctgaggtcaagcaatatgcccacctcggcctcccaaggt
gctgggattacaggtgtgagccacagtgctcggcctaagtcactgcagttttta

Tau Exon 10 is highlighted in Red, 3X flag tag in Yellow, Exon 11 in Blue, Exon
12 in Green. Tau Alu elements indicated in lowercase bold and underlined. Sequencing
primers Exon 11 forward: GTGTGCAAATAGTCTACAAACCA Exon 12 reverse:
AGGGACCCAATCTTCGACTG. V337M mutation GTG to ATG is Bold and underlined
in exon 12.
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Supplemental Figure 5-8 Description of Expression Constructs
Expression Construct Name Description
ZKSCAN Alu Tau 10-12 WT

pcDNA3.1 expression vector with CMV promoter.
Contains ZKSCAN1 Alu-elements, short intronic
regions, on the left and right side of tau cDNA.
Contains Tau cDNA exons 10-12 with a 3X flag tag
15 nt downstream in exon 10.

ZKSCAN Alu Tau 10-12 KM

pcDNA3.1 expression vector with CMV promoter.
Contains ZKSCAN1 Alu-elements, short intronic
regions, on the left and right side of tau cDNA.
Contains Tau cDNA exons 10-12 with a 3X flag tag
15 nt downstream in exon 10. FTDP-17 mutation
K317M in exon 11.

ZKSCAN Alu Tau 10-12 VM

pcDNA3.1 expression vector with CMV promoter.
Contains ZKSCAN1 Alu-elements, short intronic
regions, on the left and right side of tau cDNA.
Contains Tau cDNA exons 10-12 with a 3X flag tag
15 nt downstream in exon 10. FTDP-17 mutation
V337M in exon 12.

ZKSCAN Alu Tau 7-12 WT

pcDNA3.1 expression vector with CMV promoter.
Contains ZKSCAN1 Alu-elements, short intronic
regions, on the left and right side of tau cDNA.
Contains Tau cDNA exons 7,9-12 with a 3X flag tag
12 nt downstream in exon 7.

Tau authentic Alu 10-12 WT

pcDNA3.1 expression vector with CMV promoter.
Contains authentic tau Alu-elements, short intronic
regions in the left intron of exon 10 along with the
MER5A repeat. The right intron of exon 12 contains
the MER5B and THE1B repeat with the tau Alu. Tau
cDNA exons 10-12 with a 3X flag tag 15 nt
downstream in exon 10.

Tau authentic Alu 10-12 KM

pcDNA3.1 expression vector with CMV promoter.
Contains authentic tau Alu-elements, short intronic
regions in the left intron of exon 10 along with the
MER5A repeat. The right intron of exon 12 contains
the MER5B and THE1B repeat with the tau Alu. Tau
cDNA exons 10-12 with a 3X flag tag 15 nt
downstream in exon 10. Contains the FTDP-17
mutation K317M in exon 11.
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Tau authentic Alu 10-12 VM

pcDNA3.1 expression vector with CMV promoter.
Contains authentic tau Alu-elements, short intronic
regions in the left intron of exon 10 along with the
MER5A repeat. The right intron of exon 12 contains
the MER5B and THE1B repeat with the tau Alu. Tau
cDNA exons 10-12 with a 3X flag tag 15 nt
downstream in exon 10. Contains the FTDP-17
mutation V337M in exon 12.
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CHAPTER 6. CONCLUDING REMARKS
6.1

Summary

6.2

Major Findings

In this dissertation, we have discovered that the MAPT gene generates two circular
RNAs consisting of exons 10-12 (12à10) and exons 7, 9-12 (12à7) (43). The tau locus
contains repeat elements that have regions of base complementarity and provide the basis
of loop formation. Some of the repeat elements are known as Alu elements, and the tau
locus has at least 83 Alu elements, where 56 are on the sense strand and 27 are on the
antisense strand (144). In humans, Alu elements comprise around 11% of the human
genome (57) and are primate specific. Mice do not have Alu elements or the human specific
tau circular RNAs 12à7 and 12à10 and therefore may explain why they do not get
Alzheimer’s like humans.
We then looked for a correlation of circular RNA abundance and Alzheimer’s disease
severity and found no statistically significant correlation. The tau circular RNAs have
unique properties where both circular RNAs are divisible by three, giving them a reading
frame. Neither the 12à7 nor 12à10 circular RNA has a stop codon, and when translation
occurs, we predicted it would be translated in a rolling circle giving rise to multiple proteins
at different sizes. The 12à7 circular RNA has one methionine start codon in exon 9, where
the 12à10 circular RNA does not have a methionine. Therefore, we looked into whether
or not the circular RNAs are translated into protein and identified that the 12à7 circular
RNA is translated forming proteins at approximately 25 kDa, 30 kDa, 40 kDa. The 12à10
circular RNA is only translated when mutations introduce methionine start codons or
catalytically active RNA editing enzymes (ADARs) are present. The protein generated
from the tau circular RNA is predicted to consist of only the microtubule binding domains
of the linear protein, where the 12à7 circular RNA contains repeats R1-R4 and the 12à10
circular RNA contains R2-R4. The K18 neurotoxic peptide consist only of the tau
microtubule binding domains, repeat regions R1-R4 (6, 7). The tau circular RNAs protein
may also contribute to tau pathology and form neurofibrillary tangles and paired helical
filaments.
We identified an interaction and potential function of the protein generated from
both tau circular RNAs with the eukaryotic initiation factor 4B (EIF4B). The protein
generated from the tau circular RNAs may have a physiological role, but when the system
gets stressed, there may be a gain of function that deregulates gene regulation and
translation.
The novel pathway discovered with the circular tau RNAs can now be a new target
for drug therapy. Research has mainly been focused on the linear RNA and its respected
protein which could explain why there has not been much advancement in tauopathies. We
designed siRNAs to target the backsplice junction of the tau circular RNAs 12à7 and
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12à10 so that they will not affect the linear RNA. The siRNAs can be used as a
therapeutic drug since they prohibit the production of the protein generated from the
circular RNAs.
The pathway involving the human tau circular RNAs significantly increases our
knowledge of the MAPT locus. Now that we have identified a new pathway, further
research can look into this mechanism for other tauopathies.
6.3

Limitations and Future Directions

In order to validate circular RNA expression, it must be noted that reverse
transcription polymerase chain reaction (RT-PCR) for circular RNAs can give false
positives and PCR artifacts. One way we eliminated this, was by validating the circular
RNA detection by RNase protection. RNase protection is less sensitive, and by designing
probes that bind to the junction, one will see the hybridized probe protected from RNase
digestion.
Also, when transfecting cells with pcDNA3.1 expression vector that contains a CMV
promoter, multiple copies of the transfected DNA are incorporated into the genome. Due
to multiple copies being incorporated the results of the circular RNA from cells could also
give a false positive and actually be a concatemer. The concatemer would be the linear
repeat giving rise to the exon junction that would appear to only be from the circular RNA.
The tau circular RNAs are expressed in human brain tissue. Therefore, we use the cell
culture expressing the tau circular RNAs to detect the protein.
We are currently making stable cell lines that will incorporate only one copy into the
genome using HEK 293 Flp-In T-REx cells. HEK 293 Flp-In T-REx cells contain a single
stably integrated FRT site at a transcriptionally active genomic locus. Co-transfecting an
expression vector, pcDNA 5/FRT that contains your gene of interest with the Flp
recombinase vector, pOG44, results in target integration of the expression vector to the
same locus in every cell, ensuring homogenous levels of gene expression. The tau cDNA
constructs are cloned into the pcDNA 5/FRT expression vector. The polyA tail was
removed so that this expression construct would only give rise to the circular RNAs and
have one copy incorporated into the genome. The HEK 293 Flp-In T-REx cell line will
validate the authenticity of the circular RNAs being made are circular and not linear and
that they are not concatemers.
We are analyzing human brain tissue by Mass Spectrometry to detect the protein
encoded by the backsplice junction generated from the circular 12à7 RNA. The expected
protein sequence is rather difficult to analyze because the junction sequence contains two
lysine residues that will be cleaved by trypsin. Trypsin is a common digestive enzyme used
in mass spectrometry because it is specific and active. The enzymes we need to digest the
protein to obtain the backsplice junction are less specific and are being optimized under
different conditions.
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We are moving our model in vivo using zebrafish to test the pathology generated
from the wild type and mutant circular RNAs. So far, the zebrafish are sterile. Different
human brain tissue regions will also be analyzed and compared for circular RNA
abundance and severity of Alzheimer’s pathology.
6.4

Conclusion

We propose a model that adds a new feature (Figure 6.1 in Yellow) to the human tau
biology. The MAPT gene generates circular RNAs that contain exons 7,9-12 and 10-12 due
to exon 12 backsplicing. In Alzheimer’s disease it has been shown that there is more exon
10 inclusion in these patients. However, an increase in exon 10 inclusion does not affect
circular RNA abundance, nor is there an effect on circular RNA abundance and
Alzheimer's severity indicated by Braak stages. The circular RNAs are cytosolic and in
synaptosomes indicating they can play a role in translation or gene regulation.
These circular RNAs are naturally occurring in humans where the 12à7 is translated
due to the methionine start codon in exon 9. The 12à10 circular RNA is only translated
when mutations introduce start codons or RNA editing enzymes (ADARs) are present.
Since EIF4B is required for translational initiation of highly structured mRNAs, the
circular tau RNAs function may be to regulate gene expression due to the interaction with
EIF4B. ADAR enzymes have been shown to be deregulated in Alzheimer’s disease (145)
and have an effect on tau circular RNA translation. The circular RNAs may be edited
creating new start codons enabling more protein to be produced. Increasing protein
production may lead to tau aggregation and neurodegeneration.
Thus, this work allows a novel therapeutic approach with siRNAs that target the tau
circular RNAs backsplice junction reducing their expression and prohibiting translation, as
an intervention for Alzheimer’s disease.
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Figure 6-1 Tau model of pre-mRNA processing forming linear and circular RNAs

Known knowledge is in gray and my finding is in yellow.
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A. Schematic of the shortened pre-mRNA of the tau locus and how it is alternatively
spliced.
B. After alternative splicing six major RNA isoforms are formed.
C. The six major protein isoforms are translated and interacts with tubulin stabilizing
microtubules.
D. When tau no longer binds to tubulin and forms tau aggregates, disease pathology forms,
causing tubulin disassembly leading to Tauopathies.
E. The novel discovery in yellow, two circular RNAs form due to the backsplicing of exon
12 onto either exon 7 or exon 10 (12à7, 12à10).
F. 12à7 circular tau RNA is translated in a rolling circle.
G. The circular tau RNAs can be destroyed or reduced with siRNAs targeting the
backsplice junction inhibiting protein translation.
H. The 12à10 circular RNA is translated with FTDP-17 mutations K317M and V337M.
Editing enzymes (ADAR1 and ADAR2) increase protein production due to RNA editing.
The translated regions of the circular tau RNA 12à10 is predicted to be similar to the
neurotoxic peptide called K18.
I. Both circular RNAs 12à and 12à10 are translated forming multiple proteins of
different sizes, a possible indication of multiple rounds of translation. Editing enzymes
(ADAR1 and ADAR2) increase protein production due to RNA editing. The translated
region of the circular tau RNAs is predicted to be similar to the neurotoxic peptide called
K18.
J. EIF4B interacts with the protein from the tau circular RNAs possibly influencing
translation
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APPENDIX: LIST OF ABBREVIATIONS
ADAR

Adenosine Deaminase Acting on RNA

ADAR1

ADAR

ADAR2

ADARB1

ADAR3

ADARB2

AD

Alzheimer’s Disease

DNA

Deoxyribonucleic Acid

EIF4B

Eukaryotic Initiation Factor 4B

FTDP-17

Frontotemporal Dementia with Parkinsonism linked to Chromosome 17

HEK 293T

Human Embryonic Kidney Cells

IP

Immunoprecipitation

KM

Lysine to Methionine Mutation

MAPT

Microtubule Associated Protein Tau

mRNA

Messenger RNA

PBS

Phosphate Buffered Saline

PCR

Polymerase Chain Reaction

PEI

Polyethyleneimine

qRT-PCR

Quantitative Real Time Polymerase Chain Reaction

RNA

Ribonucleic Acid

RPA

RNase Protection Assay

RT-PCR

Reverse Transcription Polymerase Chain Reaction

SDS

Sodium Dodecyl Sulphate

siRNA

Small Interfering RNA

VM

Valine to Methionine Mutation

WB

Western Blot

WT

Wild Type
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